US20040039212A1 - Sphingolipid derivatives and their methods of use - Google Patents
Sphingolipid derivatives and their methods of use Download PDFInfo
- Publication number
- US20040039212A1 US20040039212A1 US10/647,801 US64780103A US2004039212A1 US 20040039212 A1 US20040039212 A1 US 20040039212A1 US 64780103 A US64780103 A US 64780103A US 2004039212 A1 US2004039212 A1 US 2004039212A1
- Authority
- US
- United States
- Prior art keywords
- another embodiment
- cooh
- octanoyl
- compound
- mannoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003408 sphingolipids Chemical class 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 77
- 150000001875 compounds Chemical class 0.000 claims abstract description 141
- 102000003923 Protein Kinase C Human genes 0.000 claims abstract description 51
- 108090000315 Protein Kinase C Proteins 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 47
- 201000011510 cancer Diseases 0.000 claims abstract description 42
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 27
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 102100030497 Cytochrome c Human genes 0.000 claims abstract description 16
- 108010075031 Cytochromes c Proteins 0.000 claims abstract description 16
- 230000002159 abnormal effect Effects 0.000 claims abstract description 13
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 11
- 208000035475 disorder Diseases 0.000 claims abstract description 11
- 230000024245 cell differentiation Effects 0.000 claims abstract description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 85
- 125000001424 substituent group Chemical group 0.000 claims description 75
- -1 1,4-disubstituted benzene group Chemical group 0.000 claims description 69
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 58
- 229940106189 ceramide Drugs 0.000 claims description 48
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 44
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 44
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 44
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 44
- 239000003008 fumonisin Substances 0.000 claims description 41
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 32
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 claims description 32
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- XSDVOEIEBUGRQX-RBUKOAKNSA-N dihydroceramide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC=O XSDVOEIEBUGRQX-RBUKOAKNSA-N 0.000 claims description 22
- 108020003175 receptors Proteins 0.000 claims description 21
- 102000005962 receptors Human genes 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 210000004379 membrane Anatomy 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 15
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 229910052727 yttrium Inorganic materials 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 230000008685 targeting Effects 0.000 claims description 13
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 12
- 229910019142 PO4 Inorganic materials 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000010452 phosphate Substances 0.000 claims description 10
- 229910052720 vanadium Inorganic materials 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 208000028774 intestinal disease Diseases 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- CILLLUONWCSDCK-PXKIYYGHSA-N CCCCCCCCCCCCCC(O)C[C@@H](O)[C@H](C)N Chemical compound CCCCCCCCCCCCCC(O)C[C@@H](O)[C@H](C)N CILLLUONWCSDCK-PXKIYYGHSA-N 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 108010066657 azoreductase Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 201000005962 mycosis fungoides Diseases 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 108700012359 toxins Proteins 0.000 claims description 6
- 208000003200 Adenoma Diseases 0.000 claims description 5
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 5
- 102000009016 Cholera Toxin Human genes 0.000 claims description 5
- 108010049048 Cholera Toxin Proteins 0.000 claims description 5
- 241000193155 Clostridium botulinum Species 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 241000606768 Haemophilus influenzae Species 0.000 claims description 5
- 241000590002 Helicobacter pylori Species 0.000 claims description 5
- 241000711408 Murine respirovirus Species 0.000 claims description 5
- 101710138657 Neurotoxin Proteins 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 5
- 108010017898 Shiga Toxins Proteins 0.000 claims description 5
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 5
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
- 229940095731 candida albicans Drugs 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 5
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 5
- 229940037467 helicobacter pylori Drugs 0.000 claims description 5
- 239000002581 neurotoxin Substances 0.000 claims description 5
- 231100000618 neurotoxin Toxicity 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 5
- 125000006850 spacer group Chemical group 0.000 claims description 5
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 206010001233 Adenoma benign Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 4
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 4
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
- 206010043276 Teratoma Diseases 0.000 claims description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229950006137 dexfosfoserine Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 150000002243 furanoses Chemical class 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 201000009019 intestinal benign neoplasm Diseases 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000032177 Intestinal Polyps Diseases 0.000 claims description 3
- 206010051606 Necrotising colitis Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims description 3
- 150000007942 carboxylates Chemical class 0.000 claims description 3
- 108091008039 hormone receptors Proteins 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 3
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 206010004272 Benign hydatidiform mole Diseases 0.000 claims description 2
- 206010004992 Bladder adenocarcinoma stage unspecified Diseases 0.000 claims description 2
- 208000007690 Brenner tumor Diseases 0.000 claims description 2
- 206010073258 Brenner tumour Diseases 0.000 claims description 2
- 201000005262 Chondroma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 2
- 208000007659 Fibroadenoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 208000006937 Hydatidiform mole Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 201000004462 Leydig Cell Tumor Diseases 0.000 claims description 2
- 206010024612 Lipoma Diseases 0.000 claims description 2
- 206010025219 Lymphangioma Diseases 0.000 claims description 2
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 claims description 2
- 206010027145 Melanocytic naevus Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 208000007256 Nevus Diseases 0.000 claims description 2
- 208000002163 Phyllodes Tumor Diseases 0.000 claims description 2
- 206010071776 Phyllodes tumour Diseases 0.000 claims description 2
- 208000034541 Rare lymphatic malformation Diseases 0.000 claims description 2
- 208000005678 Rhabdomyoma Diseases 0.000 claims description 2
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 2
- 201000006587 bladder adenocarcinoma Diseases 0.000 claims description 2
- 201000001531 bladder carcinoma Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000003149 breast fibroadenoma Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 210000005002 female reproductive tract Anatomy 0.000 claims description 2
- 201000008361 ganglioneuroma Diseases 0.000 claims description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 claims description 2
- 201000011066 hemangioma Diseases 0.000 claims description 2
- 208000022013 kidney Wilms tumor Diseases 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 2
- 208000010943 meningeal sarcoma Diseases 0.000 claims description 2
- 201000003776 meninges sarcoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 208000008588 molluscum contagiosum Diseases 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 208000008798 osteoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 230000001855 preneoplastic effect Effects 0.000 claims description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 229920000294 Resistant starch Polymers 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000021254 resistant starch Nutrition 0.000 claims 1
- 239000000651 prodrug Substances 0.000 abstract description 20
- 229940002612 prodrug Drugs 0.000 abstract description 20
- 210000001519 tissue Anatomy 0.000 abstract description 19
- 230000004663 cell proliferation Effects 0.000 abstract description 14
- 210000000936 intestine Anatomy 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 230000035755 proliferation Effects 0.000 abstract description 11
- 210000003470 mitochondria Anatomy 0.000 abstract description 10
- 230000002792 vascular Effects 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 8
- 230000018109 developmental process Effects 0.000 abstract description 8
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract description 8
- 230000006882 induction of apoptosis Effects 0.000 abstract description 7
- 230000004968 inflammatory condition Effects 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 4
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 375
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 43
- 230000015572 biosynthetic process Effects 0.000 description 41
- 238000003786 synthesis reaction Methods 0.000 description 41
- 230000006907 apoptotic process Effects 0.000 description 40
- 239000000203 mixture Substances 0.000 description 38
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- 230000000694 effects Effects 0.000 description 33
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 32
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 32
- 229940088598 enzyme Drugs 0.000 description 31
- 239000011541 reaction mixture Substances 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 28
- 238000003756 stirring Methods 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- 230000004137 sphingolipid metabolism Effects 0.000 description 25
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- 150000002632 lipids Chemical class 0.000 description 21
- 102000055102 bcl-2-Associated X Human genes 0.000 description 20
- 150000003410 sphingosines Chemical class 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 229910001868 water Inorganic materials 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 17
- 102100029855 Caspase-3 Human genes 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 17
- 108090000397 Caspase 3 Proteins 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 230000004060 metabolic process Effects 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 238000001819 mass spectrum Methods 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 230000001640 apoptogenic effect Effects 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
- 230000000112 colonic effect Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 0 CCC(C)C([V])C([Y])C(C)*C[W] Chemical compound CCC(C)C([V])C([Y])C(C)*C[W] 0.000 description 12
- 210000001072 colon Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 231100000504 carcinogenesis Toxicity 0.000 description 9
- 230000030833 cell death Effects 0.000 description 9
- 210000000172 cytosol Anatomy 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 150000001982 diacylglycerols Chemical class 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000002438 mitochondrial effect Effects 0.000 description 9
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 8
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 8
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 208000005623 Carcinogenesis Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 230000036952 cancer formation Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 150000004702 methyl esters Chemical class 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 8
- 102100024308 Ceramide synthase Human genes 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 108010061814 dihydroceramide desaturase Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- UCIDYSLOTJMRAM-UHFFFAOYSA-N hexadec-1-yne Chemical class CCCCCCCCCCCCCCC#C UCIDYSLOTJMRAM-UHFFFAOYSA-N 0.000 description 7
- 239000002480 mineral oil Substances 0.000 description 7
- 235000010446 mineral oil Nutrition 0.000 description 7
- XTCPLAOSDRPLKZ-UHFFFAOYSA-N non-8-yn-1-ol Chemical compound OCCCCCCCC#C XTCPLAOSDRPLKZ-UHFFFAOYSA-N 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 102000001253 Protein Kinase Human genes 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 150000002270 gangliosides Chemical class 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000002644 phorbol ester Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 6
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 102000051485 Bcl-2 family Human genes 0.000 description 5
- 108700038897 Bcl-2 family Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108010044467 Isoenzymes Proteins 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- UVBUBMSSQKOIBE-DSLOAKGESA-N fumonisin B1 Chemical compound OC(=O)C[C@@H](C(O)=O)CC(=O)O[C@H]([C@H](C)CCCC)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N UVBUBMSSQKOIBE-DSLOAKGESA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 150000004633 phorbol derivatives Chemical class 0.000 description 5
- 150000003906 phosphoinositides Chemical class 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- APWORUOFRJOEKK-UHFFFAOYSA-N 1,3-oxazolidine-2-carbaldehyde Chemical compound O=CC1NCCO1 APWORUOFRJOEKK-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 241000557626 Corvus corax Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000053187 Glucuronidase Human genes 0.000 description 4
- 108010060309 Glucuronidase Proteins 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- NJUISRMVIKYYCN-UHFFFAOYSA-N acetic acid;chloroform;methanol;hydrate Chemical compound O.OC.CC(O)=O.ClC(Cl)Cl NJUISRMVIKYYCN-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 150000001345 alkine derivatives Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 150000001783 ceramides Chemical class 0.000 description 4
- 229930183167 cerebroside Natural products 0.000 description 4
- 150000001784 cerebrosides Chemical class 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 150000002373 hemiacetals Chemical class 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
- 150000004682 monohydrates Chemical class 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- XERDOEKKHDALKJ-UHFFFAOYSA-N non-2-yn-1-ol Chemical compound CCCCCCC#CCO XERDOEKKHDALKJ-UHFFFAOYSA-N 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000019254 respiratory burst Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 3
- PYTMBSDYMPHFOQ-UHFFFAOYSA-N 2,2,2-trichloro-n-[4-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=C(NC(=O)C(Cl)(Cl)Cl)C=C1 PYTMBSDYMPHFOQ-UHFFFAOYSA-N 0.000 description 3
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 3
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 231100000678 Mycotoxin Toxicity 0.000 description 3
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108050002653 Retinoblastoma protein Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 3
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- YFHNDHXQDJQEEE-UHFFFAOYSA-N acetic acid;hydrazine Chemical compound NN.CC(O)=O YFHNDHXQDJQEEE-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 108700041737 bcl-2 Genes Proteins 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002339 glycosphingolipids Chemical class 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002636 mycotoxin Substances 0.000 description 3
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 3
- VOVWQRQDSCYAEA-UHFFFAOYSA-N n-[chloro(methoxy)phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound COP(Cl)N(C(C)C)C(C)C VOVWQRQDSCYAEA-UHFFFAOYSA-N 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- ATCNYMVVGBLQMQ-UHFFFAOYSA-N oct-7-yn-1-ol Chemical compound OCCCCCCC#C ATCNYMVVGBLQMQ-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- UFGPGIQISUZXOS-UHFFFAOYSA-N pentadec-14-yn-1-ol Chemical compound OCCCCCCCCCCCCCC#C UFGPGIQISUZXOS-UHFFFAOYSA-N 0.000 description 3
- PFHRFJSUAGQBFE-UHFFFAOYSA-N pentadec-2-yn-1-ol Chemical compound CCCCCCCCCCCCC#CCO PFHRFJSUAGQBFE-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229950004354 phosphorylcholine Drugs 0.000 description 3
- 150000003019 phosphosphingolipids Chemical class 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 108010035597 sphingosine kinase Proteins 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- KUWPCJHYPSUOFW-RMPHRYRLSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(2-nitrophenoxy)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-RMPHRYRLSA-N 0.000 description 2
- NGEZPLCPKXKLQQ-VOTSOKGWSA-N (e)-4-(3-methoxyphenyl)but-3-en-2-one Chemical compound COC1=CC=CC(\C=C\C(C)=O)=C1 NGEZPLCPKXKLQQ-VOTSOKGWSA-N 0.000 description 2
- LJKCPJOLKILGIR-FNQQTZKRSA-N (e,2r)-n-[(2s,3r)-1,3-dihydroxyoctadecan-2-yl]-2-hydroxyoctadec-3-enamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(=O)[C@H](O)\C=C\CCCCCCCCCCCCCC LJKCPJOLKILGIR-FNQQTZKRSA-N 0.000 description 2
- WWUZIQQURGPMPG-NVGHFZOBSA-N (e,2r,3r)-2-aminooctadec-4-ene-1,3-diol Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](N)CO WWUZIQQURGPMPG-NVGHFZOBSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- OKTWQKXBJUBAKS-WQADZSDSSA-N 2-[[(e,2r,3s)-2-amino-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC\C=C\[C@H](O)[C@H](N)COP(O)(=O)OCC[N+](C)(C)C OKTWQKXBJUBAKS-WQADZSDSSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- AERBNCYCJBRYDG-RGBJRUIASA-N 4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCC(O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-RGBJRUIASA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000007416 Aberrant Crypt Foci Diseases 0.000 description 2
- 108090000531 Amidohydrolases Proteins 0.000 description 2
- 102000004092 Amidohydrolases Human genes 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 2
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 241000233732 Fusarium verticillioides Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 108091006671 Ion Transporter Proteins 0.000 description 2
- 102000037862 Ion Transporter Human genes 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 231100000757 Microbial toxin Toxicity 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SXZWBNWTCVLZJN-NMIJJABPSA-N N-tricosanoylsphing-4-enine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC SXZWBNWTCVLZJN-NMIJJABPSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000002579 Sphingosine N-acyltransferase Human genes 0.000 description 2
- 108020004714 Sphingosine N-acyltransferase Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241000200270 Symbiodinium sp. Species 0.000 description 2
- LJKCPJOLKILGIR-UHFFFAOYSA-N Symbioramide Natural products CCCCCCCCCCCCCCCC(O)C(CO)NC(=O)C(O)C=CCCCCCCCCCCCCCC LJKCPJOLKILGIR-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- PKSROMPNLONTJT-UHFFFAOYSA-N azanium;chloroform;methanol;hydroxide Chemical compound N.O.OC.ClC(Cl)Cl PKSROMPNLONTJT-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 108700000711 bcl-X Proteins 0.000 description 2
- 102000055104 bcl-X Human genes 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000009134 cell regulation Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000010428 chromatin condensation Effects 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 230000004736 colon carcinogenesis Effects 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- XNRAUTMOUDUPET-UHFFFAOYSA-N dodec-11-yn-1-ol Chemical compound OCCCCCCCCCCC#C XNRAUTMOUDUPET-UHFFFAOYSA-N 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229930182479 fructoside Natural products 0.000 description 2
- UXDPXZQHTDAXOZ-STOIETHLSA-N fumonisin B2 Chemical compound OC(=O)C[C@@H](C(O)=O)CC(=O)O[C@H]([C@H](C)CCCC)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)C[C@@H](C)CCCCCC[C@@H](O)C[C@H](O)[C@H](C)N UXDPXZQHTDAXOZ-STOIETHLSA-N 0.000 description 2
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002305 glucosylceramides Chemical class 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- GOQJMMHTSOQIEI-UHFFFAOYSA-N hex-5-yn-1-ol Chemical compound OCCCCC#C GOQJMMHTSOQIEI-UHFFFAOYSA-N 0.000 description 2
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000027829 mitochondrial depolarization Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- DONJGKADZJEXRJ-UHFFFAOYSA-N pentadec-1-yne Chemical compound CCCCCCCCCCCCCC#C DONJGKADZJEXRJ-UHFFFAOYSA-N 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000037050 permeability transition Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 2
- 229940033329 phytosphingosine Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920005646 polycarboxylate Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- RTQVJTLVVBJRJG-UHFFFAOYSA-N (2S,3R,4E,8E)-4,8-sphingadienine Natural products CCCCCCCCCC=CCCC=CC(O)C(N)CO RTQVJTLVVBJRJG-UHFFFAOYSA-N 0.000 description 1
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 1
- JIDDDPVQQUHACU-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbaldehyde Chemical group O=C[C@@H]1CCCN1 JIDDDPVQQUHACU-YFKPBYRVSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- RZGWHFMRNRMJRF-YFKPBYRVSA-N (4r)-4-formyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylic acid Chemical compound CC1(C)OC[C@H](C=O)N1C(O)=O RZGWHFMRNRMJRF-YFKPBYRVSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KODLUXHSIZOKTG-UHFFFAOYSA-N 1-aminobutan-2-ol Chemical group CCC(O)CN KODLUXHSIZOKTG-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- BBYWOYAFBUOUFP-JOCHJYFZSA-N 1-stearoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCCN BBYWOYAFBUOUFP-JOCHJYFZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- OMLOASXVBUNPTN-UHFFFAOYSA-N 2,4-dimethylcyclohexane-1-carbaldehyde Chemical compound CC1CCC(C=O)C(C)C1 OMLOASXVBUNPTN-UHFFFAOYSA-N 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical group C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- KIFPIAKBYOIOCS-UHFFFAOYSA-N 2-methyl-2-(trioxidanyl)propane Chemical compound CC(C)(C)OOO KIFPIAKBYOIOCS-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- KSPDSMOWMQFPBL-UHFFFAOYSA-N 5-fluoropyrimidine Chemical compound FC1=CN=CN=C1 KSPDSMOWMQFPBL-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 108010005413 AP24 apoptotic protease Proteins 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920001685 Amylomaize Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 description 1
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 101150033765 BAG1 gene Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000006166 Brown acetylene zipper reaction Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NMZPZUSTBGXUKR-UHFFFAOYSA-N C1=CC=C2C=CC=C2C2=C3CC3=CC=C21 Chemical class C1=CC=C2C=CC=C2C2=C3CC3=CC=C21 NMZPZUSTBGXUKR-UHFFFAOYSA-N 0.000 description 1
- HTJSZHKGNMXZJN-YIVRLKKSSA-N C20 sphingosine Chemical compound CCCCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO HTJSZHKGNMXZJN-YIVRLKKSSA-N 0.000 description 1
- OMCUOYGFCSQIEY-VRVQHWPMSA-N CC(=O)O.CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CCOC1(C)CCC(C)(O)CO1.CCCCCCCCCCCCCCCC(C)=O.CO.CO Chemical compound CC(=O)O.CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CCOC1(C)CCC(C)(O)CO1.CCCCCCCCCCCCCCCC(C)=O.CO.CO OMCUOYGFCSQIEY-VRVQHWPMSA-N 0.000 description 1
- VVMKZCAWGGFQJJ-UHFFFAOYSA-N CC(C)(C)OC(N(C)C(C)(C)OC)=O Chemical compound CC(C)(C)OC(N(C)C(C)(C)OC)=O VVMKZCAWGGFQJJ-UHFFFAOYSA-N 0.000 description 1
- KDONEIVYYVZFQD-UHFFFAOYSA-N CC(C)(C)OC(N1C(C)(C)CCC1C=O)=O Chemical compound CC(C)(C)OC(N1C(C)(C)CCC1C=O)=O KDONEIVYYVZFQD-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- OHDBDYPXRFDHRS-QUBRSVJISA-N CCCCCCCCCCCCC/C=C/C(O)C(N)CO.CCCCCCCCCCCCCC(O)CC(O)C(C)N.CCCCCCCCCCCCCCCC(O)C(N)CO Chemical compound CCCCCCCCCCCCC/C=C/C(O)C(N)CO.CCCCCCCCCCCCCC(O)CC(O)C(C)N.CCCCCCCCCCCCCCCC(O)C(N)CO OHDBDYPXRFDHRS-QUBRSVJISA-N 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- CPCRJSQNWHCGOP-KUHXKYQKSA-N Fumonisin B3 Chemical compound OC(=O)CC(C(O)=O)CC(=O)O[C@H]([C@H](C)CCCC)[C@@H](OC(=O)CC(CC(O)=O)C(O)=O)C[C@@H](C)C[C@H](O)CCCCCC[C@@H](O)[C@H](C)N CPCRJSQNWHCGOP-KUHXKYQKSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000924629 Homo sapiens Apoptotic protease-activating factor 1 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- FOCMISOLVPZNSV-CANPYCKCSA-N N-[(E,2R,3S)-1-[5-[5-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3NC(C)=O)C(O)C2O)C(O)C1O)[C@@H](O)\C=C\CCCCCCCCCCCCC FOCMISOLVPZNSV-CANPYCKCSA-N 0.000 description 1
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 description 1
- RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108010069394 Phosphatidate Phosphatase Proteins 0.000 description 1
- 102000001107 Phosphatidate Phosphatase Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000000159 Synaptotagmin II Human genes 0.000 description 1
- 108010055445 Synaptotagmin II Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000000254 aspartoyl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 101150055276 ced-3 gene Proteins 0.000 description 1
- 101150112018 ced-4 gene Proteins 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 201000011024 colonic benign neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- OKKJLVBELUTLKV-MICDWDOJSA-N deuteriomethanol Chemical compound [2H]CO OKKJLVBELUTLKV-MICDWDOJSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 150000002001 dihydroceramides Chemical class 0.000 description 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- MIDXCKJJIFQOLT-UHFFFAOYSA-N dodec-9-yn-1-ol Chemical compound CCC#CCCCCCCCCO MIDXCKJJIFQOLT-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- IGUYEXXAGBDLLX-UHFFFAOYSA-N ethyl 3-(3,5-dichlorophenyl)-5-methyl-2,4-dioxo-1,3-oxazolidine-5-carboxylate Chemical class O=C1C(C(=O)OCC)(C)OC(=O)N1C1=CC(Cl)=CC(Cl)=C1 IGUYEXXAGBDLLX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 108010006620 fodrin Proteins 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- WYYKRDVIBOEORL-JLCKPESSSA-N fumonisin B4 Chemical compound OC(=O)C[C@@H](C(O)=O)CC(=O)O[C@H]([C@H](C)CCCC)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)C[C@@H](C)CCCCCCCC[C@H](O)[C@H](C)N WYYKRDVIBOEORL-JLCKPESSSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002298 globosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PSWHODJVUOXHKA-UHFFFAOYSA-N hept-3-yn-1-ol Chemical compound CCCC#CCCO PSWHODJVUOXHKA-UHFFFAOYSA-N 0.000 description 1
- NVDRTKDQNXWZSY-UHFFFAOYSA-N hept-5-yn-1-ol Chemical compound CC#CCCCCO NVDRTKDQNXWZSY-UHFFFAOYSA-N 0.000 description 1
- BVRCLEXKQNWTDK-UHFFFAOYSA-N hept-6-yn-1-ol Chemical compound OCCCCCC#C BVRCLEXKQNWTDK-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid group Chemical group C(CCCCCC)(=O)O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BTUSGZZCQZACPT-YYZTVXDQSA-N hexadecasphing-4-enine Chemical compound CCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO BTUSGZZCQZACPT-YYZTVXDQSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- UKJFVOWPUXSBOM-UHFFFAOYSA-N hexane;oxolane Chemical compound C1CCOC1.CCCCCC UKJFVOWPUXSBOM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000050495 human APAF1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- CXLVBVPYZYXEFY-UHFFFAOYSA-N n-(chlorophosphanyloxymethyl)-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)COPCl CXLVBVPYZYXEFY-UHFFFAOYSA-N 0.000 description 1
- VELGMVLNORPMAO-JTFNWEOFSA-N n-[(e)-1-[(3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxym Chemical compound O[C@@H]1[C@@H](O)C(OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 VELGMVLNORPMAO-JTFNWEOFSA-N 0.000 description 1
- PTGGMPLMNDBPGB-CXISOLTFSA-N n-[(e,2s,3r)-1,3-dihydroxyoctadec-4-en-2-yl]formamide Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC=O PTGGMPLMNDBPGB-CXISOLTFSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LBQAJLBSGOBDQF-UHFFFAOYSA-N nitro azanylidynemethanesulfonate Chemical compound [O-][N+](=O)OS(=O)(=O)C#N LBQAJLBSGOBDQF-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- UMIPWJGWASORKV-UHFFFAOYSA-N oct-1-yne Chemical compound CCCCCCC#C UMIPWJGWASORKV-UHFFFAOYSA-N 0.000 description 1
- LRZGRGVRZSDRTK-UHFFFAOYSA-N oct-3-yn-1-ol Chemical compound CCCCC#CCCO LRZGRGVRZSDRTK-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- CRWVOXFUXPYTRK-UHFFFAOYSA-N pent-4-yn-1-ol Chemical compound OCCCC#C CRWVOXFUXPYTRK-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- HHJTWTPUPVQKNA-PIIMIWFASA-N psychosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HHJTWTPUPVQKNA-PIIMIWFASA-N 0.000 description 1
- HHJTWTPUPVQKNA-UHFFFAOYSA-N psychosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)COC1OC(CO)C(O)C(O)C1O HHJTWTPUPVQKNA-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000018866 regulation of programmed cell death Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- BZWKPZBXAMTXNQ-UHFFFAOYSA-N sulfurocyanidic acid Chemical compound OS(=O)(=O)C#N BZWKPZBXAMTXNQ-UHFFFAOYSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- DZEFNRWGWQDGTR-UHFFFAOYSA-N tetradec-1-yne Chemical compound CCCCCCCCCCCCC#C DZEFNRWGWQDGTR-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005454 tryptophanyl group Chemical group 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- YUQZOUNRPZBQJK-UHFFFAOYSA-N undec-10-yn-1-ol Chemical compound OCCCCCCCCCC#C YUQZOUNRPZBQJK-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- MJIBOYFUEIDNPI-HBNMXAOGSA-L zinc 5-[2,3-dihydroxy-5-[(2R,3R,4S,5R,6S)-4,5,6-tris[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy]-2-[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxymethyl]oxan-3-yl]oxycarbonylphenoxy]carbonyl-3-hydroxybenzene-1,2-diolate Chemical class [Zn++].Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c([O-])c([O-])c2)c1 MJIBOYFUEIDNPI-HBNMXAOGSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
- C07F9/1411—Esters of phosphorous acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
- C07F9/143—Esters of phosphorous acids with unsaturated acyclic alcohols
Definitions
- This application is in the area of pharmaceutical chemistry, and in particular includes sphingolipid derivatives, prodrugs and pharmaceutical compositions and salts thereof for the treatment of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue.
- the invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof. Further, the invention provides a method for treating bacterial infections, including those that influence colon cancer and other disorders of the intestine, that includes administering an effective amount of one of the active compounds identified herein.
- Sphingosine is the common name for D-erythro-4-trans-sphinganine, the prevalent long-chain base of most mammalian sphingolipids. It most often has 18 carbon atoms and the stereochemistry shown in FIG. 1.
- Sphingolipids generally are composed of a long-chain (sphingoid) base (sphingosine, sphinganine, 4-hydroxysphinganine, or a related compound) as the backbone moiety (Karlsson, K. A. Chem. Phys. Lipids, 5:6-43, 1970), which is usually modified by an amide-linked long-chain fatty acid (for ceramides), and a head group at position 1, as illustrated in FIG. 2.
- sphingolipids Over 300 classes of sphingolipids are known, most of which have head groups with simple to complex carbohydrates (see Merrill & Sweeley, New Comprehensive Biochemistry: Biochemistry of Lipids, Lipoproteins, and Membranes, (Vance, D. E. & Vance, J. E., eds.), pp. 309-338, Elsevier Science, Amsterdam, 1996). It is a common misconception from the names of these compounds (e.g., ceramide, sphingomyelin, gangliosides, etc.) that sphingolipids are only found in neuronal tissues.
- sphingolipids are major constituents of all eukaryotic (and some prokaryotic) organisms, including plants (Lynch, D. V., Lipid Metabolism in Plants (T. S. Moore, Jr., ed.), pp. 285-308, CRC Press, Boca Raton, Fla. 1993). This nomenclature merely reflects their initial discovery in brain tissues by classic studies a century ago (Thudichum, J. L. W., A Treatise on the Chemical Constitution of Brain, Bailliere, Tindall & Cox, (London) 1884).
- Mammalian sphingolipid compounds typically vary in the presence or absence of: (I) the 4,5-trans-double bond (for example, sphingosine has a double bond whereas sphinganine (also referred to as dihydrosphingosine) does not); (ii) double bond(s) at other positions, such as position 8; (iii) a hydroxyl group at position 4 (D-1-hydroxysphinganine, also called “phytosphingosine”) or elsewhere (Robson et al., J. Lipid Res.
- methyl group(s) on the alkyl side chain or on the amino group such as N,N,-dimethylsphingosine
- acylation of the amino group for example ceramide (also referred to as N-acylsphingosine), and dihydroceramide (also referred to as N-acyl-sphinganine)
- the 4-hydroxysphinganines are the major long-chain bases of yeast (Wells, G. B. and Lester, R. L., J. Biol. Chem., 258:10200-10203, 1983), plants (Lynch, D. V., Lipid Metabolism in Plants (T. S.
- C 16 sphingosine is a substantial component of milk sphingomyelin
- Morrison Biochim. Biophys. Acta., 176:537-546, 1969.
- One difficulty in studying these compounds is that relatively few are commercially available in chemically-pure form.
- most of the sphinganine that can be purchased from various vendors is a mixture of the D and L enantiomers (therefore, commercially available dihydroceramides are also mixtures) and the metabolism, and some of the functions, of these compounds are sensitive to stereochemistry (Stroffel and Bister, Hoppe - Seyler's Z. Physiol. Chem.
- Sphingosines and other long-chain bases are cationic amphiphiles, which distinguishes them from most other naturally occurring lipids, which are neutral (including zwitterionic) or anionic. In the protonated form, they affect the phase behavior of both zwitterionic (Koiv et al., Chem. Phys. Lipids. 66:123-134, 1993; López-Garcia et al., Biochim. Biophys. Acta., 1194:281-288, 1994) and acidic (Koiv et al., Chem. Phys. Lipids, 66:123-134, 1993; López-Garcia et al., Biochim. Biophys. Acta. 1194:281-288, 1994) phospholipids.
- sphingolipids Many microorganisms, microbial toxins and viruses bind to cells via sphingolipids. Specific organisms that have been reported as binding to sphingolipids include cholera toxin (ganglioside GMI) (Thompson, et al., Biochem. Pharmacol. 56: 591-597, 1998); verotoxin (globosides) (Farkas-Himsley et al., Proc. Natl. Acad. Sci. (USA) 92: 6996-7000, 1995; Bast et al., Infect.
- cholera toxin ganglioside GMI
- verotoxin globosides
- bacteria utilize sphingolipids to adhere to cell.
- Escherichia coli galactosylceramide
- Bactet al. Infect. & Immun. 61: 2526-2531, 199; Payne et al., Infect. & Immun. 61: 3673-3677, 1993; Khan et al., Infect. & Immun. 64: 3688-3693, 1996
- Haemophilus influenzae gangliotetraosylceramide and gangliotriosylceramide
- Virus binding can be mediated via sphingolipids, including HIV-1 gp120 (galactosylceramide) (Fantini et al., J. Biol. Chem. 272: 7245-7252, 1997), Sendai virus (ganglioside GD1a) (Epand et al., Biochemistry 34: 1084-1089, 1995); and influenza viruses (gangliosides, sulfatides and polyglycosylceramides) (Fakih et al., Infect. & Immun.
- HIV-1 gp120 galactosylceramide
- Sendai virus ganglioside GD1a
- influenza viruses gangliosides, sulfatides and polyglycosylceramides
- Sphingolipids are significant components of foods.
- the types of sphingolipids differ among organisms (and for different types of cells within an organism); for examples, the predominant sphingolipid classes for plants are cerebrosides (Lynch, D. V., Lipid Metabolism in Plants (T. S. Moore, Jr., ed.), pp. 285-308, CRC Press, Boca Raton, Fla. 1993), ceramide phosphoinositols for yeast (Lester et al., Biochim. Biophys. Acta. 1165:314-320, 1993), and sphingomyelin (plus a wide spectrum of neutral and acidic glycolipids) for mammals (Hakomori, J. Biol. Chem.
- Sphingoid bases with a double bond at position 8 have been seen in mammalian sphingolipids (Karlsson, K. A., Chem. Phys. Lipids, 5:6-43, 1970), but have never been shown to be synthesized by mammalian cells; therefore, it is likely that they are acquired by mammals by consumption of plant sphingolipids.
- Sphingolipids not only help define the structural properties of membranes, but also play important roles in cell-cell and cell-substratum interactions, and help regulate growth and differentiation by a variety of mechanisms, such as inhibition of growth factor receptor kinases and effects on numerous cellular signal transduction systems (for reviews see Hakomori, J. Biol. Chem. 265:18713-18716, 1991; Bell et al., Advances in Lipid Research: Sphingolipids and Their Metabolites, vols. 25 and 26, Academic Press, San Diego, 1993; Merrill and Sweeley, New Comprehensive Biochemistry: Biochemistry ofLipids, Lipoproteins, and Membranes (Vance, D. E. & Vance, J.
- sphingosine activates and inhibits several protein kinases, and affects a large number of signal transduction systems.
- researchers thereafter uncovered additional bioactive sphingolipid “backbones” such as ceramides (Hannun, J. Biol. Chem. 269:3125-3128, 1994; Kolesnick, Cell 77:325-328, 1994), sphingosine 1-phosphate (Zhang et al., J. Cell Biol. 114:155-167, 1991; Spiegel et al., J. Lipid Mediators 8:169-175, 1993), and N-methyl-sphingosines (Igarashi, J. Biol. Chem.
- sphingolipids are important in membrane structure, especially specialized membrane functions such as are found in calveolae. They also interact with cell surface receptors for growth factors, and the extracellular matrix.
- the lipid backbones (ceramide, sphingosine and sphingosine 1-phosphate) function as “second messengers” to affect protein kinases, phosphoprotein phosphatases, ion transporters, and other regulatory machinery, as illustrated in FIG. 3.
- tumor necrosis factor- ⁇ , interleukin 1 ⁇ , and nerve growth factor induce sphingomyelin hydrolysis to ceramide as a second messenger (Hannun, J. Biol.
- Carcinogenesis involves progressive genetic mutations leading to the loss of cell growth regulation and, as importantly, loss of regulation of programmed cell death (apoptosis).
- the genetic abnormalities have been studied extensively for colorectal cancer and include activation of oncogenes and loss of tumor suppressor genes as cells progress from early premalignant lesions to carcinomas (Fearon and Vogelstein, 1990; Jen et al., 1994; Kinzler and Vogelstein, 1996), and a progressive inhibition of apoptosis (Bedi et al., 1995).
- ceramide (Okazaki et al., J. Biol. Chem. 265:15823-15831, 1990) can promote cell differentiation; and, ceramide (Obeid et al., Science 259:1769-1771, 1993; Hannun and Obeid, Trends Biochem. Sci. 20:73-77, 1995; Kolesnick and Fuks, 1995) as well as sphingosine (Ohta et al., Cancer Res. 55:691-697, 1995) can induce apoptosis, apparently through suppression of Bcl-2 (Sakakura et al., FEBS Lett. 379:177-180, 1996; Chen et al., Cancer Res.
- mice Female CF1 mice (6 weeks of age, 10 mice per group) were fed a standard, defined diet (AIN76A) (without sphingolipid supplementation), then treated with 1,2-dimethylhydrazine (DMH) in 6 weekly injections (40 mg/kg).
- DMH 1,2-dimethylhydrazine
- Sphingomyelin caused a significant (50%) reduction in the number of aberrant colonic crypts induced by DMH (Dillehay et al., J. Nutr. 124:615-620, 1994). All of the aberrant crypts were found in the distal third of the colon.
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice per group mice per group
- mice fed sphingomyelin had about half of the tumor incidence of the control.
- a control group fed sphingomyelin, but not treated with DMH had no signs of a deleterious effect of consumption of sphingolipids, and developed no tumors.
- sphingolipids and especially sphingosine and ceramide, are highly bioactive compounds with potential to serve as naturally occurring modulators of diverse cell behaviors that include neoplastic transformation.
- glycosphingolipids may be more effective than phosphosphingolipids because when they are hydrolyzed to a lysosphingolipid (such as psychosine for cerebrosides) the product is also cytotoxic, in contrast to lysosphingomyelin, which is mitogenic.
- U.S. Pat. Nos. 5,232,837 and 5,518,147 issued to Merrill, Wong, and Riley disclose a method of altering the metabolism of sphingolipids in a cell comprising exposure of the cell to fumonisins, or an analog thereof.
- Fumonisins are a family of mycotoxins produced by Fusarium moniliforme and related fungi that are common contaminants of maize, sorgum, and related grains. Fumonisins and sphingosine share a 2-amino-3-ol head group and possess backbone carbon chains of approximately equal size.
- sphingosine is hydroxyl-substituted at carbon I while fumonisin B 1 and B 2 are hydroxyl-substituted at carbon 5.
- the fumonisins possess polycarboxylate moieties attached to the tail of the backbone carbon chain. Similarities between sphingosine and Fumonisin in their head groups and tails are responsible for the activity of the fumonisins. It was discovered that fumonisin acts as an inhibitor of ceramide synthase, and thus alters the metabolism of the conversion of sphinganine to dihydroceramide.
- U.S. Pat. No. 5,190,876 and U.S. Pat. No. 5,459,057 to Merrill, Kinkade, and Stevens disclose a method and composition for enhancing the action of biological response modifiers, such as promoting cellular differentiation, by administration of an effective amount of Vitamin A or an analog thereof with sphingosine or an analog thereof.
- U.S. Pat. No. 5,635,536 to Lyons discloses emulsions suitable for administration of sphingolipids.
- sphingolipids play a fundamental role in a number of metabolic pathways, including cell proliferation and programmed cell death, it would be of benefit to provide new sphingolipid derivatives that have improved properties, bioavailability, or are targeted to desired locations for effective therapy.
- X, Y, V, and Q are independently hydrogen, OR 1 , NR 2 , CN, alkyl, acyl (i.e., C(O)R), carboxylate (i.e., OC(O)R), and wherein alternatively, V and Y, Y and Q or Q and A can together constitute a double or triple bond;
- W no substituent, H, alkyl, aryl, alkenyl, alkynyl, alkaryl, aralkyl, C(O)(CH 2 ) n CO 2 H, C(O)(CH 2 ) n CW′ 2 CO 2 H, or OR 1 ;
- W′ is selected independently from H, alkyl, aryl, (CH 2 ) n CO 2 H; (CH 2 ) n CH(CO 2 H)CH 2 CO 2 H; and (CH 2 )nCH(CO 2 H)CH(CH 2 CO 2 H)CO 2 H;
- Z is H, O, NH, NR, NHC(O), C(O)OR 1 , C(O)NH, or C(O)NR;
- R is selected independently from H, alkyl, acyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, or heteroaryl;
- R 1 is R or R 2 ;
- R 2 is phosphate (OP(OR 3 ), wherein at least one R is not hydrogen), b-D-galactoside, N-acetyl-b-D-glucosamine, a-D-mannoside, an organic azo-bond containing moiety that can be reduced by an azoreductase, b-D-cellobiosides, b-D-glucopyranosides, b-D-galactopyranosides, b-D-glucuronides, starch (such as maize starch, amylo-maize starch, pectin and others found in wheat flour, potato and beans), lactose, raffinose, stachyose, fructooligosaccharides (such as oligofructose and inulin), an amide or ester of b-cyclodextrin, dextran linked via succinate and glutarate, an amino acid or peptide, or a polyamino acid
- prodrugs which increase the level of active compound that is delivered to the active site of interest.
- the prodrug is cleaved by an appropriate enzyme in vivo to release a parent sphingolipid moiety for desired therapy.
- Certain derivatives of Formula I are especially suited for treatment of disorders of the lower intestinal tract, including but not limited to colon cancer, intestinal polyps, intestinal tumors, inflammatory bowel diseases including ulcerative colitis and Crohn's disease, necrotizing enterocolitis, and ileocecitis, other inflammations of the lower bowel, and antibiotic associated colitis, as the enzymes which free the sphingolipid from its prodrug form are concentrated in the lower intestine.
- These prodrugs are resistant to hydrolysis in the upper gastrointestinal tract, and are more readily cleaved in the cecum and the colon. This invention thus addresses the problem to date of low bioavailability of these important compounds at the target site.
- R 2 is a “targeting moiety” that binds to a receptor molecule on the target membrane's surface.
- targeting molecules include steroids, hormones (including but not limited to melanin), hormone receptors, cell specific receptors and ligands that bind to cell specific receptors (including but not limited to sugars, proteins, peptides, and glycoproteins), antibodies (for example, the Her 2-Nu antibody for the treatment of breast cancer), antibody fragments (such as the Fab or Fab 2 antibody fragments), antigens, T-cell receptor fragments including T-cell receptor variable regions.
- a steroid that binds to the membrane of a cancer cell is used as the targeting moiety.
- the active compounds are administered in an effective amount to alter sphingolipid metabolism, and thus are useful in the treatment of abnormal cell proliferation, including tumors, cancer, psoriasis, and familial polyposis; in the promotion of cell differentiation, in the induction of apoptosis, in the inhibition of protein kinase C; and in the modification of the colonization of microflora that influence colon cancer and other intestinal disorders, and in the treatment of inflammatory conditions.
- These compounds either exhibit activity in themselves or act as a prodrug of a parent compound.
- the compounds can be administered alone or in combination with other biologically active compounds to achieve the desired effect.
- These compounds can in particular be used to treat infections caused by bacteria (gram negative and gram positive) and viruses which have receptors for sphingolipids as anchoring means for colonization.
- microorganisms that can be treated using this method include cholera toxin, verotoxin, Shiga-like toxin 2e, Clostridium botulinum type B neurotoxin, Escherichia coli, Haemophilus influenzae; Helicobacter pylori; Borrelia burgdorferi, Pseudomonas aeruginosa, Candida albicans , HIV, Sendai virus, and influenza viruses.
- an effective amount of a selected compound falling within the above formula is administered to decrease or prevent colonization of the selected microorganism.
- a derivative of a fumonisin that includes at least one covalently bound R 2 group.
- R 2 group a covalently bound R 2 group.
- These compounds are also useful in the treatment of abnormal cell hyperproliferation, including cancer and tumors, most notable when used in combination with other antitumor compounds.
- the derivatives can be used to target cells, including solid tumors such as colon or urogenital tract tumors including kidney, bladder, prostate, as well as the uterus and cervix, for enhanced therapy.
- sphingolipid derivatives are also useful for the modification of the colonization of microfora that influence colon cancer and other intestinal disorders.
- sphingoid bases including naturally occurring compounds that share this structural motif, such as the fumonisins
- these compounds are thus useful in the treatment of any disorder which is mediated by, or benefited by, regulation of cell growth, differentiation, and/or induction of cell death.
- treatment with sphingolipids has been shown to down-regulate Bcl-2 levels, which further sensitizes cancer cells to apoptosis induced by other apoptotic stimuli including chemotherapeutic drugs, ⁇ -radiation and Fas ligand. Therefore, treatment with sphingolipids sensitizes cancer cells simultaneously by promoting the cytosolic accumulation of cytochrome c and by down-regulating Bcl-2, which acts as a barrier to this event.
- FIG. 1 is an illustration of the stereochemical configuration of sphingosine.
- FIG. 2 is an illustration of the structure, metabolic reactions, and biological activities of the representative sphingolipids sphinganine, dihydroceramide, ceramide, sphingomyelin, ceramide, and sphingosine.
- FIG. 3 is an illustration of bioactive sphingolipids, such as ganglioside G M3 , lactosylceramide, sphingomyelin, ceramide, sphingosine and sphingosine 1-phosphate.
- bioactive sphingolipids such as ganglioside G M3 , lactosylceramide, sphingomyelin, ceramide, sphingosine and sphingosine 1-phosphate.
- FIG. 4 is an illustration of biological pathways that include sphingolipids.
- FIGS. 5 ( a ) and 5 ( b ) are illustrations of representative fumonisins.
- FIG. 6 is a schematic of one example of a synthesis of saturated and unsaturated 3-O-benzoylceramides (8a,b), key intermediates in the syntheses of glyco- and phosphosphingolipids.
- This process can be adapted for the preparation of other 3-O-protected ceramides (Acetyl, Pivaloyl, t-Butyldimethylsilyl, t-Butyl-diphenylsilyl), commonly used in the syntheses of sphingomyelins and glycosphingolipids.
- FIG. 7 is a schematic of a synthesis of sphingomyelins that involves a phosphite triester.
- the scheme includes the steps of phosphitilation of 3-O-benzoylceramides (8a,b) with chloro(N,N-diisopropylamino)-methoxyphosphine in the presence of triethylamine, the condensation of the crude amidites (13a,b) with 4-5-times excess of tosylate choline in the presence of 1H-tetrazole, oxidation with tert-butylhydroxyperoxide and removing of the blocking groups in the phosphoric acid residue with tert-butylamine and hydroxy group at C3 with sodium methoxide.
- FIGS. 8 and 9 together are a schematic of a synthesis of ⁇ -D-glucuronylceramide (23).
- FIG. 8 illustrates the preparation of protected imidate (22) using literature procedures, which include the treatment of commercially-available D-glucuronolactone (18) with sodium methoxide in methanol, following the acetylation of methyl ester (19) with acetic anhydride, hydrolysis of ⁇ -acetoxyglucuronic acid methyl ester (20) with hydrazine acetate, and treatment of the resulting hemiacetal (21) with trichloroacetonitrile.
- FIG. 9 illustrates the glycosylation and deprotection steps of the synthesis.
- FIG. 10 is a schematic of one example of the preparation of an intermediate 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (30) which can be used in the synthesis of polar sphingolipids.
- FIG. 11 is a schematic of the synthesis of sphingosine from key intermediate 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (30).
- FIG. 12 is a bar chart graph of the percent inhibition of aberrant crypt foci formation by glucuronoylceramide as a function of percent of glucuronoylceramide in the diet in mice.
- FIGS. 13 a and b are bar chart graphs of the reduction of cell proliferation by glucuronoylceramide as a function of percent of glucuronoylceramide in the diet in mice in the upper half of colonic crypts (13a) and the lower half of colonic crypts (13b).
- FIG. 14 is a graph of treatment concentration in micromolar of sphingosine, sphinganine and 1-deoxy-5-hydroxy-sphinganine versus the optical density of formazan crystals as a means to illustrate the induction of cell death by sphingolipids as shown by MTT assay.
- the present invention includes derivatives and analogs of sphingolipids and fumonisins (referred to below as “sphingolipid metabolism altering compounds”), and pharmaceutical compositions and salts thereof, as well as methods to modify cellular metabolism, including by inhibiting abnormal cell proliferation, promoting cell differentiation, inducing apoptosis, modifying the colonization of microfora that influence colon cancer and other intestinal disorders, inhibiting protein kinase C activity, decreasing inflammatory reactions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue that includes administering an effective amount of the sphingolipid metabolism altering compound to a host animal in need thereof, either alone or in combination with another bioactive agent.
- X, Y, V, and Q are independently hydrogen, OR 1 , NR 2 , CN, alkyl, acyl (i.e., C(O)R), carboxylate (i.e., OC(O)R), and wherein alternatively, V and Y, Y and Q or Q and A can together constitute a double or triple bond;
- W no substituent, H, alkyl, aryl, alkenyl, alkynyl, alkaryl, aralkyl, C(O)(CH 2 ) n CO 2 H, C(O)(CH 2 ) n CW′ 2 CO 2 H, or OR 1 ;
- W′ is selected independently from H, alkyl, aryl, (CH 2 ) n CO 2 H; (CH 2 ) n CH(CO 2 H)CH 2 CO 2 H; and (CH 2 )nCH(CO 2 H)CH(CH 2 CO 2 H)CO 2 H;
- Z is H, O, NH, NR, NHC(O), C(O)OR, —C(O)NH, or C(O)NR;
- R is selected independently from H, alkyl, acyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, or heteroaryl;
- R 1 is R or R 2 ;
- R 2 is phosphate (OP(OR 3 ), wherein at least one R is not hydrogen), b-D-galactoside, N-acetyl-b-D-glucosamine, a-D-mannoside, an organic azo-bond containing moiety that can be reduced by an azoreductase, b-D-cellobiosides, b-D-glucopyranosides, b-D-galactopyranosides, b-D-glucuronides, starch (such as maize starch, amylo-maize starch, pectin and others found in wheat flour, potato and beans), lactose, raffinose, stachyose, fructooligosaccharides (such as oligofructose and inulin), an amide or ester of b-cyclodextrin, dextran linked via succinate and glutarate, an amino acid or peptide, or a polyamino acid
- R 2 is a biologically active molecule linked to a second “targeting molecule” either directly or through a linking moiety, including, but not limited to A.
- the targeting molecule is a moiety that binds to a receptor molecule on the target membrane's surface, as described in more detail below.
- a derivative of a fumonisin includes at least one covalently bound R 2 group.
- Fumonisins are a family of mycotoxins produced by Fusarium moniliforme and related fungi that are common contaminants of maize, sorgum, and related grains. Fumonisins, and their analogs, are known to affect the biosynthetic pathway of sphingolipids. Fumonisins and their analogs are generally referred to collectively as “fumonisin” or “fumonisins” herein.
- the present invention provides a method of altering the metabolism of sphingolipids in a cell comprising contacting the cell with a metabolism altering amount of a fumonisin, or an analog thereof, that includes at least one covalently bound R 2 group, either directly or through a spacer group.
- a fumonisin or an analog thereof, that includes at least one covalently bound R 2 group, either directly or through a spacer group.
- “Fumonisin analog” means any compound which has structural similarity to fumonisin B 1 , B 2 , B 3 , or B 4 and can alter the metabolism of sphingolipids.
- structural similarity to a fumonisin refers to three basic units as given in FIG.
- alkyl refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon of C 10 to C 20 , and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.
- the alkyl group can be optionally substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., “Protective Groups in Organic Synthesis,” John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.
- protected refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes.
- oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
- aryl refers to phenyl, biphenyl, or naphthyl, and preferably phenyl.
- the aryl group can be optionally substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, halo, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., “Protective Groups in Organic Synthesis,” John Wiley and Sons, Second Edition, 1991.
- alkaryl or alkylaryl refers to an alkyl group with an aryl substituent.
- aralkyl or arylalkyl refers to an aryl group with an alkyl substituent.
- halo includes chloro, bromo, iodo, and fluoro.
- heteroaryl or heteroaromatic refers to an aromatic moiety that includes at least one sulfur, oxygen, or nitrogen in the aromatic ring.
- Non-limiting examples are furyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isoxazolyl, pyrrolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolinyl, phthala
- Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.
- alkenyl refers to a straight, branched, hydrocarbon of C 2 to C 20 with at least one double bond.
- acyl refers to moiety of the formula —C(O)R 3 , wherein R 3 is alkyl; aryl, alkaryl, aralkyl, heteroaromatic, alkoxyalkyl including methoxymethyl; arylalkyl including benzyl; aryloxyalkyl such as phenoxymethyl; aryl including phenyl optionally substituted with halogen, C 1 to C 4 alkyl or C 1 to C 4 alkoxy, or the residue of an amino acid.
- the acyl group is the residue of a saturated or unsaturated fatty acid.
- fatty acid refers to a long chain (C 6 to C 26 ) aliphatic carboxylic acid, including saturated and unsaturated acids, including ⁇ -hydroxy fatty acids.
- Non-limiting examples of fatty acids are lauric, oleic, caproic, linoleic, linolenic, caprylic, capric, perlargonic, neononanoic, neodecanoic, palmitelaidoic, myristic, palmitic, stearic, arachidic, behenic, lignoceric, heptanoic, nonanoic, undecanoic, tridecanoic, pentadecanoic, heptadecanoic, nonadecanoic, heneicosanoic, tricosanoic, arachidonic, docosahexanoic, elaidic, erucic, nervonic, palmitoleic and petriselinic acid.
- enantiomerically enriched refers to a compound that is a mixture of enantiomers in which one enantiomer is present in excess, and preferably present to the extent of 95% or more, and more preferably 98% or more, including 100%.
- amino acid includes naturally occurring and synthetic amino acids, and includes but is not limited to, alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, and histidinyl.
- salts refers to salts that retain the desired biological activity of the herein-identified compounds and exhibit minimal undesired toxicological effects.
- Non-limiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid; (b) base addition salts formed with metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with
- the active compounds are administered in an effective amount to alter sphingolipid metabolism, and thus are useful in the treatment of abnormal cell proliferation, including tumors, cancer, psoriasis, and familial polyposis; in the promotion of cell differentiation, in the induction of apoptosis, in the treatment of infections caused by microorganisms which have sphingolipid receptors which allow colonization of the microorganism; in the modification of microfora that influence colon cancer and other intestinal disorders; in the inhibition of protein kinase C activity, and in the treatment of inflammatory conditions including psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue.
- These compounds either exhibit activity in themselves or act as a prodrug of a parent compound.
- the compounds can be administered alone or in combination with other biologically active compounds to achieve the desired effect.
- the compound is 1-deoxy-5-hydroxy-sphinganine, wherein at least one R 2 is covalently bound to either hydroxyl group or the amino function of the molecule.
- sphingolipids as therapeutic agents are those that they can be metabolized before they reach the target location. This can be a particular problem if the target location is distant from the site of administration. For example, perhaps only 5-10% of a sphingolipid reaches the lower intestine in the delivered form. Since sphingolipids of milk origin have been determined to have a therapeutic effect on intestinal tumors, the low bioavailability to that region is troublesome.
- Certain derivatives of Formula I are especially suited for treatment of disorders of the lower intestinal tract, including but not limited to colon cancer, intestinal polyps, intestinal tumors, inflammatory bowel diseases including ulcerative colitis and Crohn's disease, necrotizing enterocolitis, ileocecitis, other inflammations of the lower bowel, and antibiotic associated colitis, as the enzymes which free the sphingolipid from its prodrug form are concentrated in the lower intestine.
- These prodrugs are resistant to hydrolysis in the upper gastrointestinal tract, and are more readily cleaved in the cecum and the colon. It is not necessary that the compound undergo no metabolism in the upper GI tract, rather, that a sufficient portion survive and be cleaved in the colon. It should also be noted that this same approach can apply to the delivery of prodrug sphingolipids or analogs or physiological derivatives thereof via other routes, including blood circulation.
- the glucuronide of the compounds of Formula I are cleaved by the colonic beta-glucuronidase(s).
- Phosphodiesterases can cleave the disclosed phosphosphingolipids.
- Sphingomyelinase can act on sphingomyelin derivatives, as well as ceramide phospho-inositols.
- the b-D-galactoside derivatives of Formula I can be cleaved by b-D-galactosidase.
- N-acetyl-b-D-glucosamine derivatives can be acted on by N-acetyl-b-D-glucosaminidase.
- the a-D-mannoside derivatives of Formula I are substrates for a-D-mannosidase.
- the organic azo-bond containing moiety can be reduced by an azoreductase.
- the b-D-cellobiosides, b-D-glucopyranosides, b-D-galactopyranosides, and b-D-glucuronides are substrates for glycosylhydrolases.
- Multiple enzymes from colonic bacteria are able to digest starch (such as maize starch, amylomaize starch, pectin and others found in wheat flour, potato and beans).
- Multiple enzymes of colonic bacteria are also capable of cleaving lactose, raffinose, stachyose, and fructooligosaccharide (such as oligofructose and insulin) derivatives of Formula I.
- Compounds of Formula I which are amides and esters of b-cyclodextrin or dextrans linked via succinate and glutarate are substrates for amidases and esterases.
- Derivatives of compounds of Formula I which are poly(L-aspartic acid) and other amino acids and peptides are substrates for peptidases and esterases.
- the active compound which is a substrate for the colonic enzyme can be administered by any suitable means, including orally.
- the active compound is administered in a way that promotes the intestinal microflora that produce the enzymes that cleave these pro-drugs.
- the active compound (such as the ⁇ -glucuronide of ceramide) contains a group that is poorly cleaved by enzymes in the upper intestine, but will be acted upon by enzymes produced by microorganisms in the colon.
- the active compound can be co-administered with another sphingolipid analog (such as a fumonisin) that alters the metabolism of the active compound to promote better delivery to the target tissue and/or a longer tissue lifetime.
- another sphingolipid analog such as a fumonisin
- a method for the delivery of a biologically active molecule to a specific site, for example, a plasma membrane surface or a nucleus of a particular cell type.
- a biologically active molecule is linked to a second “targeting molecule” either directly or through a linking moiety, including, but not limited to A.
- the targeting molecule is a moiety that binds to a receptor molecule on the target membrane's surface.
- steroids can be used to deliver chemotherapy to a variety of pathogenic cells.
- examples include estrogens or testosterone (for malignant breast and prostate tumors), sex hormones (responsive sebaceous and pilosebaceous units); and corticosteroids (lymphocytes, antigen presenting cells and other immune cells, etc.).
- antibody includes monoclonal and polyclonal antibodies as well as antibody fragments which bind specifically but reversibly to a desired epitope on a target abnormally proliferating cell. It is preferred that the monoclonal antibody or monoclonal antibody fragment is derived from a monoclonal antibody or antibody fragment. Preparation of monoclonal and polyclonal antibodies to an antigen can be achieved using any known method, and for example, those described in Zola, H., “ Monoclonal Antibodies—A manual of techniques” CRC Press (1988), and Antibodies: A Laboratory Manual, Harlow & Lane; Cold Spring Harbor (1988), incorporated herein by reference.
- animals are immunized with the antigen, and preferably an adjuvant.
- Booster immunizations are optionally continued with antigen in PBS and mixed with adjuvant at periodic intervals.
- the animals are then bled following the immunizations.
- the serum can be assayed by ELISA (enzyme-linked immunosorbent assay).
- ELISA enzyme-linked immunosorbent assay
- spleens are harvested from animals immunized with the antigen, and preferably an adjuvant.
- Spleen cells are separated and fused with immortal myeloma cells using polyethylene glycol.
- the fused hybridoma cells are selected and cultured in vitro.
- the hybridoma cell culture fluids are tested for the presence of hybridoma antibodies having the desired specificity.
- the selection technique for identifying the appropriate monoclonal or polyclonal antibody is an important aspect in obtaining desired immunospecificity.
- the hybridoma cells can be tested for the presence of antibodies specific for the antigen, for example, with an ELISA conducted by standard methods.
- variable heavy (V H ) and variable light (V L ) domains of the antibody are involved in antigen recognition, a fact first recognized by early protease digestion experiments. Further confirmation was found by “humanization” of rodent antibodies. Variable domains of rodent origin can be fused to constant domains of human origin such that the resultant antibody retains the antigenic specificity of the rodent parented antibody (Morrison et al., Proc. Nat. Acad. Sci. USA, 81:6851-6855, 1984). “CDR grafting” can be used to humanize rodent antibodies. Additionally or alternatively, recombinant monoclonal antibodies may be “primatized,” i.e.
- variable regions are derived from two different primate species, preferably the variable regions of the antibody from the macaque monkey, and the constant regions from human.
- the advantages of such antibodies include high homology to human immunoglobulin, presence of human effector functions, reduced immunogenicity and longer serum half-life (Newman et al. Biotechnology, 10:1455, 1992).
- the region specific for the antigen can be expressed as part of a bacteriophage, for example, using the technique of McCafferty et al. Nature, 348:552-554, 1990.
- Antibody-like molecules of the invention can be selected from phage display libraries using the methods described in Griffiths et al. EMBO J., 12:725-734, 1993. in which the antigens are immobilized and used to select phages. Also, appropriate cells grown in monolayers and either fixed with formaldehyde or glutaraldehyde or unfixed can be used to bind phages. Irrelevant phages are washed away and bound phages recovered by disrupting their binding to the antigen and reamplifying in bacteria. This selection and amplification process is done several times to enrich the phage population for those molecules which are the antibody-like molecules of the invention.
- Antibody fragments include Fab-like molecules (Better et al. Science 240:1041, 1988); Fv molecules (Skerra et al., Science. 240:1038 1988); single-chain Fv (ScFv) molecules where the V H and V L partner domains are linked via a flexible oligopeptide (Bird et al., Science. 242:423, 1988) Huston et al., Proc. Natl. Acad. Sci. USA. 85:5879 1988) and single domain antibodies (dAbs) comprising isolated V domains (Ward et al., Nature. 341:544 1989).
- dAbs single domain antibodies
- Antibody fragments including but not limited to Fab, (Fab) 2 , Fv, scFv and dAb fragments are included in this invention.
- Antibody-like molecules can be prepared using the recombinant DNA techniques of WO 84/03712, the disclosure of which is herein incorporated by reference.
- the antibody can be coupled, i.e., conjugated, to a sphingolipid or a sphingolipid metabolism altering compound.
- conjugates have a “binding portion,” which consists of the antibody of the invention, and a “functional portion,” which consists of the sphingolipid or sphingolipid metabolism altering compound.
- the binding portion and the functional portion can be separated by a linking or spacing moiety.
- the binding portion and the functional portion of the conjugate can be linked together by any of the conventional ways of cross-linking polypeptides, such as those generally described in O'Sullivan et al., Anal. Biochem. 100: 100-108, 1979.
- one portion can be enriched with thiol groups and the other portion reacted with a bifunctional agent capable of reacting with those thiol groups, for example the N-hydroxysuccinimide ester of iodoacetic acid (NHIA) or N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP).
- Amide and thioether bonds for example achieved with m-maleimidobenzoyl-N-hydroxysuccinimide ester, are generally more stable in vivo than disulfide bonds.
- the binding portion contains carbohydrates, such as would be the case for an antibody or some antibody fragments
- the functional portion can be linked via the carbohydrate portion using the linking technology in EP 0 088 695.
- the functional portion of the conjugate can be or include an enzyme for converting a prodrug into a drug, using technology similar to that described by Bagshawe and his colleagues (Bagshawe, Br. J. Cancer. 56: 531, 1987; Bagshawe et al., Br. J. Cancer. 58: 700, 1988; WO 88/07378). It may not be necessary for the whole enzyme to be present in the conjugate but, of course, the catalytic portion must be present. So-called “abzymes” can be used, in which a monoclonal antibody is raised to a compound involved in the reaction one wishes to catalyze, usually the reactive intermediate state. The resulting antibody can then function as an enzyme for the reaction.
- Non-limiting examples of enzymes that can be used in this manner include beta-glucuronidase(s), phosphodiesterases, sphingomyelinase, b-D-galactosidase, N-acetyl-b-D-glucosamimidase, ⁇ -D-mannosidase, azoreductase, glycosylhydrolases, amidases, peptidases, and esterases.
- the conjugate can be purified by size exclusion or affinity chromatography, and tested for dual biological activities.
- the antigen immunoreactivity can be measured using an enzyme-linked immunosorbent assay (ELISA) with immobilized antigen and in a live cell radio-immunoassay.
- ELISA enzyme-linked immunosorbent assay
- An enzyme assay can be used for ⁇ -glucosidase using a substrate which changes in absorbance when the glucose residues are hydrolyzed, such as o-NPG (o-nitrophenyl- ⁇ -D-glucopyranoside), liberating 2-nitrophenol which is measured spectrophotometrically at 405 nm.
- Stability of the conjugate can be tested in vitro initially by incubating at 37° C. in serum, followed by size exclusion HPLC analysis. Stability in vivo can be tested in the same way in mice by analyzing the serum at various times after injection of the conjugate. In addition, it is possible to radiolabel the antibody with 125 I, and the enzyme with 125 I before conjugation, and to determine the biodistribution of the conjugate, free antibody and free enzyme in mice.
- the conjugate can be produced as a fusion compound by recombinant DNA techniques whereby a length of DNA comprises respective regions encoding the two portions of the conjugate either adjacent to one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.
- a length of DNA comprises respective regions encoding the two portions of the conjugate either adjacent to one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.
- the two functional portions of the compound can overlap wholly or partly.
- the DNA is then expressed in a suitable host in known ways.
- the antibody conjugates can be administered in any suitable way, usually parenterally, for example intravenously or intra peritoneally, in standard sterile, non-pyrogenic formulations of diluents and carriers, for example isotonic saline (when administered intravenously).
- diluents and carriers for example isotonic saline (when administered intravenously).
- the conjugate Once the conjugate has bound to the target cells and been cleared from the bloodstream (if necessary), which typically takes a day or so, if the conjugate is an antibody/enzyme or abzyme conjugate, the sphingolipid prodrug can be administered, usually as a single infused dose. If needed, because the conjugate can be immunogenic, cyclosporin or some other immunosuppressant can be administered to provide a longer period for treatment but usually this will not be necessary.
- the present invention includes a method of altering the metabolism of sphingolipids in a cell comprising contacting the cell with a metabolism altering amount of a compound of the Formula I, or a pharmaceutically acceptable salt thereof, or with a fumonisin derivative to which is covalently bound, either directly or indirectly, an R 2 group, collectively referred to as “sphingosine metabolic altering compounds.”
- sphingolipids mediate a number of fundamental pathways in vivo.
- the sphingolipid metabolic altering compounds can be used to alter these pathways.
- the compounds inhibit “ceramide synthase,” which is an enzyme or enzymes which add in N-acyl linkage to sphingosine, sphinganine and other long-chain bases.
- ceramide synthase an enzyme or enzymes which add in N-acyl linkage to sphingosine, sphinganine and other long-chain bases.
- ceramide synthase both sphinganine N-acyltransferase, which catalyzes in the conversion of sphinganine to dihydroceramide
- sphingosine N-acyltransferase which catalyzes the conversion of sphingosine to ceramide
- analog of dihydroceramide or ceramide means a compound which can be catalyzed by a fumonisin or an analog.
- the catabolism of sphingosine and other bioactive “sphingoid bases” can be blocked by administration of an inhibitor of sphingosine kinase,
- “Altering the metabolism” as used herein means either an increase or a decrease in the concentration of the metabolites of both the sphingolipid biosynthetic and catabolic pathways.
- ceramide synthase sphinganine-N-acyltransferase
- ceramide synthase sphinganine-N-acyltransferase
- ceramide synthase sphinganine-N-acyltransferase
- the concentration of any compound above the site of action can be increased and the concentration of any compound below the site of action can be decreased using the fumonisin or fumonisin analog.
- the amounts of various compounds of the pathway can depend on the time period after inhibition or their relationship to other related pathways.
- a fumonisin can bind sphingosine-N-acyltransferase, which would increase the amount of sphingosine by preventing the conversion back to ceramide and a fumonisin can also bind ceramide synthase (sphinganine-N-acyltransferase), which would decrease the amount of sphingosine by decreasing the amount of ceramide which can be converted to sphingosine.
- the fumonisin can cause both the increase and/or decrease of sphingosine, depending on which pathway is dominant. Such increases or decreases at various times after fumonisin ingestion can be routinely determined by standard methods.
- Methodabolism altering amount means a quantity of a sphingolipid metabolism altering compound capable of effecting a change in the sphingolipid metabolism in cells. This amount can vary depending on the environment in which the cells are contained. For in vivo administration, the precise quantity of the compound to elicit the desired effect can be determined by standard administration and monitoring until optimal dosage is determined. Such amounts can vary from subject to subject depending on size and condition of the subject.
- the invention also provides a method for treating an abnormal condition in a subject associated with an alteration in sphingolipid metabolism.
- This method comprises administering a sphingolipid metabolism altering compound, or an analog thereof, to the subject in a metabolism altering amount.
- the subject can be a human or a non-human animal and the abnormal condition can be caused by numerous disorders in sphingolipid metabolism.
- the condition can be an access of sphingosine resulting in Neimann-Picks syndrome, Tay-Sachs disease, a neoplastic condition or toxicity.
- the effect of the sphingolipid metabolism altering compound may be complex.
- the sphingolipid metabolism altering compound in a neoplastic condition, can, due to its structural similarity to sphingosine, prevent the formation of a sphingolipid required for growth of the cells and can also act as an inducer of differentiation and thus treat the neoplastic condition.
- the sphingolipid metabolism altering compound can be administered specifically to treat abnormal cell proliferation, and in particular, cell hyperproliferation.
- abnormal cell proliferation include, but are not limited to:
- benign tumors including, but not limited to papilloma, adenoma, firoma, chondroma, osteoma, lipoma, hemangioma, lymphangioma, leiomyoma, rhabdomyoma, meningioma, neuroma, ganglioneuroma, nevus, pheochromocytoma, neurilemona, fibroadenoma, teratoma, hydatidiform mole, granuosa-theca, Brenner tumor, arrhenoblastoma, hilar cell tumor, sex cord mesenchyme, interstitial cell tumor, and thyoma as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue;
- malignant tumors including but not limited to carcinoma, including renal cell carcinoma, prostatic adenocarcinoma, bladder carcinoma, and adenocarcinoma, fibrosarcoma, chondrosarcoma, osteosarcoma, liposarcoma, hemangiosarcoma, lymphangiosarcoma, leiomyosarcoma, rhabdomyosarcoma, myelocytic leukemia, erythroleukemia, multiple myeloma, glioma, meningeal sarcoma, thyoma, cystosarcoma phyllodes, nephroblastoma, teratoma choriocarcinoma, cutaneous T-cell lymphoma (CTCL), cutaneous tumors primary to the skin (for example, basal cell carcinoma, squamous cell carcinoma, melanoma, and Bowen's disease), breast and other tumors infiltrating the
- preneoplastic lesions mycosis fungoides, psoriasis, dermatomyositis, rheumatoid arthritis, viruses (for example, warts, herpes simplex, and condyloma acuminata), molluscum contagiosum, premalignant and malignant diseases of the female genital tract (cervix, vagina, and vulva).
- viruses for example, warts, herpes simplex, and condyloma acuminata
- molluscum contagiosum premalignant and malignant diseases of the female genital tract (cervix, vagina, and vulva).
- the compounds can also be used to induce abortion.
- the sphingolipid metabolism altering compound is administered in an effective treatment amount to decrease the hyperproliferation of the target cells.
- the sphingolipid metabolism altering compound can be modified to include a targeting moiety that concentrates the compound at the active site.
- Targeting moieties can include an antibody or antibody fragment that binds to a protein on the surface of the target cell, including but not limited to epidermal growth factor receptor (EGFR), c-Esb-2 family of receptors and vascular endothelial growth factor (VEGF).
- EGFR epidermal growth factor receptor
- VEGF vascular endothelial growth factor
- the compounds when used as an antiproliferative, can be administered in combination with another compound that increases the effectiveness of the therapy, including but not limited to an antifolate, a 5-fluoropyrimidine (including 5-fluorouracil), a cytidine analogue such as ⁇ -L-1,3-dioxolanyl cytidine or ⁇ -L-1,3-dioxolanyl 5-fluorocytidine, antimetabolites (including purine antimetabolites, cytarabine, fudarabine, floxuridine, 6-mercaptopurine, methotrexate, and 6-thioguanine), hydroxyurea, mitotic inhibitors (including CPT-11, Etoposide (VP-21), taxol, and vinca alkaloids such as vincristine and vinblastine, an alkylating agent (including but not limited to busulfan, chlorambucil, cyclophosphamide, ifofamide, mech
- an alkylating agent
- the compounds of the present invention can also be used in combination with enzyme therapy agents and immune system modulators such as an interferon, interleukin, tumor necrosis factor, macrophage colony-stimulating factor and colony stimulating factor.
- Certain sphingoid bases are known to induce the DNA fragmentation and morphologic features of apoptosis in cancer and leukemia cells.
- Apoptosis is the active and gene-directed form of cell death, with well-characterized biochemical and morphologic features.
- the biochemical features include the generation of lethal and large-sized or endonucleolytic internucleosomal DNA fragmentation.
- the morphologic features include cell-shrinkage, chromatin condensation and membrane-bound apoptotic bodies.
- Apoptosis is triggered by the activation of a family of aspartate-specific cysteine proteases designated as caspases. There is a growing list of substrates that are cleaved and degraded by caspases.
- caspase-3 the key caspase that is cleaved and activated early in the molecular cascade is caspase-3 (CPP32 ⁇ /Yama).
- Caspase activity results in the degradation of lamins, poly (ADP-ribose) polymerase (PARP), PKC ⁇ , Rb protein, DNA-PK, ⁇ -actin, fodrin, gel solution, etc., resulting in the morphologic and biochemical features of apoptosis.
- PARP poly (ADP-ribose) polymerase
- PKC ⁇ polymerase
- Rb protein DNA-PK
- ⁇ -actin ⁇ -actin
- fodrin ⁇ -actin
- gel solution etc.
- caspase-3 cleavage and activity is initiated by the cytosolic accumulation of cytochrome c (cyt c) released from mitochondria, which is triggered by apoptotic stimuli as a pre-apoptotic event.
- the gene-product of the anti-apoptotic Bcl-2 gene is localized to the outer mitochondrial membrane, where it blocks the egress of cyt c from mitochondria, thereby preventing the generation of caspase-3 cleavage and activity and resulting apoptosis.
- Down-regulation of Bcl-2 levels tilts the balance and sensitizes cells to undergo apoptosis.
- sphingoid bases including the sphingolipid metabolism altering compounds described herein, trigger the release of cytochrome c from mitochondria into the cytosol, resulting in the cleavage and activity of caspase-3 and apoptosis.
- treatment with sphingosine has been shown to down-regulate Bcl-2 levels, which further sensitizes cancer cells to apoptosis induced by other apoptotic stimuli including chemotherapeutic drugs, ⁇ -radiation and Fas ligand. Therefore, treatment with sphingosine may sensitize cancer cells simultaneously by promoting the cytosolic accumulation of cytochrome c and by down-regulating Bcl-2, which acts as a barrier to this event.
- the present invention includes a method to trigger the release of cytochrome c that includes administering an effective amount of a sphingolipid (for example those illustrated in FIGS. 1 and 2), or a sphingolipid metabolism altering compound, to a host in need thereof.
- Cytochrome c accumulation in the cytosol not only mediates apoptosis of cancer cells, but also apoptosis of T-lymphocytes that may be mediating anti-immune diseases or apoptosis of viral infected cells. Therefore, in these cells, cytochrome c accumulation in the cytosol due to sphingolipids such as sphingosine may also result in apoptosis of these cells thereby ameliorating the diseases they cause.
- apoptotic stimuli causes release of cytochrome c from the mitochondrial inner membrane space into the cytosol, where in the presence of dATP, and other cytosolic factors it promotes the cleavage and activity of caspase-3, degradation of a number of substrates and the DNA fragmentation of apoptosis (Liu, X., et al., Cell, 86: 147-157, 1996; Yang, J., et al., Science, 275: 1129-1132, 1997).
- cyt c release precedes mitochondrial membrane depolarization;
- cytosolic cyt c participates in activating caspase-3, whereas the 50 kD mitochondrial factor (AIF) directly induces apoptotic changes in the nuclei; and
- activated caspase-3 induces apoptotic changes in nuclei only in the presence of cytosol, and such changes can be blocked by the presence of sub-micromolar concentrations of the tetrapeptide caspase-3 inhibitor (Yang, J., et al., Science, 275: 1129-1132, 1997).
- AIF once released from mitochondria upon depolarization, functions without cytosol and is insensitive to the caspase-3 inhibitor (Kroemer, G., J. Exp. Med., 182: 367377, 1995).
- cyt c and AIF-mediated may work together to complete apoptosis.
- the pre-apoptotic mitochondrial perturbations include a rise in the reactive oxygen species (ROS) as well as the loss of ⁇ m (Kim, C. N., et al., Cancer Res., 57: 3115-3120, 1997).
- cyt c promotes the cleavage of caspase-3 in the presence of dATP and two additional apoptotic protease activation factors (APAF-1 and APAF-3) (Liu, X., et al., Cell, 86: 147-157, 1996). Therefore, down-regulation of intracellular Bcl-2 levels by sphingosine may abrogate the antiapoptotic activity of a number of proteins that exert their effects through Bcl-2. Also, the lowering of Bcl-2 levels may allow the proapoptotic Bax, Bak and Bcl-X s to exact their proapoptotic effects more efficiently.
- Caspase-3 activity has also been shown to cleave and activate a recently cloned DNA fragmentation factor (DFF), which results in the DNA fragmentation of apoptosis (Liu, X., et al., Cell, 89: 175, 1997). More recently, the gene encoding the human APAF-1 has been cloned and shown to possess, in its N terminus domains, sequence homology to the ced-4 and ced-3 genes of c. elegans, the latter gene being homologous to caspase-3 (Zou, H., Cell, in press).
- DFF DNA fragmentation factor
- Bcl-2 family of genes
- the prototype Bcl-2 gene encodes for p26Bcl-2 protein which inhibits apoptosis (Reed, J. C., Nature, 387: 773, 1997).
- chemotherapeutic agents as well as Fas death receptor apoptotic signaling (Tang, C., Leukemia, 8: 1960-1969, 1994; Kroemer, G., Nature Med., 3: 614-620, 1997).
- Bax is a member of the Bcl-2 family (Yang, E., et al., Blood, 88: 386-401, 1996). Bax dimerizes with Bcl-2, and the formation of Bax homodimers promotes apoptosis due to death signals (Yin, X. M., et al., Nature, 369: 321-323, 1994). Recent reports indicate that selected mutations within the conserved BH1 and BH2 regions of Bcl-2 disrupt its heterodimerization with Bax and abrogate the ability of Bcl-2 to inhibit apoptosis (Yin, X. M., et al., Nature, 369: 321-323, 1994; Zha, H., J. Biol.
- Bcl-2/Bax ratio is inherent to the cell, drugs—including taxanes—or other apoptotic stimuli may be able to reset this rheostat (Ibrado, A. M., et al, Cancer Res., 57: 1109-1115, 1997; Oltvai, Z. N., et al., Cell, 79: 189-192, 1994).
- a low ratio of Bcl-2 to Bax by increasing free Bax, promotes cell death due to taxanes (Oltvai, Z. N., et al., Cell, 79: 189-192, 1994; Strobel, T., et al., Proc. Natl. Acad. Sci.
- Bcl-x is another member of the Bcl-2 family and shares sequence homology with the conserved BH1 and BH2 regions of the Bcl-2 gene (Boise, L., Cell, 74: 597-608, 1993).
- Bcl-x encodes for two important protein isoforms of which the longer p29Bcl-x L inhibits apoptosis (Boise, L., Cell, 74: 597-608, 1993).
- the in vivo pattern of Bcl-XL expression is distinct form the Bcl-2 (Boise, L., Cell, 74: 597-608, 1993).
- p29Bcl-x L also renders cancer cells resistant to a variety of anticancer agents, including taxanes, Fas signaling, oxidants and radiation (Ibrado, A. M., et al., Cell Growth & Differ. 7: 1087-1094, 1996; Ibrado, A. M., et al., Cancer Res., 57: 1109-1115, 1997; Minn, A. J., et al., Blood 86: 1903-1910, 1995; Datta, R., et al., Cell Growth & Differ. 6: 363-370, 1995; Ibrado, A. M., Cancer Res., 56: 4743-4748, 1996).
- taxanes Fas signaling, oxidants and radiation
- Bcl-x L has also been shown to block apoptosis where Bcl-2 is ineffectual (Gottschalk, A. R., et al., Proc. Natl. Acad. Sci. USA, 91: 7350-7354, 1994).
- Bak a new member of the Bcl-2 family called Bak has also been isolated which like Bax promotes apoptosis (Keifer, M. C., et al, Nature, 374: 736-739, 1995). Bak heterodimerizes with Bcl-x L but not Bcl-2, and may also facilitate the generation of free Bax resulting in the formation of Bax homodimers (Keifer, M.
- Bag-1 which binds to Bcl-2 but is not its homolog, synergizes with Bcl-2 to inhibit apoptosis (Takayama, S., Cell, 80: 275-284, 1995).
- Bcl-x L has been shown to have two central hydrophobic helices surrounded by five amphipathic helices, as well as a 60-residue flexible loop domain (Muchmore, S. W., et al., Nature, 381: 335-341, 1996). This structure has homology to the pore-forming domains of bacterial toxins. Similarly, in the membranes, Bcl-x L forms an ion-conducting channel that displays multiple conductance states (Minn, A. J., et al., Nature, 385: 353-357, 1997).
- Bcl-x L conductance states of Bcl-x L , including a more complex large conductance channel, could result either from interaction with the other members of the pore-forming Bcl-2 families of proteins or from the distinct conformations that Bcl-x L may adopt (Minn, A. J., et al., Nature, 385: 353-357, 1997).
- the channel property of Bcl-x L may influence the mitochondrial permeability transition and other important mitochondrial functions (Zoratti, M., et al., Biochimica et Biophysica Acta, 1241: 139-176, 1994).
- Bcl-x L may facilitate the passage of other important proteins, such as cyt c, that trigger the cleavage and activity of caspase-3 and apoptosis (Golstein, P., Science, 275: 1081-1082, 1997). Interaction of Bcl-x L with Bax or other Bcl-2-related proteins could also influence the channel function of Bcl-x L for cyt c (Gajewski, T. F., et al., Cell, 87: 589-592, 1996).
- Bcl-2 and Bcl-x L by phosphorylation may also modulate its channel function, because Bcl-2 phosphorylation has been shown to be associated with an increase in free Bax levels and induction of apoptosis (Ibrado, A. M., et al., Cancer Res. 57: 1109-1115, 1997; Halder S., et al., Proc. Natl. Acad. Sci USA, 92: 4507-4511, 1995; Blagosklonny, M. V., et al., Cancer Res., 57: 130, 1997).
- Protein kinase C (calcium/phospholipid protein kinase; referred to below as PKC) catalyzes the phosphorylation of the amino acids serine and threonine (Edelman, A., et al., Ann. Rev. Biochem. 56:567, 1987).
- the enzyme was first characterized from brain tissue (Takei, et al., J. Biol. Chem. 252:3692, 1977) and is now known to occur in virtually all tissues of the body (Kuo, et al., Proc. Natl. Acad. Sci. USA. 97:7039, 1980). At least seven isozymes of PKC have been purified, cloned, and expressed.
- the isozymes of PKC have been shown to have a varying dependency on three allosteric modulators: Ca 2+ , phosphatidylserine, and diacylglycerol (Nishizuka, Y., Nature 334:661, 1988).
- the mechanism of PKC activation by diacylglycerol, Ca 2+ , and phospholipid is complex and not entirely understood.
- Inactive PKC is largely cytosolic, and upon activation, is rapidly translocated to biological membranes.
- Phosphatidylserine is the most effective phospholipid in activating PKC when added with diacylglycerol and probably serves to mimic a biological membrane to which active PKC always binds.
- DAG diacylglycerol
- the relative potencies of various phorbol esters to cause PKC translocation are similar to their stimulatory effects on white cell superoxide production (Myers, M., et al., J. Immunol. 135:3411, 1985).
- the bacterial cell wall-derived peptide, formyl-Met-Leu-Phe (fMLP), a very potent chemotactic factor for leukocytes increases membrane-associated PKC at concentrations that also stimulate respiratory burst (Pike, M., et al. Blood 67:909, 1986; McPhail, L., et al. Fed. Proc. 43:1661, 1984).
- interleukin-1 is a primary mediator of inflammatory diseases such as rheumatoid arthritis, and evidence exists to suggest that PKC mediates some of the effects of interleukin-1.
- a PKC inhibitor may be useful for treatment of inflammatory disease, blocking the effects of interleukin-1 as well as other inflammatory mediators such as bradykinin and substance P. Since activation of PKC serves as a powerful proliferative signal in many tissues, a PKC inhibitor may also be of utility in proliferative diseases such as psoriasis, cancer and other metastatic illnesses.
- a PKC inhibitor may find utility in certain neurological or endocrine diseases.
- a vascular PKC inhibitor may have utility as a therapy for essential hypertension.
- PKC inhibitors include sphingosine and certain related sphingolipids.
- This group of compounds compete with the phorbol ester binding site and thus have the potential for specificity.
- sphingosine also been reported to inhibit Ca 2+ /calmodulin protein kinase (Jefferson, A. and Schulman, H., J. Biol. Chem. 263:15241, 1988), but sphingosines may inhibit other biological processes in a nonselective manner (Pittet, D., et al., J. Biol. Chem. 262:10072, 1987; Winicov, I. and Gershengorn, M., J. Biol. Chem. 263:12179, 1988).
- a sphingolipid metabolic altering compound is administered in an effective treatment amount to inhibit protein kinase C in a host in need of treatment.
- R 2 is either one of the listed groups that can be cleaved by an enzyme in vivo, or wherein R 2 is a targeting moiety
- R 2 is a targeting moiety
- this targeting would be the feeding of complex sphingolipids that are digested in the colon to release the sphingoid base (for example, sphingosine) backbone, to inhibit protein kinase C in colon tumors.
- inflammatory disorders that are mediated by PKC can be treated by administration of an antiinflammatory treatment amount of a sphingolipid metabolism altering compound, or its pharmaceutically acceptable salt.
- An inflammatory response is a pathologic condition that can occur in response to immunologically non-specific injury, either from physical (such as trauma), chemical, or biologic agents.
- An inflammatory response is characterized by increased blood flow and redness in the inflamed area, increased capillary permeability and edema, and recruitment of immunologically non-specific white blood cells, especially neutrophils, that remove injurious material and promote repair.
- Cellular products of lymphocytes may contribute to or induce an inflammatory response.
- Examples of inflammatory disorders that may be treated by the sphingolipid metabolism altering compound include but are not limited to inflammatory bowel disease, psoriasis, proliferation of smooth muscle cells in the course of development of plaques in vascular tissue.
- the initial phase of anaphylaxis is due largely to degranulation and mediator release from mast cells (Friedman, M. and Kaliner, M., Am. Rev. Respir. Dis. 135:1157, 1987; Kaplan, A. and Silverberg, M., Methods Enzymol. 163:3, 1988).
- mediators including histamine and several eicosanoids, cause airway smooth muscle spasm, vasodilation and plasma extravasation, and are the major culprits in acute allergic inflammation.
- the biochemical mechanisms leading to cell activation subsequent to IgE binding to and cross-linking of its receptors on the mast cell surface are not completely understood.
- mast cell mediator release is calcium-dependent (Pearce, F., I. Asthma Reviews, I :95, edited by Morley J. (London: Academic Press Ltd., 1987)); (Siraganian, R., Inflammation: Basic Principles and Clinical Correlates, edited by Gallin, J., et al. (New York: Raven Press Ltd., 513, 1988)).
- Increased turnover of mast cell phosphoinositides (PI) following both IgE-mediated and pharmacological stimulation has been established (Pearce, F., I. Asthma Reviews, Volume 1, edited by Morley J. London: Academic Press Ltd., 95, 1987), and PI turnover closely correlates with histamine secretion.
- the PI response generates arachidonic acid, that is metabolized further to produce thromboxane, prostanoids and leukotrienes.
- the PI cycle generates DAG which, as has already been discussed, stimulates PKC.
- PKC acts synergistically in many cells to evoke the secretory response (Drummond, A. and Maclntyre, D., Trends Pharmacol. Sci. 6:233, 1985).
- phorbol esters by activating PKC, stimulate mediator secretion both from mast cells and basophils (Siraganian, R., Inflammation: Basic Principles and Clinical Correlates, 513, edited by Gallin, J., et al.
- sphingolipid analogs including but not limited to the compounds described herein, in the prodrug state or as metabolized, serves to (i) decrease the colonization of the microorganism, and (ii) modify the colonization of microfora that influence colon cancer and other disorders of the intestine.
- the compound binds to the sphingolipid receptor of the microorganism, saturating the receptor and facilitating elimination of the organisms and toxins.
- a process for modifying the colonization of microfora that influence colon cancer and other intestinal disorders comprises administering an effective amount of a sphingolipid derivative to a host.
- These compounds can in particular be used to treat infections caused by bacteria (gram negative and gram positive) and viruses which have receptors for sphingolipids as anchoring means for colonization.
- microorganisms that can be treated using this method include cholera toxin, verotoxin, Shiga-like toxin 2e, Clostridium botulinum type B neurotoxin, Escherichia coli, Haemophilus influenzae; Helicobacter pylori; Borrelia burgdorferi, Pseudomonas aeruginosa, Candida albicans , HIV, Sendai virus, and influenza viruses.
- an effective amount of a selected compound falling within the above formula is administered to decrease or prevent colonization of the selected microorganism.
- FIG. 6 illustrates a short seven-step synthesis of D-erythro-3-O-benzoylceramides (8a,b), that includes use of commercially available N-Boc-L-Ser-OMe (1) as the starting material.
- the synthesis provided yields of 27 and 31%, respectively.
- Phosphytilation with O-methyl-N,N-diisopropylaminophosphorochloridite was employed for the introduction of the phosphoryl choline moiety into (8a,b).
- tert-Butylhydroperoxide, DIBAL-H, n-BuLi (1.6 M solution in hexanes), LAH (1.0 M solution in THF) were purchased from Aldrich.
- Pentadecyne was purchased from Lancaster. Choline tosylate was purchased from Sigma or prepared from choline hydroxide (from Aldrich) and p-oluenesulfonic acid monohydrate. All melting points are uncorrected. Unless otherwise stated, IR spectra were recorded as a film with mineral oil on sodium chloride discs using an Impact 400 IR spectrometer and only the structurally important peaks are listed. 1 H and 13 C NMR spectra were recorded on a General Electric QE-300 (300 MHZ 1H, 75.5 MHZ 13 C) spectrometer in deuteromethanol and/or deuterochloroform. The positive and negative ion FAB mass spectra were taken on JEOL spectrometer.
- N-Palmitoylsphingomyelin D-erythro-2-N-Palmitoylsphingenine-1-phosphorylcholine (N-Palmitoylsphingomyelin) (17a).
- N-Palmitoylsphingomyelin 3-O-benzoylsphingomyelin (16a) (2.06 g, 2.55 mmol) in methanol (25 mL) was added 2M sodium methoxide solution in methanol (2.5 mL), and the reaction mixture was allowed to stir at 20-25° C. for 2 h.
- Coupling a protected alkynyl derivative to an oxazolidine aldehyde is an efficient and versatile preparation of sphingolipids with a polar terminus, such as an amine, hydroxyl, or carboxyl group. After the addition reaction, a terminal hydroxyl group is available for conversion into a variety of other functionality.
- These terminally polar sphingolipids are an important class of molecules because they can attach to a solid support creating an affinity column for enzymes (Raun, F., et al., Tetrahedron Lett., 36:6615, 1995; and Kozikowski, A., et al., Tetrahedron Lett., 37:3279, 1996). They are also interesting because they are structurally similar to a class of mycotoxins called the Fumonisins.
- the oxazolidine aldehyde (31) was prepared according to a procedure by Garner (Garner, P. et al., J. Org. Chem., 52:2361, 1987).
- the coupling of protected alkynyl derivatives to (31) was accomplished by first producing the litheate of the alkyne with LDA and then slowly adding (31).
- the propargyl alcohol (32) was protected as the acetate by treating with triethylamine and acetic anhydride.
- the silyl ether was cleaved by stirring (33) in the presence of an acidic resin, Amberlyst-15.
- the compound (33a) may be modified in several ways: oxidation to produce the acid or ester, fluorination, elimination, or substitution.
- an amine terminus was desired. This functionality was introduced by first preparing the mesylate of (34) by adding triethylamine and methansulfonyl chloride. Displacement of the mesylate with sodium azide in DMF produced compound (35). Azide reduction with thiophenol, tin chloride, and triethylamine gives (36). Reduction of the triple bond with Red-AI efficiently produces the E isomer (37).
- the same procedure for 8-nonyn-1-ol was followed with 3-heptyn-1-ol (7.96 g, 71.0 mmol), KH (8.54 g, 21.3 mmol), and 1,3-diaminopropane (70 mL).
- the same procedure for 8-nonyn-1-ol was followed with 9-dodecyn-1-ol (4.68 g, 25.7 mmol), KH (3.09 g, 77.0 mmol), and 1,3-diaminopropane (70 mL).
- oxazolidine alkyne (55) (2.89 g, 6.75 mmol) and CH 2 Cl 2 (50 mL).
- Et 3 N (1.71 g, 16.9 mmol
- Ac 2 O 9.827 g, 8.10 mmol
- a catalytic amount of DMAP (10 mg) was added and the reaction was stirred for 24 h.
- the reaction was poured into water and extracted with Et 2 O. The organic layers were combined, washed with water and brine, dried with MgSO 4 ; and concentrated.
- the acylated oxazolidine alkyne (56) (2.17 g, 4.61 mmol) was dissolved in MeOH (40 mL) in a 100 mL-flask. The solution was stirred with a magnetic stir bar under a nitrogen atmosphere and cooled to 0° C. Amberlyst-15 was washed with MeOH (20 mL) on a fritted glass funnel before being added to the solution in one portion. The reaction was stirred at 0° C. for 45 min before being warmed to room temperature and stirred for an additional hour. The reaction was filtered through celite and concentrated to give 1.85 g of pale yellow oil.
- N-Palmitoyl-FB 1 FB 1 (1 mg, 1.38 ⁇ mol) and 4.4 mg of palmitic anhydride (6.92 ⁇ mol) were dissolved in 1 ml of methanol (MeOH):CHCl 3 (1:1). The mixture was kept at room temperature for up to 48 hr. The reaction was checked by TLC using silica 60 TLC plates and CHCl 3 :MeOH:H 2 O (90:20:0.5) as solvent system. To detect fumonisins, the plates were sprayed with a 0.5% p-anisaldehyde solution in MeOH:acetic acid:sulfuric acid (85:10:5), heated to 100° C. for 10 minutes, and visually examined.
- N-Palmitoyl-AP 1 (the product of removal of the tricarballylic acids from FB 1 ) (0.91 mg, 2.67 ⁇ mol) and 5.3 mg of palmitic anhydride (10.68 ⁇ mol) were dissolved in 1.5 ml of MeOH:CHCl 3 (1:1). The mixture was kept at room temperature for up to 48 hr. The reaction was checked by TLC as described above. The reaction mixture (0.5 ml) was applied to a SiO 2 SPE column (waters, 500 mg capacity), which was preconditioned with CHCl 3 . The minicolumn was washed with 6 ml of CHCl 3 followed by 6 ml of CHCl 3 /MeOH (95:5).
- Glucoronoylceramide (GluAcCer), a ceramide with a glucuronic acid headgroup was synthesized according to the methods described above.
- the metabolism of GluAcCer requires ⁇ -glucuronidase, an enzyme found in bacteria but not in human intestinal cells. Accordingly, dietary GluAcCer cannot be digested in the small intestine but should be hydrolyzed in the colon by the colonic microflora. This digestion would result in releasing the same metabolites as seen from the other dietary sphingolipids, namely ceramide and sphingosine.
- the ability of GluAcCer to be cleaved by bacterial enzymes was established using ⁇ -glucuronidase from E. coli (Sigma) assayed according to the supplier's instructions.
- mice were injected with DMH to initiate colonic tumors. After initiation, the mice were fed and AIN 76A diet supplemented with GluAcCer (0.025 or 0.1% of the diet). The control group was fed the AIN 76A diet without supplements (one group without DMH and the other with DMH only). After four weeks, the mice were killed, the colons excised, and evaluated for the appearance of ACF.
- Mammals, and specifically humans, suffering from any of the above-described conditions can be treated by the topical or systemic administration to the patient of an effective amount of one or more of the compounds described herein, including a sphingolipid metabolism altering compound, or pharmaceutically acceptable salt, optionally in the presence of a pharmaceutically acceptable carrier or diluent.
- the sphingolipid compound is administered subcutaneously, intravenously, intra peritoneally, intramuscularly, parenterally, orally, submucosally, by inhalation, transdermally via a slow release patch, or topically, in an effective dosage range to treat the target condition.
- Typical systemic dosages for all of the herein described conditions are those ranging from 0.1 mg/kg to 500 mg/kg of body weight per day as a single daily dose or divided daily doses.
- Typical dosages for topical application are those ranging from 0.001 to 100% by weight of the active compound.
- the compound is administered for a sufficient time period to alleviate the undesired symptoms and the clinical signs associated with the condition being treated.
- the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutic amount of compound in vivo in the absence of serious toxic effects.
- the concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
- the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
- compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
- the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- the dosage unit form when it is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil.
- dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
- the compound or its salts can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
- a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
- the compound can also be mixed with other active materials which do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, antiinflammatories, antivirals, or other immunosuppressive agents.
- Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- preferred carriers are physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- physiological saline bacteriostatic water
- Cremophor ELTM BASF, Parsippany, N.J.
- PBS phosphate buffered saline
- the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers.
- liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the compound is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
- appropriate lipid(s) such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol
- Suitable vehicles or carriers for topical application can be prepared by conventional techniques, such as lotions, suspensions, ointments, creams, gels, tinctures, sprays, powders, pastes, slow-release transdermal patches, suppositories for application to rectal, vaginal, nasal or oral mucosa.
- thickening agents include petrolatum, beeswax, xanthan gum, or polyethylene, humectants such as sorbitol, emollients such as mineral oil, lanolin and its derivatives, or squalene.
- a number of solutions and ointments are commercially available, especially for ophthalmic applications.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
are provided wherein the substituents are as defined in the specification and wherein there is at least one R2 substituent in the sphingolipid derivative. The compounds are useful in the treatment of of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof. Further, the invention provides a method for treating bacterial infections, including those that influence colon cancer and other disorders of the intestine, that includes administering an effective amount of one of the active compounds identified herein.
Description
- [0001] This application claims priority to U.S. provisional application No. 60/074,536, filed on Feb. 12, 1998. The U.S. government has rights in this invention arising out of funding by federal grant nos. GM46368 and CA61820 from the National Institutes of Health.
- This application is in the area of pharmaceutical chemistry, and in particular includes sphingolipid derivatives, prodrugs and pharmaceutical compositions and salts thereof for the treatment of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof. Further, the invention provides a method for treating bacterial infections, including those that influence colon cancer and other disorders of the intestine, that includes administering an effective amount of one of the active compounds identified herein.
- Sphingosine is the common name for D-erythro-4-trans-sphinganine, the prevalent long-chain base of most mammalian sphingolipids. It most often has 18 carbon atoms and the stereochemistry shown in FIG. 1. Sphingolipids generally are composed of a long-chain (sphingoid) base (sphingosine, sphinganine, 4-hydroxysphinganine, or a related compound) as the backbone moiety (Karlsson, K. A.Chem. Phys. Lipids, 5:6-43, 1970), which is usually modified by an amide-linked long-chain fatty acid (for ceramides), and a head group at
position 1, as illustrated in FIG. 2. Over 300 classes of sphingolipids are known, most of which have head groups with simple to complex carbohydrates (see Merrill & Sweeley, New Comprehensive Biochemistry: Biochemistry of Lipids, Lipoproteins, and Membranes, (Vance, D. E. & Vance, J. E., eds.), pp. 309-338, Elsevier Science, Amsterdam, 1996). It is a common misconception from the names of these compounds (e.g., ceramide, sphingomyelin, gangliosides, etc.) that sphingolipids are only found in neuronal tissues. In fact, sphingolipids are major constituents of all eukaryotic (and some prokaryotic) organisms, including plants (Lynch, D. V., Lipid Metabolism in Plants (T. S. Moore, Jr., ed.), pp. 285-308, CRC Press, Boca Raton, Fla. 1993). This nomenclature merely reflects their initial discovery in brain tissues by classic studies a century ago (Thudichum, J. L. W., A Treatise on the Chemical Constitution of Brain, Bailliere, Tindall & Cox, (London) 1884). - Mammalian sphingolipid compounds typically vary in the presence or absence of: (I) the 4,5-trans-double bond (for example, sphingosine has a double bond whereas sphinganine (also referred to as dihydrosphingosine) does not); (ii) double bond(s) at other positions, such as position 8; (iii) a hydroxyl group at position 4 (D-1-hydroxysphinganine, also called “phytosphingosine”) or elsewhere (Robson et al.,J. Lipid Res. 35:2060-2068, 1994); (iv) methyl group(s) on the alkyl side chain or on the amino group, such as N,N,-dimethylsphingosine; and (v) acylation of the amino group (for example ceramide (also referred to as N-acylsphingosine), and dihydroceramide (also referred to as N-acyl-sphinganine)). The 4-hydroxysphinganines are the major long-chain bases of yeast (Wells, G. B. and Lester, R. L., J. Biol. Chem., 258:10200-10203, 1983), plants (Lynch, D. V., Lipid Metabolism in Plants (T. S. Moore, Jr., ed.), pp. 285-308, CRC Press, Boca Raton, Fla. 1993), and fungi (Merrill et al., Fungal Lipids (R. Prasad and M. Ghanoum, eds.), CRC Press, Boca Raton, Fla., 1995a), but are also made by mammals (Crossman and Hirschberg, J. Biol. Chem, 252:5815-5819, 1977). Other modifications of the long-chain base backbone include phosphorylation at the hydroxyloxygen of carbon I (Buehrer and Bell, Adv. Lipid Res. 6:59-67, 1993), and acylation (Merrill and Wang, Methods Enzymol,. 209:427-437, 1992) (Igarashi and Hakomori, Biochim. Biophys. Res. Commun. 164:1411-1416, 1989; Felding-Habermann et al., Biochemistry 29:6314-6322, 1990) of the amino group. Each of these compounds can be found in various alkyl chain lengths, with 18 carbons predominating in most sphingolipids, but other homologs can constitute a major portion of specific sphingolipid (as exemplified by the large amounts of C20 sphingosine in brain gangliosides) (Valsecchi et al., J. Neurochem., 60:193-196, 1993) and in different sources (e.g., C16 sphingosine is a substantial component of milk sphingomyelin) (Morrison, Biochim. Biophys. Acta., 176:537-546, 1969). One difficulty in studying these compounds is that relatively few are commercially available in chemically-pure form. For example, most of the sphinganine that can be purchased from various vendors is a mixture of the D and L enantiomers (therefore, commercially available dihydroceramides are also mixtures) and the metabolism, and some of the functions, of these compounds are sensitive to stereochemistry (Stroffel and Bister, Hoppe-Seyler's Z. Physiol. Chem. 354:169-181, 1973; Buehrer and Bell, J. Biol. Chem. 267:3154-3159, 1992; Adv. Lipid Res. 26:59-67, 1993; Hauser et al., J. Biol. Chem. 269:6803-6809, 1994; Olivera et al., J. Biol. Chem. 269:17924-17930, 1994). For example, sphingosine kinase (which forms the signaling compound sphingosine 1-phosphate) will act only on the erythro stereoisomers—the threo stereoisomers are inhibitors of the enzyme (Buehrer and Bell, J. Biol. Chem. 267:3154-3159, 1992; Adv. Lipid Res. 26:59-67, 1993). Release of intracellular calcium is limited to D-(+)-erythro-sphingosine 1-phosphate.
- Sphingosines and other long-chain bases are cationic amphiphiles, which distinguishes them from most other naturally occurring lipids, which are neutral (including zwitterionic) or anionic. In the protonated form, they affect the phase behavior of both zwitterionic (Koiv et al.,Chem. Phys. Lipids. 66:123-134, 1993; López-Garcia et al., Biochim. Biophys. Acta., 1194:281-288, 1994) and acidic (Koiv et al., Chem. Phys. Lipids, 66:123-134, 1993; López-Garcia et al., Biochim. Biophys. Acta. 1194:281-288, 1994) phospholipids.
- The hydroxyl groups at
positions - Many microorganisms, microbial toxins and viruses bind to cells via sphingolipids. Specific organisms that have been reported as binding to sphingolipids include cholera toxin (ganglioside GMI) (Thompson, et al., Biochem. Pharmacol. 56: 591-597, 1998); verotoxin (globosides) (Farkas-Himsley et al., Proc. Natl. Acad. Sci. (USA) 92: 6996-7000, 1995; Bast et al., Infect. & Immun., 57:969-74, 1997); Shiga-like toxin 2e (globotriaosylceramide, Gb3) (Jacewicz et al., J. Clin. Invest. 96:1328-1335, 1995; Keusch et al., Infect. & Immun. 63: 1138-1141; 1995); and Clostridium botulinum type B neurotoxin (to synaptotagmin II associated with gangliosides GT1b/GD1a) (Nishiki et al., FEBS Lett. 378: 253-257, 1996).
- Furthermore, many bacteria utilize sphingolipids to adhere to cell. Examples known in the art includeEscherichia coli (galactosylceramide) (Blomberg et al., Infect. & Immun. 61: 2526-2531, 199; Payne et al., Infect. & Immun. 61: 3673-3677, 1993; Khan et al., Infect. & Immun. 64: 3688-3693, 1996); Haemophilus influenzae (gangliotetraosylceramide and gangliotriosylceramide) (Hartmann et al., Infect. Immun. 65: 1729-1733, 1997); Helicobacter pylori (gangliotetraosylceramide, gangliotriaosylceramide, sulfatides and GM3) (Huesca et al., Infect. & Immun. 64: 2643-2648, 1996; Kamisago et al., Infect. & Immun. 64:624-628, 1996; Simon et al., Infect Immun. 65: 750-757, 1997; Wadstrom et al., Curr. Mircrobiol. 34: 267-272, 1997); Borrelia burgdorferi (galactocerebroside; Virulent strain 297: glucosylceramide, lactosylceramide, and galactosylgloboside) (Garcia Monco et al., Neurology 42:1341-1348, 1992; Kaneda et al., Infect. & Immun. 65: 1138-1141, 1997); and Pseudomonas aeruginosa and Candida albicans (asialo GM1) (Yu et al., Infect. & Immun. 62: 5213-5219, 1994).
- Virus binding can be mediated via sphingolipids, including HIV-1 gp120 (galactosylceramide) (Fantini et al., J. Biol. Chem. 272: 7245-7252, 1997), Sendai virus (ganglioside GD1a) (Epand et al., Biochemistry 34: 1084-1089, 1995); and influenza viruses (gangliosides, sulfatides and polyglycosylceramides) (Fakih et al., Infect. & Immun. 65: 1695-1700, 1997; Matrosovich et al., Virology 233: 224-234,1997; Matrosovich et al., Virology 223: 413-416,1996; Sato et al., Biochim. Biophys. Acta 1285: 14-20, 1996; Suzuki et al., Biochem. J. 318:389-393, 1996).
- Sphingolipids are significant components of foods. The types of sphingolipids differ among organisms (and for different types of cells within an organism); for examples, the predominant sphingolipid classes for plants are cerebrosides (Lynch, D. V.,Lipid Metabolism in Plants (T. S. Moore, Jr., ed.), pp. 285-308, CRC Press, Boca Raton, Fla. 1993), ceramide phosphoinositols for yeast (Lester et al., Biochim. Biophys. Acta. 1165:314-320, 1993), and sphingomyelin (plus a wide spectrum of neutral and acidic glycolipids) for mammals (Hakomori, J. Biol. Chem. 265:18713-18716, 1983). There are also differences in the nature of the sphingoid-base backbones because plants contain predominantly 4-hydroxysphingenine (t 18:1) isomers and 4,8-sphingadienine (d18:2) isomers (Lynch, D. V., Lipid Metabolism in Plants (T. S. Moore, Jr., ed.), pp. 285-308, CRC Press, Boca Raton, Fla. 1993), ceramide phosphoinositols for yeast (Lester et al., Biochim. Biophys. Acta., 1165:314-320, 1993). Furthermore, considerable structural diversity exists among the sphingoid base (and fatty acid) composition of glucocerebrosides isolated from different plant tissues. Sphingoid bases with a double bond at position 8 have been seen in mammalian sphingolipids (Karlsson, K. A., Chem. Phys. Lipids, 5:6-43, 1970), but have never been shown to be synthesized by mammalian cells; therefore, it is likely that they are acquired by mammals by consumption of plant sphingolipids.
- Sphingolipids not only help define the structural properties of membranes, but also play important roles in cell-cell and cell-substratum interactions, and help regulate growth and differentiation by a variety of mechanisms, such as inhibition of growth factor receptor kinases and effects on numerous cellular signal transduction systems (for reviews see Hakomori,J. Biol. Chem. 265:18713-18716, 1991; Bell et al., Advances in Lipid Research: Sphingolipids and Their Metabolites, vols. 25 and 26, Academic Press, San Diego, 1993; Merrill and Sweeley, New Comprehensive Biochemistry: Biochemistry ofLipids, Lipoproteins, and Membranes (Vance, D. E. & Vance, J. E., eds.), 1996; Spiegel and Merrill,
FASEB J 10, 1388-1397, 1996). The backbones of dietary sphingolipids (ceramides and sphingoid bases) are assumed to induce cellular responses that are normally regulated by intracellular sphingolipid second messengers. This may have implications far beyond just their effects on carcinogenesis, such as restenosis, where there is proliferation of smooth muscle cells in the course of development of plaques in vascular tissue, and closing off of the artery after angioplasty. - Interest in these lipid backbones as bioactive compounds began when Hannun, Loomis and Bell at Duke University serendipitously discovered that sphingosine is a potent inhibitor of protein kinase C in vitro (Hannun et al.,J. Bio. Chem. 261:12604-12609, 1986), and by the finding that sphingoid bases also inhibit diverse cell functions requiring protein kinase C (Hannun et al., J. Bio. Chem. 261:12604-12609, 1986; Wilson et al., J. Biol. Chem. 261:12616-12623, 1986; Merrill et al., J. Biol. Chem. 261:12610-12615, 1986). Subsequent studies have found that sphingosine activates and inhibits several protein kinases, and affects a large number of signal transduction systems. Researchers thereafter uncovered additional bioactive sphingolipid “backbones” such as ceramides (Hannun, J. Biol. Chem. 269:3125-3128, 1994; Kolesnick, Cell 77:325-328, 1994), sphingosine 1-phosphate (Zhang et al., J. Cell Biol. 114:155-167, 1991; Spiegel et al., J. Lipid Mediators 8:169-175, 1993), and N-methyl-sphingosines (Igarashi, J. Biol. Chem. 265:5385-5389, 1990). As the cellular targets of these compounds have been studied, they have turned out to be as complex as for other lipid-signaling pathways in cells, i.e., they involve activation and inhibition of protein kinases, phosphoprotein phosphatases, ion transporters, and “cross-talk” with other signaling pathways.
- The current paradigm for the action of sphingolipids in cell regulation is that complex sphingolipids are important in membrane structure, especially specialized membrane functions such as are found in calveolae. They also interact with cell surface receptors for growth factors, and the extracellular matrix. The lipid backbones (ceramide, sphingosine and sphingosine 1-phosphate) function as “second messengers” to affect protein kinases, phosphoprotein phosphatases, ion transporters, and other regulatory machinery, as illustrated in FIG. 3. As examples, tumor necrosis factor-α, interleukin 1β, and nerve growth factor induce sphingomyelin hydrolysis to ceramide as a second messenger (Hannun,J. Biol. Chem. 269:3125-3128, 1994; Kolesnick, Cell 77:325-328, 1994); other agonists, such as platelet-derived growth factor, trigger further hydrolysis of ceramide to sphingosine, and activate sphingosine kinase to form sphingosine 1-phosphate (Olivera and Spiegel, Nature 365:557-560, 1993; Coroneos et al., J. Biol. Chem. 270:23305-23309, 1995). Depending on the cell type, these metabolites can either stimulate or inhibit growth. While the details of growth regulation by ceramide, sphingosine, and sphingosine 1-phosphate are still being uncovered (Spiegel and Merrill, FASEB J., 1996), depending on the system, it appears to involve calcium mobilization from intracellular stores, and activation of the MAP (and Jun) kinase pathways and transcription factors (AP1) (Su et al., J. Biol. Chem. 269:16512-16517, 1994), induction of retinoblastoma protein dephosphorylation (Pushkareva et al., Biochemistry, 34:1885-1892, 1995), and in some cases, induction of apoptosis (Obeid et al., Science, 259:1769-1771, 1993; Jarvis et al., Cancer Res. 54:1707-1714, 1994).
- Carcinogenesis involves progressive genetic mutations leading to the loss of cell growth regulation and, as importantly, loss of regulation of programmed cell death (apoptosis). The genetic abnormalities have been studied extensively for colorectal cancer and include activation of oncogenes and loss of tumor suppressor genes as cells progress from early premalignant lesions to carcinomas (Fearon and Vogelstein, 1990; Jen et al., 1994; Kinzler and Vogelstein, 1996), and a progressive inhibition of apoptosis (Bedi et al., 1995).
- It has been determined that free sphingoid bases and ceramide, through inhibition of protein kinase C (Hannun et al.,J. Biol. Chem. 261:12604-12609, 1986; Stevens et al., Biochem. Biophys. Acta 1051:37-45, 1990a) or induction of retinoblastoma protein dephosphorylation (Pushkareva, Biochemistry 34:1885-1892, 1995; Obeid & Hannun, Trends Biochem. Sci. 20:73-77, 1995) can inhibit cell growth; sphingoid bases (Stevens et al., Cancer Res. 50:222-226, 1990b) and ceramide (Okazaki et al., J. Biol. Chem. 265:15823-15831, 1990) can promote cell differentiation; and, ceramide (Obeid et al., Science 259:1769-1771, 1993; Hannun and Obeid, Trends Biochem. Sci. 20:73-77, 1995; Kolesnick and Fuks, 1995) as well as sphingosine (Ohta et al., Cancer Res. 55:691-697, 1995) can induce apoptosis, apparently through suppression of Bcl-2 (Sakakura et al., FEBS Lett. 379:177-180, 1996; Chen et al., Cancer Res. 55:991-994, 1995). Wright et al. (FASEB J 10:325-332, 1996) have recently reported that U937 cells that were isolated based on their resistance to TNF-induced apoptosis have a defect in the activation of sphingomyelinase and the 24 kDa apoptotic protease (AP24); furthermore, this also makes the cells resistant to UV-induced apoptosis. This raises the possibility that some tumors could be defective in apoptosis because they have mutation(s) in upstream regulators of sphingomyelin turnover to ceramide. If so, addition of exogenous ceramide (and/or sphingosine or synthetic analogs of either) might bypass this (these) defects.
- There have been few studies of the relevance of these compounds to carcinogenesis. Several years ago, it was explored whether free sphingoid bases could inhibit transformation using C3H 10T1/2 cells initiated by γ-irradiation or chemical carcinogens as a model system (Borek et al.,Proc. Natl. Acad. Sci. USA 88:1953-1957, 1991; Borek and Merrill, Antimutagenesis and Anticarcinogenesis Mechanisms III (G. Bronzetti et al. eds., Plenum Publishing Corp., New York), 1993). These studies showed that sphingosine and sphinganine completely blocked “promotion” of transformed foci by phorbol esters, and reduced the number of transformed foci in cells treated with just γ-irradiation. The sphingoid bases were added at levels that affected protein kinase C but were not noticeably cytotoxic; therefore, the effects were not due to non-specific killing by a lipid “detergent.”
- In another study, female CF1 mice (6 weeks of age, 10 mice per group) were fed a standard, defined diet (AIN76A) (without sphingolipid supplementation), then treated with 1,2-dimethylhydrazine (DMH) in 6 weekly injections (40 mg/kg). One week after the last DMH administration, some of the mice were changed to diets supplemented with 0.05% sphingomyelin, and analyzed on week 7 for aberrant colonic crypts (McLellan et al.,Cancer Res. 51:5270-5274, 1991; Pretlow et al., Cancer Res. 51:1564-1567, 1991). Sphingomyelin caused a significant (50%) reduction in the number of aberrant colonic crypts induced by DMH (Dillehay et al., J. Nutr. 124:615-620, 1994). All of the aberrant crypts were found in the distal third of the colon.
- Aberrant colonic crypt foci are one of the earliest morphological changes of colonic cells to dysplasia. It is thought that some of these lesions will eventually develop into adenomas and carcinomas (McLellan & Bird,Cancer Res. 51:5270-5274, 1991; Pretlow et al., Cancer Res. 51:1564-1567, 1991; Bruce et al., Mutat. Res. 290:111-118, 1993; Toribara and Sleisenber, 1995), which makes aberrant crypt foci a useful biomarker for studies of agents that may inhibit (or enhance) colon carcinogenesis. The effect of sphingomyelin on DMH-induced carcinogenesis was evaluated in a pilot experiment (15 mice per group) conducted with milk sphingomyelin, and a larger experiment (40 mice per group) with buttermilk sphingomyelin. Mice fed sphingomyelin had about half of the tumor incidence of the control. A control group fed sphingomyelin, but not treated with DMH, had no signs of a deleterious effect of consumption of sphingolipids, and developed no tumors.
- A second study with buttermilk sphingomyelin gave a somewhat different, but nonetheless very interesting result. There was no reduction in the number of overall tumors, but histological analyses revealed that mice fed sphingomyelin had a shift in tumor type such that there were more adenomas versus adenocarcinomas than for the control (defined as polypoid adenomas by the presence of an intact muscularis mucosa versus invasion of neoplastic cells through the muscularis mucosa, which is characteristic of adenocarcinomas).
- The first studies of sphingolipid digestion were published by Nilsson approximately 30 years ago (Nilsson, A.,Biochim. Biophy. Acta. 164:575-584, 1968; Biochim. Biophys.
Acta 1°7: 113-121, 1969) and indicated that sphingomyelin was metabolized in the small intestine and up to 30% of the radiolabel could be recovered in lymph. However, 21 to 46% of the radiolabel was found in feces, mainly as ceramide, which indicated that the digestion of sphingomyelin is not very efficient, but may continue in the lower bowel (probably with the involvement of intestinal microflora). Secondly, the time course for the absorption of radiolabel was somewhat curious, withpeak absorption 10 hours after feeding the sphingolipid, which may indicate that coprophagy had occurred. A similar study with the glycolipids glucosylceramide and galactosylceramide (Nilsson, Biochim. Biophy. Acta. 164: 575-584, 1969) found that glycolipids are also only partially digested. - Follow-up studies of sphingolipid digestion by rats and mice were conducted using several approaches (Schmelz et al.,Journal of Nutrition, 124: 702-712, 1994). The first is a simpler model, the use of isolated segments of the intestine in which the animal is anesthetized and the intestines are flushed, tied-off, and then injected with the radio labeled compound of interest. The advantage of this technique is that the intestine retains most of its normal blood supply, and nutrient absorption can be fairly simply assessed by the disappearance of the radiolabel (or appearance in the tissue or blood). When [3-Hsphingosyl] sphingomyelin was added to segments of the jejunum, ileum, and caecum, or colon, very little radiolabel was lost from the segments; radiolabel became associated with the tissue in a form that was not removed by washing. It was found that the [3H-sphingosyl] backbone had been incorporated into other classes of sphingolipids. This established that the sphingolipid had undergone some hydrolysis, cellular uptake and metabolism. It is not known whether hydrolysis occurred before or after cellular uptake, and subsequent double labeling experiments have indicated that both the [3H-sphingosyl] backbone and [14C] choline head group are taken up.
- In a second approach (Schmelz et al.,Journal of Nutrition. 124; 702-712, 1994), [3H-sphingosyl]-sphingomyelin was given to mice by gavage, and then the animals were killed after different time intervals and the amount of radiolabel in different intestinal segments measured. From 3 to 5% of the radiolabel had progressed into the colon within about 2 hours, which confirmed the earlier observation by Nilsson (Biochim. Biophys. Acta., 164: 575-584, 1968) that at least some sphingomyelin escapes digestion by the upper intestine and arrives in the colon. About 5% of the label appeared in liver, sphingolipids, so there is some uptake of the sphingoid base from the diet, and incorporation into the tissues of the animal. The lack of an effect on weight gain was important because carcinogenesis studies would be more difficult to interpret if sphingolipids had affected growth (Birt et al., 1992).
- Current knowledge about sphingolipids and the recent findings summarized above establish four points. First, sphingolipids, and especially sphingosine and ceramide, are highly bioactive compounds with potential to serve as naturally occurring modulators of diverse cell behaviors that include neoplastic transformation. Second, findings in various cell culture systems and animal models for carcinogenesis suggest strongly that sphingolipids suppress carcinogenesis. Third, glycosphingolipids may be more effective than phosphosphingolipids because when they are hydrolyzed to a lysosphingolipid (such as psychosine for cerebrosides) the product is also cytotoxic, in contrast to lysosphingomyelin, which is mitogenic. As a result, they may be selectively cleaved in the lower GI track. Fourth, based on the above-described dietary studies, only a small amount of orally administered sphingolipid survives to the lower intestine, and logically, to other distant sites of the body which might be in need of treatment.
- U.S. Pat. Nos. 5,232,837 and 5,518,147 issued to Merrill, Wong, and Riley disclose a method of altering the metabolism of sphingolipids in a cell comprising exposure of the cell to fumonisins, or an analog thereof. Fumonisins (see FIGS. 5 & 6) are a family of mycotoxins produced byFusarium moniliforme and related fungi that are common contaminants of maize, sorgum, and related grains. Fumonisins and sphingosine share a 2-amino-3-ol head group and possess backbone carbon chains of approximately equal size. However, sphingosine is hydroxyl-substituted at carbon I while fumonisin B1 and B2 are hydroxyl-substituted at carbon 5. In addition, the fumonisins possess polycarboxylate moieties attached to the tail of the backbone carbon chain. Similarities between sphingosine and Fumonisin in their head groups and tails are responsible for the activity of the fumonisins. It was discovered that fumonisin acts as an inhibitor of ceramide synthase, and thus alters the metabolism of the conversion of sphinganine to dihydroceramide.
- An abstract published inJ. Urol., 155(5):653A, Abst. 1367, 1996, disclosed that the administration of fumonisin in combination with doxirubicin exhibited a striking ability to treat renal cell carcinoma. This abstract showed that Fumonisin B has cytostatic activity using the Soft Agar thymidine incorporation in vitro assay model of human carcinomas against renal bladder and colon cancer cell lines. It confirmed that Fumonisin B can augment the cytotoxicity of other cytotoxic agents in this model system.
- U.S. Pat. No. 5,190,876 and U.S. Pat. No. 5,459,057 to Merrill, Kinkade, and Stevens, disclose a method and composition for enhancing the action of biological response modifiers, such as promoting cellular differentiation, by administration of an effective amount of Vitamin A or an analog thereof with sphingosine or an analog thereof.
- U.S. Pat. No. 5,110,987 to Liotta and Merrill discloses a method for preparing sphingosine derivatives.
- U.S. Pat. No. 5,635,536 to Lyons discloses emulsions suitable for administration of sphingolipids.
- In light of the fact that sphingolipids play a fundamental role in a number of metabolic pathways, including cell proliferation and programmed cell death, it would be of benefit to provide new sphingolipid derivatives that have improved properties, bioavailability, or are targeted to desired locations for effective therapy.
- It is therefore an object of the present invention to provide new sphingolipids with biological activity, and in particular, sphingolipids that are useful in the treatment of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C activity, the modification of the colonization of microfora in the body, and the treatment of inflammatory conditions including psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue.
- It is therefore an object of the present invention to provide sphingolipids in a prodrug form that can be cleaved to a parent sphingolipid in vivo to increase bioavailability and or efficacy. It is another object of the present invention to provide sphingolipids in a manner that efficiently targets them to a desired location.
- It is still another object of the present invention to provide a method and composition that increases the level of sphingolipid that is delivered to a desired location in a host animal.
- It is a further object of the present invention to provide new sphingolipid compositions for the treatment of cancer, including colon cancer.
- It is yet another object of the present invention to provide new methods for the treatment of bacterial infections.
- It is still another object of the present invention to provide new sphingolipid compositions for the modification of the colonization of microfora that influence colon cancer and other intestinal disorders.
-
- are provided wherein:
- A is a spacer group which is (CH2)m where m=0-14, where any of the hydrogens may be independently replaced by R1 or X and where any two adjacent carbons may be independently replaced by a C3-C8 cycloalkyl group, a 1,2-, 1,3-, or 1,4-disubstituted benzene group, or a 2,3-, 2,4- or 2,5-disubstituted thiophene, furan or pyrrole group;
- X, Y, V, and Q are independently hydrogen, OR1, NR2, CN, alkyl, acyl (i.e., C(O)R), carboxylate (i.e., OC(O)R), and wherein alternatively, V and Y, Y and Q or Q and A can together constitute a double or triple bond;
- W=no substituent, H, alkyl, aryl, alkenyl, alkynyl, alkaryl, aralkyl, C(O)(CH2)nCO2H, C(O)(CH2)nCW′2CO2H, or OR1;
- W′ is selected independently from H, alkyl, aryl, (CH2)nCO2H; (CH2)nCH(CO2H)CH2CO2H; and (CH2)nCH(CO2H)CH(CH2CO2H)CO2H;
- Z is H, O, NH, NR, NHC(O), C(O)OR1, C(O)NH, or C(O)NR;
- R is selected independently from H, alkyl, acyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, or heteroaryl;
- R1 is R or R2;
- R2 is phosphate (OP(OR3), wherein at least one R is not hydrogen), b-D-galactoside, N-acetyl-b-D-glucosamine, a-D-mannoside, an organic azo-bond containing moiety that can be reduced by an azoreductase, b-D-cellobiosides, b-D-glucopyranosides, b-D-galactopyranosides, b-D-glucuronides, starch (such as maize starch, amylo-maize starch, pectin and others found in wheat flour, potato and beans), lactose, raffinose, stachyose, fructooligosaccharides (such as oligofructose and inulin), an amide or ester of b-cyclodextrin, dextran linked via succinate and glutarate, an amino acid or peptide, or a polyamino acid or polypeptide, furanose and pyranose carbohydrates, sulfonate (and esters thereof), phosphocholine, phosphoserine, and phosphoethanolamine;
- wherein there is at least one R2 substituent in the sphingolipid derivative.
- It has been discovered that biologically important sphingolipids can be administered as prodrugs which increase the level of active compound that is delivered to the active site of interest. The prodrug is cleaved by an appropriate enzyme in vivo to release a parent sphingolipid moiety for desired therapy. Certain derivatives of Formula I are especially suited for treatment of disorders of the lower intestinal tract, including but not limited to colon cancer, intestinal polyps, intestinal tumors, inflammatory bowel diseases including ulcerative colitis and Crohn's disease, necrotizing enterocolitis, and ileocecitis, other inflammations of the lower bowel, and antibiotic associated colitis, as the enzymes which free the sphingolipid from its prodrug form are concentrated in the lower intestine. These prodrugs are resistant to hydrolysis in the upper gastrointestinal tract, and are more readily cleaved in the cecum and the colon. This invention thus addresses the problem to date of low bioavailability of these important compounds at the target site.
- In another alternative embodiment of the invention, R2 is a “targeting moiety” that binds to a receptor molecule on the target membrane's surface. Examples of targeting molecules include steroids, hormones (including but not limited to melanin), hormone receptors, cell specific receptors and ligands that bind to cell specific receptors (including but not limited to sugars, proteins, peptides, and glycoproteins), antibodies (for example, the Her 2-Nu antibody for the treatment of breast cancer), antibody fragments (such as the Fab or Fab2 antibody fragments), antigens, T-cell receptor fragments including T-cell receptor variable regions. In one embodiment, a steroid that binds to the membrane of a cancer cell is used as the targeting moiety.
- The active compounds are administered in an effective amount to alter sphingolipid metabolism, and thus are useful in the treatment of abnormal cell proliferation, including tumors, cancer, psoriasis, and familial polyposis; in the promotion of cell differentiation, in the induction of apoptosis, in the inhibition of protein kinase C; and in the modification of the colonization of microflora that influence colon cancer and other intestinal disorders, and in the treatment of inflammatory conditions. These compounds either exhibit activity in themselves or act as a prodrug of a parent compound. The compounds can be administered alone or in combination with other biologically active compounds to achieve the desired effect.
- These compounds can in particular be used to treat infections caused by bacteria (gram negative and gram positive) and viruses which have receptors for sphingolipids as anchoring means for colonization. Nonlimiting examples of microorganisms that can be treated using this method include cholera toxin, verotoxin, Shiga-like toxin 2e, Clostridium botulinum type B neurotoxin,Escherichia coli, Haemophilus influenzae; Helicobacter pylori; Borrelia burgdorferi, Pseudomonas aeruginosa, Candida albicans, HIV, Sendai virus, and influenza viruses. In this embodiment, an effective amount of a selected compound falling within the above formula is administered to decrease or prevent colonization of the selected microorganism.
- In yet another embodiment of the invention, a derivative of a fumonisin is provided that includes at least one covalently bound R2 group. These compounds are also useful in the treatment of abnormal cell hyperproliferation, including cancer and tumors, most notable when used in combination with other antitumor compounds. In particular, the derivatives can be used to target cells, including solid tumors such as colon or urogenital tract tumors including kidney, bladder, prostate, as well as the uterus and cervix, for enhanced therapy.
- In yet another embodiment of the invention, sphingolipid derivatives are also useful for the modification of the colonization of microfora that influence colon cancer and other intestinal disorders.
- It has also now been discovered that sphingoid bases (including naturally occurring compounds that share this structural motif, such as the fumonisins), including but not limited to those in Formula I and in FIGS.1-5 trigger the release of cytochrome c from mitochondria into the cytosol, resulting in the cleavage and activity of caspase-3 and thereafter, apoptosis. These compounds are thus useful in the treatment of any disorder which is mediated by, or benefited by, regulation of cell growth, differentiation, and/or induction of cell death. In addition, treatment with sphingolipids has been shown to down-regulate Bcl-2 levels, which further sensitizes cancer cells to apoptosis induced by other apoptotic stimuli including chemotherapeutic drugs, γ-radiation and Fas ligand. Therefore, treatment with sphingolipids sensitizes cancer cells simultaneously by promoting the cytosolic accumulation of cytochrome c and by down-regulating Bcl-2, which acts as a barrier to this event.
- It has also been discovered that compounds of the above formula can be used to treat bacterial infections.
- It is still another object of the present invention to provide new sphingolipid compositions for the modification of the colonization of microfora that influence colon cancer and other intestinal disorders.
- FIG. 1 is an illustration of the stereochemical configuration of sphingosine.
- FIG. 2 is an illustration of the structure, metabolic reactions, and biological activities of the representative sphingolipids sphinganine, dihydroceramide, ceramide, sphingomyelin, ceramide, and sphingosine.
- FIG. 3 is an illustration of bioactive sphingolipids, such as ganglioside GM3, lactosylceramide, sphingomyelin, ceramide, sphingosine and sphingosine 1-phosphate.
- FIG. 4 is an illustration of biological pathways that include sphingolipids.
- FIGS.5(a) and 5(b) are illustrations of representative fumonisins.
- FIG. 6 is a schematic of one example of a synthesis of saturated and unsaturated 3-O-benzoylceramides (8a,b), key intermediates in the syntheses of glyco- and phosphosphingolipids. This process can be adapted for the preparation of other 3-O-protected ceramides (Acetyl, Pivaloyl, t-Butyldimethylsilyl, t-Butyl-diphenylsilyl), commonly used in the syntheses of sphingomyelins and glycosphingolipids.
- FIG. 7 is a schematic of a synthesis of sphingomyelins that involves a phosphite triester. The scheme includes the steps of phosphitilation of 3-O-benzoylceramides (8a,b) with chloro(N,N-diisopropylamino)-methoxyphosphine in the presence of triethylamine, the condensation of the crude amidites (13a,b) with 4-5-times excess of tosylate choline in the presence of 1H-tetrazole, oxidation with tert-butylhydroxyperoxide and removing of the blocking groups in the phosphoric acid residue with tert-butylamine and hydroxy group at C3 with sodium methoxide.
- FIGS. 8 and 9 together are a schematic of a synthesis of β-D-glucuronylceramide (23). FIG. 8 illustrates the preparation of protected imidate (22) using literature procedures, which include the treatment of commercially-available D-glucuronolactone (18) with sodium methoxide in methanol, following the acetylation of methyl ester (19) with acetic anhydride, hydrolysis of β-acetoxyglucuronic acid methyl ester (20) with hydrazine acetate, and treatment of the resulting hemiacetal (21) with trichloroacetonitrile. FIG. 9 illustrates the glycosylation and deprotection steps of the synthesis.
- FIG. 10 is a schematic of one example of the preparation of an intermediate 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (30) which can be used in the synthesis of polar sphingolipids.
- FIG. 11 is a schematic of the synthesis of sphingosine from key intermediate 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (30).
- FIG. 12 is a bar chart graph of the percent inhibition of aberrant crypt foci formation by glucuronoylceramide as a function of percent of glucuronoylceramide in the diet in mice.
- FIGS. 13a and b are bar chart graphs of the reduction of cell proliferation by glucuronoylceramide as a function of percent of glucuronoylceramide in the diet in mice in the upper half of colonic crypts (13a) and the lower half of colonic crypts (13b).
- FIG. 14 is a graph of treatment concentration in micromolar of sphingosine, sphinganine and 1-deoxy-5-hydroxy-sphinganine versus the optical density of formazan crystals as a means to illustrate the induction of cell death by sphingolipids as shown by MTT assay.
- The present invention includes derivatives and analogs of sphingolipids and fumonisins (referred to below as “sphingolipid metabolism altering compounds”), and pharmaceutical compositions and salts thereof, as well as methods to modify cellular metabolism, including by inhibiting abnormal cell proliferation, promoting cell differentiation, inducing apoptosis, modifying the colonization of microfora that influence colon cancer and other intestinal disorders, inhibiting protein kinase C activity, decreasing inflammatory reactions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue that includes administering an effective amount of the sphingolipid metabolism altering compound to a host animal in need thereof, either alone or in combination with another bioactive agent.
- I. Active Compounds
- a) Sphingolipid Derivatives
-
- are provided wherein:
- A is a spacer group which is (CH2)m where m=0-14, where any of the hydrogens may be independently replaced by R1 and X and where any two adjacent carbons may be independently replaced by a C3-C8 cycloalkyl group, a 1,2-, 1,3-, or 1,4-disubstituted benzene group, or a 2,3-, 2,4- or 2,5-disubstituted thiophene, furan or pyrrole group,
- X, Y, V, and Q are independently hydrogen, OR1, NR2, CN, alkyl, acyl (i.e., C(O)R), carboxylate (i.e., OC(O)R), and wherein alternatively, V and Y, Y and Q or Q and A can together constitute a double or triple bond;
- W=no substituent, H, alkyl, aryl, alkenyl, alkynyl, alkaryl, aralkyl, C(O)(CH2)nCO2H, C(O)(CH2)nCW′2CO2H, or OR1;
- W′ is selected independently from H, alkyl, aryl, (CH2)nCO2H; (CH2)nCH(CO2H)CH2CO2H; and (CH2)nCH(CO2H)CH(CH2CO2H)CO2H;
- Z is H, O, NH, NR, NHC(O), C(O)OR, —C(O)NH, or C(O)NR;
- R is selected independently from H, alkyl, acyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, or heteroaryl;
- R1 is R or R2;
- R2 is phosphate (OP(OR3), wherein at least one R is not hydrogen), b-D-galactoside, N-acetyl-b-D-glucosamine, a-D-mannoside, an organic azo-bond containing moiety that can be reduced by an azoreductase, b-D-cellobiosides, b-D-glucopyranosides, b-D-galactopyranosides, b-D-glucuronides, starch (such as maize starch, amylo-maize starch, pectin and others found in wheat flour, potato and beans), lactose, raffinose, stachyose, fructooligosaccharides (such as oligofructose and inulin), an amide or ester of b-cyclodextrin, dextran linked via succinate and glutarate, an amino acid or peptide, or a polyamino acid or polypeptide, furanose and pyranose carbohydrates, sulfonate (and esters thereof), phosphocholine, phosphoserine, and phosphoethanolamine;
- wherein there is at least one R2 substituent in the sphingolipid derivative.
- In another embodiment, R2 is a biologically active molecule linked to a second “targeting molecule” either directly or through a linking moiety, including, but not limited to A. In a preferred embodiment, the targeting molecule is a moiety that binds to a receptor molecule on the target membrane's surface, as described in more detail below.
- b) Fumonisins
- In another embodiment, a derivative of a fumonisin is provided that includes at least one covalently bound R2 group. Fumonisins are a family of mycotoxins produced by Fusarium moniliforme and related fungi that are common contaminants of maize, sorgum, and related grains. Fumonisins, and their analogs, are known to affect the biosynthetic pathway of sphingolipids. Fumonisins and their analogs are generally referred to collectively as “fumonisin” or “fumonisins” herein. Thus, the present invention provides a method of altering the metabolism of sphingolipids in a cell comprising contacting the cell with a metabolism altering amount of a fumonisin, or an analog thereof, that includes at least one covalently bound R2 group, either directly or through a spacer group. “Fumonisin analog” means any compound which has structural similarity to fumonisin B1, B2, B3, or B4 and can alter the metabolism of sphingolipids. The term “structural similarity to a fumonisin” refers to three basic units as given in FIG. 5: (a) a 1-aminobutan-2-ol head group which may be further substituted by substituents X, Y and V; (b) a spacer group consisting of an alkyl, by hydroxyalkyl or dihydroxyalkyl chain (straight or branched); and © a hydrophilic tail (Z-W) in which Z contains an oxygen or nitrogen atom which can be further functionalized to attach mono- or polycarboxylate moieties (W). Fumonisin analogs are disclosed in U.S. Pat. No. 5,232,837, incorporated herein by reference.
- The term alkyl, as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon of C10 to C20, and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. The alkyl group can be optionally substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., “Protective Groups in Organic Synthesis,” John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.
- The term “protected” as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
- The term aryl, as used herein, and unless otherwise specified, refers to phenyl, biphenyl, or naphthyl, and preferably phenyl. The aryl group can be optionally substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, halo, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., “Protective Groups in Organic Synthesis,” John Wiley and Sons, Second Edition, 1991.
- The term alkaryl or alkylaryl refers to an alkyl group with an aryl substituent.
- The term aralkyl or arylalkyl refers to an aryl group with an alkyl substituent.
- The term halo, as used herein, includes chloro, bromo, iodo, and fluoro.
- The term heteroaryl or heteroaromatic, as used herein, refers to an aromatic moiety that includes at least one sulfur, oxygen, or nitrogen in the aromatic ring. Non-limiting examples are furyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isoxazolyl, pyrrolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, and pteridinyl. Functional oxygen and nitrogen groups on the heterocyclic base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.
- The term alkenyl, as referred to herein, and unless otherwise specified, refers to a straight, branched, hydrocarbon of C2 to C20 with at least one double bond.
- The term acyl refers to moiety of the formula —C(O)R3, wherein R3 is alkyl; aryl, alkaryl, aralkyl, heteroaromatic, alkoxyalkyl including methoxymethyl; arylalkyl including benzyl; aryloxyalkyl such as phenoxymethyl; aryl including phenyl optionally substituted with halogen, C1 to C4 alkyl or C1 to C4 alkoxy, or the residue of an amino acid. In one embodiment, the acyl group is the residue of a saturated or unsaturated fatty acid. As used herein the term fatty acid refers to a long chain (C6 to C26) aliphatic carboxylic acid, including saturated and unsaturated acids, including α-hydroxy fatty acids. Non-limiting examples of fatty acids are lauric, oleic, caproic, linoleic, linolenic, caprylic, capric, perlargonic, neononanoic, neodecanoic, palmitelaidoic, myristic, palmitic, stearic, arachidic, behenic, lignoceric, heptanoic, nonanoic, undecanoic, tridecanoic, pentadecanoic, heptadecanoic, nonadecanoic, heneicosanoic, tricosanoic, arachidonic, docosahexanoic, elaidic, erucic, nervonic, palmitoleic and petriselinic acid.
- The term enantiomerically enriched, as used herein, refers to a compound that is a mixture of enantiomers in which one enantiomer is present in excess, and preferably present to the extent of 95% or more, and more preferably 98% or more, including 100%.
- The term amino acid includes naturally occurring and synthetic amino acids, and includes but is not limited to, alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, and histidinyl.
- As used herein, the term pharmaceutically acceptable salts refers to salts that retain the desired biological activity of the herein-identified compounds and exhibit minimal undesired toxicological effects. Non-limiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid; (b) base addition salts formed with metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with a cation formed from ammonia, N,N-dibenzylethylene-diamine, D-glucosamine, tetraethylammonium, or ethylenediamine; or (c) combinations of (a) and (b); e.g., a zinc tannate salt or the like.
- The active compounds are administered in an effective amount to alter sphingolipid metabolism, and thus are useful in the treatment of abnormal cell proliferation, including tumors, cancer, psoriasis, and familial polyposis; in the promotion of cell differentiation, in the induction of apoptosis, in the treatment of infections caused by microorganisms which have sphingolipid receptors which allow colonization of the microorganism; in the modification of microfora that influence colon cancer and other intestinal disorders; in the inhibition of protein kinase C activity, and in the treatment of inflammatory conditions including psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. These compounds either exhibit activity in themselves or act as a prodrug of a parent compound. The compounds can be administered alone or in combination with other biologically active compounds to achieve the desired effect.
- In one preferred embodiment, A is C13H26; Z=H; W=no substituent; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; A=H; W=no substituent; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In yet another embodiment, A=C13H26; A=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In still another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In yet another preferred embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=H and Q=O-β-glucoronide.
- In yet another embodiment, A=C13H26; Z=H; W=no substituent; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In still another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=O-oligofructoside; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=H; and Q=O-oligofructoside.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=OH; Y=O-oligofructoside; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=OH; Y=H; and Q=O-oligofructoside.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=O-fructoside; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl, R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=OH; Y=O-fructoside; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a double bond.
- In another embodiment, A=C,3H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=O-mannoside; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=H; and Q=O-mannoside.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=OH; Y=O-mannoside; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=; R1=octanoyl; R=H; V=OH; Y=H; and Q=O-mannoside.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=OH; Y=H; and Q=O-cellobioside.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C,3H26; Z=H; W=no substituent; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y=H; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C,3H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; and Q=H.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=OH; Y=H; and Q=O-cellobioside.
- In another embodiment, A=C13H26; Z=H; W=no substituent; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-pglucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-pglucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=H; and Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-pglucoronide; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; and Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=fructoside; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=H; and Q=fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R3=octanoyl; R=H; V=OH; Y=O-fructoside; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; and Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=O-mannoside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=O-cellobioside; R1=octanoyl; R=H; V=H; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1 octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=O-oligofructoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=O-oligofructoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=O-fructoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=O-fructoside; Q=. H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=O-mannoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=O-mannoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-pglucoronide; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-oligofructoside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=O-oligofructoside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-fructoside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y O-fructoside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-mannoside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=O-mannoside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-β-glucoronide; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=O-β-glucoronide; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-oligofructoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-oligofructoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=O-oligofructoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-fructoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-fructoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-fructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-fructoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=O-fructoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-mannoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-mannoside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-mannoside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=O-mannoside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=O-cellobioside; R1=octanoyl; R=H; V=OH; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=OH; R1=octanoyl; R=H; V=O-cellobioside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a double bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y and Q constitute a triple bond.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=O-cellobioside; Q=H.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H; and Q=H.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; w=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-α-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-β-glucoronide; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-β-glucoronide.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; Q OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-oligofructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; Q=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-oligofructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-fructoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-fructoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H29; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-mannoside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-mannoside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R=octanoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=O-cellobioside; Y=H; Q=OH.
- In another embodiment, A C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=O; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=octanoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=H; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=H; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH2CH2COOH; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)CH(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, A=C14H28; Z=NH; W=C(O)N(CH2COOH)2; X=H; R1=palmitoyl; R=H; V=OH; Y=H; Q=O-cellobioside.
- In another embodiment, the compound is 1-deoxy-5-hydroxy-sphinganine, wherein at least one R2 is covalently bound to either hydroxyl group or the amino function of the molecule.
- Specific examples of suitable compounds for use according to the present invention include, but are not limited to:
- Ceramide β-glucuronide; sphinganine β-glucuronide; dihydroceramide β-glucuronide; sphingomyelin β-glucuronide; sphingosine β-glucuronide; ceramide b-D-galactoside; sphinganine b-D-galactoside dihydroceramide b-D-galactoside; sphingomyelin b-D-galactoside; sphingosine b-D-galactoside; ceramide N-acetyl-b-D-glucosamine; sphinganine N-acetyl-b-D-glucosamine; dihydroceramide N-acetyl-b-D-glucosamine; sphingomyelin N-acetyl-b-D-glucosamine; sphingosine N-acetyl-b-D-glucosamine; ceramide a-D-mannoside; sphinganine a-D-mannoside; dihydroceramide a-D-mannoside; sphingomyelin a-D-mannoside; sphingosine a-D-mannoside; ceramide b-D-cellobioside; sphinganine b-D-cellobioside; dihydroceramide b-D-cellobioside; sphingomyelin b-D-cellobioside; ceramide b-D-glucopyranosides; sphinganine b-D-glucopyranosides; dihydroceramide b-D-glucopyranosides, sphingomyelin b-D-glucopyranosides; sphingosine b-D-glucopyranosides; ceramide b-D-galactopyranosides; sphinganine b-D-galactopyranosides; dihydroceramide b-D-galactopyranosides; sphingomyelin b-D-galactopyranosides; and sphingosine b-D-galactopyranosides.
- Prodrug Activity
- As discussed in the Background of the Invention, one problem associated with the administration of sphingolipids as therapeutic agents is that they can be metabolized before they reach the target location. This can be a particular problem if the target location is distant from the site of administration. For example, perhaps only 5-10% of a sphingolipid reaches the lower intestine in the delivered form. Since sphingolipids of milk origin have been determined to have a therapeutic effect on intestinal tumors, the low bioavailability to that region is troublesome.
- This problem has been addressed by providing a sphingolipid, or an analog or physiological derivative thereof, alone or in combination, as a prodrug that includes an R2 substituent, including those of Formula I, that is cleaved by an appropriate enzyme in vivo to release a parent sphingolipid moiety for desired therapy. Certain derivatives of Formula I are especially suited for treatment of disorders of the lower intestinal tract, including but not limited to colon cancer, intestinal polyps, intestinal tumors, inflammatory bowel diseases including ulcerative colitis and Crohn's disease, necrotizing enterocolitis, ileocecitis, other inflammations of the lower bowel, and antibiotic associated colitis, as the enzymes which free the sphingolipid from its prodrug form are concentrated in the lower intestine. These prodrugs are resistant to hydrolysis in the upper gastrointestinal tract, and are more readily cleaved in the cecum and the colon. It is not necessary that the compound undergo no metabolism in the upper GI tract, rather, that a sufficient portion survive and be cleaved in the colon. It should also be noted that this same approach can apply to the delivery of prodrug sphingolipids or analogs or physiological derivatives thereof via other routes, including blood circulation.
- For example, it has been discovered that the glucuronide of the compounds of Formula I are cleaved by the colonic beta-glucuronidase(s). Phosphodiesterases can cleave the disclosed phosphosphingolipids. Sphingomyelinase can act on sphingomyelin derivatives, as well as ceramide phospho-inositols. The b-D-galactoside derivatives of Formula I can be cleaved by b-D-galactosidase. N-acetyl-b-D-glucosamine derivatives can be acted on by N-acetyl-b-D-glucosaminidase. The a-D-mannoside derivatives of Formula I are substrates for a-D-mannosidase. The organic azo-bond containing moiety can be reduced by an azoreductase. The b-D-cellobiosides, b-D-glucopyranosides, b-D-galactopyranosides, and b-D-glucuronides are substrates for glycosylhydrolases. Multiple enzymes from colonic bacteria are able to digest starch (such as maize starch, amylomaize starch, pectin and others found in wheat flour, potato and beans). Multiple enzymes of colonic bacteria are also capable of cleaving lactose, raffinose, stachyose, and fructooligosaccharide (such as oligofructose and insulin) derivatives of Formula I. Compounds of Formula I which are amides and esters of b-cyclodextrin or dextrans linked via succinate and glutarate are substrates for amidases and esterases. Derivatives of compounds of Formula I which are poly(L-aspartic acid) and other amino acids and peptides are substrates for peptidases and esterases.
- The active compound which is a substrate for the colonic enzyme can be administered by any suitable means, including orally. In one embodiment, the active compound is administered in a way that promotes the intestinal microflora that produce the enzymes that cleave these pro-drugs. In one embodiment, the active compound (such as the β-glucuronide of ceramide) contains a group that is poorly cleaved by enzymes in the upper intestine, but will be acted upon by enzymes produced by microorganisms in the colon.
- In another embodiment, the active compound can be co-administered with another sphingolipid analog (such as a fumonisin) that alters the metabolism of the active compound to promote better delivery to the target tissue and/or a longer tissue lifetime.
- In another embodiment, a method is provided for the delivery of a biologically active molecule to a specific site, for example, a plasma membrane surface or a nucleus of a particular cell type. In this embodiment, a biologically active molecule is linked to a second “targeting molecule” either directly or through a linking moiety, including, but not limited to A. In a preferred embodiment, the targeting molecule is a moiety that binds to a receptor molecule on the target membrane's surface.
- As an example, steroids can be used to deliver chemotherapy to a variety of pathogenic cells. Examples include estrogens or testosterone (for malignant breast and prostate tumors), sex hormones (responsive sebaceous and pilosebaceous units); and corticosteroids (lymphocytes, antigen presenting cells and other immune cells, etc.).
- Antibodies and Antibody Fragments Conjugated to Sphingolipid Metabolism Altering Compounds
- The term “antibody,” as used herein, includes monoclonal and polyclonal antibodies as well as antibody fragments which bind specifically but reversibly to a desired epitope on a target abnormally proliferating cell. It is preferred that the monoclonal antibody or monoclonal antibody fragment is derived from a monoclonal antibody or antibody fragment. Preparation of monoclonal and polyclonal antibodies to an antigen can be achieved using any known method, and for example, those described in Zola, H., “Monoclonal Antibodies—A manual of techniques” CRC Press (1988), and Antibodies: A Laboratory Manual, Harlow & Lane; Cold Spring Harbor (1988), incorporated herein by reference.
- In one embodiment, primarily for laboratory use, animals are immunized with the antigen, and preferably an adjuvant. Booster immunizations are optionally continued with antigen in PBS and mixed with adjuvant at periodic intervals. The animals are then bled following the immunizations. After removal of clot and debris, the serum can be assayed by ELISA (enzyme-linked immunosorbent assay). Monthly, or other periodic titers can be obtained after initial immunization.
- Alternatively, spleens are harvested from animals immunized with the antigen, and preferably an adjuvant. Spleen cells are separated and fused with immortal myeloma cells using polyethylene glycol. The fused hybridoma cells are selected and cultured in vitro. The hybridoma cell culture fluids are tested for the presence of hybridoma antibodies having the desired specificity. The selection technique for identifying the appropriate monoclonal or polyclonal antibody is an important aspect in obtaining desired immunospecificity. The hybridoma cells can be tested for the presence of antibodies specific for the antigen, for example, with an ELISA conducted by standard methods.
- The variable heavy (VH) and variable light (VL) domains of the antibody are involved in antigen recognition, a fact first recognized by early protease digestion experiments. Further confirmation was found by “humanization” of rodent antibodies. Variable domains of rodent origin can be fused to constant domains of human origin such that the resultant antibody retains the antigenic specificity of the rodent parented antibody (Morrison et al., Proc. Nat. Acad. Sci. USA, 81:6851-6855, 1984). “CDR grafting” can be used to humanize rodent antibodies. Additionally or alternatively, recombinant monoclonal antibodies may be “primatized,” i.e. antibodies formed in which the variable regions are derived from two different primate species, preferably the variable regions of the antibody from the macaque monkey, and the constant regions from human. The advantages of such antibodies include high homology to human immunoglobulin, presence of human effector functions, reduced immunogenicity and longer serum half-life (Newman et al. Biotechnology, 10:1455, 1992).
- The region specific for the antigen can be expressed as part of a bacteriophage, for example, using the technique of McCafferty et al.Nature, 348:552-554, 1990. Antibody-like molecules of the invention can be selected from phage display libraries using the methods described in Griffiths et al. EMBO J., 12:725-734, 1993. in which the antigens are immobilized and used to select phages. Also, appropriate cells grown in monolayers and either fixed with formaldehyde or glutaraldehyde or unfixed can be used to bind phages. Irrelevant phages are washed away and bound phages recovered by disrupting their binding to the antigen and reamplifying in bacteria. This selection and amplification process is done several times to enrich the phage population for those molecules which are the antibody-like molecules of the invention.
- Antibody fragments include Fab-like molecules (Better et al.Science 240:1041, 1988); Fv molecules (Skerra et al., Science. 240:1038 1988); single-chain Fv (ScFv) molecules where the VH and VL partner domains are linked via a flexible oligopeptide (Bird et al., Science. 242:423, 1988) Huston et al., Proc. Natl. Acad. Sci. USA. 85:5879 1988) and single domain antibodies (dAbs) comprising isolated V domains (Ward et al., Nature. 341:544 1989). A general review of the techniques involved in the synthesis of antibody fragments which retain their specific binding sites is found in Winter and Milstein, Nature, 349:293-299, 1991.
- Antibody fragments, including but not limited to Fab, (Fab)2, Fv, scFv and dAb fragments are included in this invention. Antibody-like molecules can be prepared using the recombinant DNA techniques of WO 84/03712, the disclosure of which is herein incorporated by reference.
- There can be advantages to using antibody fragments, rather than whole antibodies. Fab, Fv, ScFv and dAb antibody fragments can all be expressed in and secreted fromE. coli, thus allowing the facile production of large amounts of the fragments.
- Whole antibodies, and F(ab′)2 fragments are “bivalent.” By “bivalent” it is meant that the antibodies and F(ab′)2 fragments have two antigen combining sites. In contrast, Fab, Fv, ScFv and dAb fragments are monovalent, having only one antigen combining site.
- The art of “antibody engineering” is advancing rapidly, as is described in Tan L. K. and Morrison, S. L.,Adv. Drug Deliv., Rev. 2: 129-142 1988, Williams, G., Tibtech. 6: 36-42, 1988, and Neuberger, M. S. et al, 8th International
Biotechnology Symposium Part 2, 792-799, 1988 (all of which are incorporated herein by reference), and is well suited to preparing antibody-like molecules derived from the antibodies of the invention. - The antibody can be coupled, i.e., conjugated, to a sphingolipid or a sphingolipid metabolism altering compound. Such conjugates have a “binding portion,” which consists of the antibody of the invention, and a “functional portion,” which consists of the sphingolipid or sphingolipid metabolism altering compound. The binding portion and the functional portion can be separated by a linking or spacing moiety.
- The binding portion and the functional portion of the conjugate (if a peptide or polypeptide containing sphingolipid metabolism altering compound) can be linked together by any of the conventional ways of cross-linking polypeptides, such as those generally described in O'Sullivan et al.,Anal. Biochem. 100: 100-108, 1979. For example, one portion can be enriched with thiol groups and the other portion reacted with a bifunctional agent capable of reacting with those thiol groups, for example the N-hydroxysuccinimide ester of iodoacetic acid (NHIA) or N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP). Amide and thioether bonds, for example achieved with m-maleimidobenzoyl-N-hydroxysuccinimide ester, are generally more stable in vivo than disulfide bonds.
- Alternatively, if the binding portion contains carbohydrates, such as would be the case for an antibody or some antibody fragments, the functional portion can be linked via the carbohydrate portion using the linking technology in EP 0 088 695.
- In an alternative embodiment, the functional portion of the conjugate can be or include an enzyme for converting a prodrug into a drug, using technology similar to that described by Bagshawe and his colleagues (Bagshawe,Br. J. Cancer. 56: 531, 1987; Bagshawe et al., Br. J. Cancer. 58: 700, 1988; WO 88/07378). It may not be necessary for the whole enzyme to be present in the conjugate but, of course, the catalytic portion must be present. So-called “abzymes” can be used, in which a monoclonal antibody is raised to a compound involved in the reaction one wishes to catalyze, usually the reactive intermediate state. The resulting antibody can then function as an enzyme for the reaction. Non-limiting examples of enzymes that can be used in this manner include beta-glucuronidase(s), phosphodiesterases, sphingomyelinase, b-D-galactosidase, N-acetyl-b-D-glucosamimidase, α-D-mannosidase, azoreductase, glycosylhydrolases, amidases, peptidases, and esterases.
- The conjugate can be purified by size exclusion or affinity chromatography, and tested for dual biological activities. The antigen immunoreactivity can be measured using an enzyme-linked immunosorbent assay (ELISA) with immobilized antigen and in a live cell radio-immunoassay. An enzyme assay can be used for β-glucosidase using a substrate which changes in absorbance when the glucose residues are hydrolyzed, such as o-NPG (o-nitrophenyl-β-D-glucopyranoside), liberating 2-nitrophenol which is measured spectrophotometrically at 405 nm.
- Stability of the conjugate can be tested in vitro initially by incubating at 37° C. in serum, followed by size exclusion HPLC analysis. Stability in vivo can be tested in the same way in mice by analyzing the serum at various times after injection of the conjugate. In addition, it is possible to radiolabel the antibody with125I, and the enzyme with 125I before conjugation, and to determine the biodistribution of the conjugate, free antibody and free enzyme in mice.
- Alternatively, the conjugate can be produced as a fusion compound by recombinant DNA techniques whereby a length of DNA comprises respective regions encoding the two portions of the conjugate either adjacent to one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate. Conceivably, the two functional portions of the compound can overlap wholly or partly. The DNA is then expressed in a suitable host in known ways.
- The antibody conjugates can be administered in any suitable way, usually parenterally, for example intravenously or intra peritoneally, in standard sterile, non-pyrogenic formulations of diluents and carriers, for example isotonic saline (when administered intravenously). Once the conjugate has bound to the target cells and been cleared from the bloodstream (if necessary), which typically takes a day or so, if the conjugate is an antibody/enzyme or abzyme conjugate, the sphingolipid prodrug can be administered, usually as a single infused dose. If needed, because the conjugate can be immunogenic, cyclosporin or some other immunosuppressant can be administered to provide a longer period for treatment but usually this will not be necessary.
- II. Alteration of Sphingosine Metabolism and Pathways
- The present invention includes a method of altering the metabolism of sphingolipids in a cell comprising contacting the cell with a metabolism altering amount of a compound of the Formula I, or a pharmaceutically acceptable salt thereof, or with a fumonisin derivative to which is covalently bound, either directly or indirectly, an R2 group, collectively referred to as “sphingosine metabolic altering compounds.”
- As discussed in the Background of the Invention, sphingolipids mediate a number of fundamental pathways in vivo. The sphingolipid metabolic altering compounds can be used to alter these pathways. One can determine without undue experimentation which of these pathways are affected by carrying out simple assays such as those set out below.
- The ability of the analog to alter sphingolipid metabolism can be established by assay of elevations in the pertinent upstream metabolite as described for fumonisins, for example, in U.S. Pat. Nos. 5,232,837 and 5,518,879. Where cellular responsiveness is unknown, this can be ascertained by analysis of the pertinent cells in culture.
- In one embodiment, the compounds inhibit “ceramide synthase,” which is an enzyme or enzymes which add in N-acyl linkage to sphingosine, sphinganine and other long-chain bases. Thus, both sphinganine N-acyltransferase, which catalyzes in the conversion of sphinganine to dihydroceramide, and sphingosine N-acyltransferase, which catalyzes the conversion of sphingosine to ceramide, are referred to as ceramide synthase herein. As also used herein, “analog of dihydroceramide or ceramide” means a compound which can be catalyzed by a fumonisin or an analog. In another embodiment, the catabolism of sphingosine and other bioactive “sphingoid bases” can be blocked by administration of an inhibitor of sphingosine kinase, the other enzyme(s) that metabolize these compounds.
- “Altering the metabolism” as used herein means either an increase or a decrease in the concentration of the metabolites of both the sphingolipid biosynthetic and catabolic pathways. Typically, since ceramide synthase (sphinganine-N-acyltransferase) is generally bound by the sphingolipid metabolism altering compound, including a fumonisin or fumonisin analog, and ceramide synthase (sphinganine-N-acyltransferase), which can also be bound by these compounds, catalyzes the conversion of sphinganine to dihydroceramide in the pathway, the concentration of any compound above the site of action can be increased and the concentration of any compound below the site of action can be decreased using the fumonisin or fumonisin analog. However, the amounts of various compounds of the pathway can depend on the time period after inhibition or their relationship to other related pathways. For example, a fumonisin can bind sphingosine-N-acyltransferase, which would increase the amount of sphingosine by preventing the conversion back to ceramide and a fumonisin can also bind ceramide synthase (sphinganine-N-acyltransferase), which would decrease the amount of sphingosine by decreasing the amount of ceramide which can be converted to sphingosine. Thus, the fumonisin can cause both the increase and/or decrease of sphingosine, depending on which pathway is dominant. Such increases or decreases at various times after fumonisin ingestion can be routinely determined by standard methods.
- “Metabolism altering amount” as used herein means a quantity of a sphingolipid metabolism altering compound capable of effecting a change in the sphingolipid metabolism in cells. This amount can vary depending on the environment in which the cells are contained. For in vivo administration, the precise quantity of the compound to elicit the desired effect can be determined by standard administration and monitoring until optimal dosage is determined. Such amounts can vary from subject to subject depending on size and condition of the subject.
- As discussed above, the invention also provides a method for treating an abnormal condition in a subject associated with an alteration in sphingolipid metabolism. This method comprises administering a sphingolipid metabolism altering compound, or an analog thereof, to the subject in a metabolism altering amount. The subject can be a human or a non-human animal and the abnormal condition can be caused by numerous disorders in sphingolipid metabolism. For example, the condition can be an access of sphingosine resulting in Neimann-Picks syndrome, Tay-Sachs disease, a neoplastic condition or toxicity. In a given condition, the effect of the sphingolipid metabolism altering compound may be complex. For example, in a neoplastic condition, the sphingolipid metabolism altering compound can, due to its structural similarity to sphingosine, prevent the formation of a sphingolipid required for growth of the cells and can also act as an inducer of differentiation and thus treat the neoplastic condition.
- III. Treatment of Abnormal Cell Proliferation
- The sphingolipid metabolism altering compound can be administered specifically to treat abnormal cell proliferation, and in particular, cell hyperproliferation. Examples of abnormal cell proliferation include, but are not limited to:
- benign tumors, including, but not limited to papilloma, adenoma, firoma, chondroma, osteoma, lipoma, hemangioma, lymphangioma, leiomyoma, rhabdomyoma, meningioma, neuroma, ganglioneuroma, nevus, pheochromocytoma, neurilemona, fibroadenoma, teratoma, hydatidiform mole, granuosa-theca, Brenner tumor, arrhenoblastoma, hilar cell tumor, sex cord mesenchyme, interstitial cell tumor, and thyoma as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue;
- malignant tumors (cancer), including but not limited to carcinoma, including renal cell carcinoma, prostatic adenocarcinoma, bladder carcinoma, and adenocarcinoma, fibrosarcoma, chondrosarcoma, osteosarcoma, liposarcoma, hemangiosarcoma, lymphangiosarcoma, leiomyosarcoma, rhabdomyosarcoma, myelocytic leukemia, erythroleukemia, multiple myeloma, glioma, meningeal sarcoma, thyoma, cystosarcoma phyllodes, nephroblastoma, teratoma choriocarcinoma, cutaneous T-cell lymphoma (CTCL), cutaneous tumors primary to the skin (for example, basal cell carcinoma, squamous cell carcinoma, melanoma, and Bowen's disease), breast and other tumors infiltrating the skin, Kaposi's sarcoma, and premalignant and malignant diseases of mucosal tissues, including oral, bladder, and rectal diseases;
- preneoplastic lesions, mycosis fungoides, psoriasis, dermatomyositis, rheumatoid arthritis, viruses (for example, warts, herpes simplex, and condyloma acuminata), molluscum contagiosum, premalignant and malignant diseases of the female genital tract (cervix, vagina, and vulva). The compounds can also be used to induce abortion.
- In this embodiment, the sphingolipid metabolism altering compound, or its pharmaceutically acceptable salt, is administered in an effective treatment amount to decrease the hyperproliferation of the target cells. The sphingolipid metabolism altering compound can be modified to include a targeting moiety that concentrates the compound at the active site. Targeting moieties can include an antibody or antibody fragment that binds to a protein on the surface of the target cell, including but not limited to epidermal growth factor receptor (EGFR), c-Esb-2 family of receptors and vascular endothelial growth factor (VEGF).
- Combination Therapy
- In another embodiment, the compounds, when used as an antiproliferative, can be administered in combination with another compound that increases the effectiveness of the therapy, including but not limited to an antifolate, a 5-fluoropyrimidine (including 5-fluorouracil), a cytidine analogue such as β-L-1,3-dioxolanyl cytidine or β-L-1,3-dioxolanyl 5-fluorocytidine, antimetabolites (including purine antimetabolites, cytarabine, fudarabine, floxuridine, 6-mercaptopurine, methotrexate, and 6-thioguanine), hydroxyurea, mitotic inhibitors (including CPT-11, Etoposide (VP-21), taxol, and vinca alkaloids such as vincristine and vinblastine, an alkylating agent (including but not limited to busulfan, chlorambucil, cyclophosphamide, ifofamide, mechlorethamine, melphalan, and thiotepa), nonclassical alkylating agents, platinum containing compounds, bleomycin, an anti-tumor antibiotic, an anthracycline such as doxorubicin and dannomycin, an anthracenedione, topoisomerase II inhibitors, hormonal agents (including but not limited to corticosteroids (dexamethasone, prednisone, and methylprednisone), androgens such as fluoxymesterone and methyltestosterone, estrogens such as diethylstilbesterol, antiestrogens such as tamoxifen, LHRH analogues such as leuprolide, antiandrogens such as flutamide, aminoglutethimide, megestrol acetate, and medroxyprogesterone), asparaginase, carmustine, lomustine, hexamethyl-melamine, dacarbazine, mitotane, streptozocin, cisplatin, carboplatin, levamasole, and leucovorin. Because sphingolipid metabolites participate in the signal transduction pathways for these compounds, and modulation of their amounts with these agents can enhance their effectiveness on the target tissues, the compounds of the present invention can also be used in combination with enzyme therapy agents and immune system modulators such as an interferon, interleukin, tumor necrosis factor, macrophage colony-stimulating factor and colony stimulating factor.
- IV. Release of Cytochrome C
- Certain sphingoid bases are known to induce the DNA fragmentation and morphologic features of apoptosis in cancer and leukemia cells. Apoptosis is the active and gene-directed form of cell death, with well-characterized biochemical and morphologic features. The biochemical features include the generation of lethal and large-sized or endonucleolytic internucleosomal DNA fragmentation. The morphologic features include cell-shrinkage, chromatin condensation and membrane-bound apoptotic bodies. Apoptosis is triggered by the activation of a family of aspartate-specific cysteine proteases designated as caspases. There is a growing list of substrates that are cleaved and degraded by caspases. Among the caspases, the key caspase that is cleaved and activated early in the molecular cascade is caspase-3 (CPP32β/Yama). Caspase activity results in the degradation of lamins, poly (ADP-ribose) polymerase (PARP), PKCδ, Rb protein, DNA-PK, β-actin, fodrin, gel solution, etc., resulting in the morphologic and biochemical features of apoptosis. Recently, it has been demonstrated that caspase-3 cleavage and activity is initiated by the cytosolic accumulation of cytochrome c (cyt c) released from mitochondria, which is triggered by apoptotic stimuli as a pre-apoptotic event. Therefore, promotion of mitochondrial cyt c triggers, while its blockage inhibits, the cleavage and activity of caspase-3 and apoptosis. The gene-product of the anti-apoptotic Bcl-2 gene is localized to the outer mitochondrial membrane, where it blocks the egress of cyt c from mitochondria, thereby preventing the generation of caspase-3 cleavage and activity and resulting apoptosis. Down-regulation of Bcl-2 levels tilts the balance and sensitizes cells to undergo apoptosis.
- It has now been discovered that the sphingoid bases, including the sphingolipid metabolism altering compounds described herein, trigger the release of cytochrome c from mitochondria into the cytosol, resulting in the cleavage and activity of caspase-3 and apoptosis. In addition, treatment with sphingosine has been shown to down-regulate Bcl-2 levels, which further sensitizes cancer cells to apoptosis induced by other apoptotic stimuli including chemotherapeutic drugs, γ-radiation and Fas ligand. Therefore, treatment with sphingosine may sensitize cancer cells simultaneously by promoting the cytosolic accumulation of cytochrome c and by down-regulating Bcl-2, which acts as a barrier to this event.
- Therefore, the present invention includes a method to trigger the release of cytochrome c that includes administering an effective amount of a sphingolipid (for example those illustrated in FIGS. 1 and 2), or a sphingolipid metabolism altering compound, to a host in need thereof. Cytochrome c accumulation in the cytosol not only mediates apoptosis of cancer cells, but also apoptosis of T-lymphocytes that may be mediating anti-immune diseases or apoptosis of viral infected cells. Therefore, in these cells, cytochrome c accumulation in the cytosol due to sphingolipids such as sphingosine may also result in apoptosis of these cells thereby ameliorating the diseases they cause.
- Detailed Background on the Mechanism by Which Cytochrome c Triggers Caspase-3 Cleavage and Activity and its Regulation by Bcl-2 Family of Proteins
- Recent reports have demonstrated that, during taxol-induced apoptosis, caspase-3 is cleaved into subunits with the generation of PARP cleavage activity, and that Bcl-2 activity or Bcl-xL over expression blocks these events and subsequent apoptosis (Tang, C., et al., Leukemia, 8: 1960-1969, 1994; Ibrado, A. M., et al., Cell Growth & Differ., 7:1087-1094, 1996; Ibrado, A. M., et al., Cancer Res., 57: 1109-1115, 1997).
- It has been discovered that apoptotic stimuli causes release of cytochrome c from the mitochondrial inner membrane space into the cytosol, where in the presence of dATP, and other cytosolic factors it promotes the cleavage and activity of caspase-3, degradation of a number of substrates and the DNA fragmentation of apoptosis (Liu, X., et al.,Cell, 86: 147-157, 1996; Yang, J., et al., Science, 275: 1129-1132, 1997). In these studies, the loss of mitochondrial cytochrome c due to apoptotic stimuli was noted to precede mitochondrial membrane depolarization and loss of membrane potential (Δψm) (Yang, J., et al., Science, 2.75: 1129-11.32, 1997). However, the precise mechanisms by which cytochrome c is released from mitochondria and the cytosolic cleavage of caspase-3 results have not been elucidated. Other reports have suggested that apoptotic stimuli cause mitochondrial permeability transition due to the loss of Δψm (Zamzami, N., et al., J. Exp. Med., 183: 1533-1544, 1996; Kroemer, G., J. Exp. Med., 182: 367-377, 1995). This results in the release from the mitochondria of a 50 kD protein (not identified, but named AIF-apoptosis inducing factor), which is able to cause chromatin condensation and DNA fragmentation when incubated with nuclei (Kroemer, G., J. Exp. Med., 182: 367-377, 1995; Zamzami, N., et al., J. Exp. Med., 182: 367-377, 1995). However, it is noteworthy that first, cyt c release precedes mitochondrial membrane depolarization; second, cytosolic cyt c participates in activating caspase-3, whereas the 50 kD mitochondrial factor (AIF) directly induces apoptotic changes in the nuclei; and finally, activated caspase-3 induces apoptotic changes in nuclei only in the presence of cytosol, and such changes can be blocked by the presence of sub-micromolar concentrations of the tetrapeptide caspase-3 inhibitor (Yang, J., et al., Science, 275: 1129-1132, 1997). In contrast, AIF, once released from mitochondria upon depolarization, functions without cytosol and is insensitive to the caspase-3 inhibitor (Kroemer, G., J. Exp. Med., 182: 367377, 1995). Despite these differences, it is possible that these two pathways (i.e., cyt c and AIF-mediated) may work together to complete apoptosis. The pre-apoptotic mitochondrial perturbations include a rise in the reactive oxygen species (ROS) as well as the loss of Δψm (Kim, C. N., et al., Cancer Res., 57: 3115-3120, 1997). Both of these perturbations may be secondary to the mitochondrial loss of cyt c, which is no longer available to donate electrons to cytochrome oxidase (Kim, C. N., et al., Cancer Res., 57: 3115-3120, 1997; Capaldi, R. A., et al., Ann. Rev. Biochem., 59: 569-596, 1990). Consequently, this key Complex IV enzyme of oxidative phosphorylation may be unable to pump protons across inner mitochondrial membrane to preserve Δψm and completely reduce molecular oxygen to H2O, thereby resulting in the loss of Δψm and rise of the ROS (Capaldi, R. A., et al., Ann. Rev. Biochem., 59: 569-596, 1990). After accumulation in the cytosol, cyt c promotes the cleavage of caspase-3 in the presence of dATP and two additional apoptotic protease activation factors (APAF-1 and APAF-3) (Liu, X., et al., Cell, 86: 147-157, 1996). Therefore, down-regulation of intracellular Bcl-2 levels by sphingosine may abrogate the antiapoptotic activity of a number of proteins that exert their effects through Bcl-2. Also, the lowering of Bcl-2 levels may allow the proapoptotic Bax, Bak and Bcl-Xs to exact their proapoptotic effects more efficiently. Caspase-3 activity has also been shown to cleave and activate a recently cloned DNA fragmentation factor (DFF), which results in the DNA fragmentation of apoptosis (Liu, X., et al., Cell, 89: 175, 1997). More recently, the gene encoding the human APAF-1 has been cloned and shown to possess, in its N terminus domains, sequence homology to the ced-4 and ced-3 genes of c. elegans, the latter gene being homologous to caspase-3 (Zou, H., Cell, in press).
- Regulations of Apoptosis by Bcl-2 and Other Bcl-X Family Members
- Among the growing list of genes that regulate apoptosis is the Bcl-2 family of genes (Yang, E., et al.,Blood, 88: 386-401, 1996). The prototype Bcl-2 gene encodes for p26Bcl-2 protein which inhibits apoptosis (Reed, J. C., Nature, 387: 773, 1997). Several studies have demonstrated that over expression of Bcl-2 confers resistance against apoptosis due to a variety of chemotherapeutic agents as well as Fas death receptor apoptotic signaling (Tang, C., Leukemia, 8: 1960-1969, 1994; Kroemer, G., Nature Med., 3: 614-620, 1997). Bax is a member of the Bcl-2 family (Yang, E., et al., Blood, 88: 386-401, 1996). Bax dimerizes with Bcl-2, and the formation of Bax homodimers promotes apoptosis due to death signals (Yin, X. M., et al., Nature, 369: 321-323, 1994). Recent reports indicate that selected mutations within the conserved BH1 and BH2 regions of Bcl-2 disrupt its heterodimerization with Bax and abrogate the ability of Bcl-2 to inhibit apoptosis (Yin, X. M., et al., Nature, 369: 321-323, 1994; Zha, H., J. Biol. Chem., 271: 7440-7444, 1996). Bax homodimerization and its heterodimerization with Bcl-2 has also been shown to occur via a novel domain (BH3), distinct from BH1 and BH2 (Zha, H., J. Biol. Chem., 271: 7440-7444, 1996). Analogous to a rheostat switch, the balance between free Bax that favors death and Bcl-2/Bax heterodimers that inhibit cell death is critical (Oltvai, Z. N., et al., Cell, 79: 189-192, 1994). Although, Bcl-2/Bax ratio is inherent to the cell, drugs—including taxanes—or other apoptotic stimuli may be able to reset this rheostat (Ibrado, A. M., et al, Cancer Res., 57: 1109-1115, 1997; Oltvai, Z. N., et al., Cell, 79: 189-192, 1994). For example, a low ratio of Bcl-2 to Bax, by increasing free Bax, promotes cell death due to taxanes (Oltvai, Z. N., et al., Cell, 79: 189-192, 1994; Strobel, T., et al., Proc. Natl. Acad. Sci. USA, 93: 14094-14099, 1996). The loss or low levels of Bax have also been correlated with poor response to chemotherapy and shorter survival in women with metastatic breast cancer (Krajewski, S., et al., Cancer Res., 55: 4471-4478, 1995). It is now well-established that the wild-type tumor suppressor gene-product p53wt can induce apoptosis, while mutations or deletion of p53 cause resistance to apoptosis, especially due to DNA-damaging drugs, but not taxol (Oren, M., Semin. Cancer Biol., 5: 221-227, 1994; Lowe, S. W., et al., Science, 266: 807-810, 194; Wahl, A. F., et al., Nature Med., 2: 72-79, 1996). Furthermore, p53wt has been demonstrated to transcriptionally up-regulate Bax and decrease Bcl-2, thereby reducing Bcl-2/Bax ratio, and inducing apoptosis (Miyashita, T., et al., Oncogene, 9: 1799-1805, 1994; Miyashita, T., Cell, 80: 293-299, 1995).
- Bcl-x is another member of the Bcl-2 family and shares sequence homology with the conserved BH1 and BH2 regions of the Bcl-2 gene (Boise, L., Cell, 74: 597-608, 1993). By alternate mRNA splicing, Bcl-x encodes for two important protein isoforms of which the longer p29Bcl-xL inhibits apoptosis (Boise, L., Cell, 74: 597-608, 1993). The in vivo pattern of Bcl-XL expression is distinct form the Bcl-2 (Boise, L., Cell, 74: 597-608, 1993). p29Bcl-xL also renders cancer cells resistant to a variety of anticancer agents, including taxanes, Fas signaling, oxidants and radiation (Ibrado, A. M., et al., Cell Growth & Differ. 7: 1087-1094, 1996; Ibrado, A. M., et al., Cancer Res., 57: 1109-1115, 1997; Minn, A. J., et al., Blood 86: 1903-1910, 1995; Datta, R., et al., Cell Growth & Differ. 6: 363-370, 1995; Ibrado, A. M., Cancer Res., 56: 4743-4748, 1996). Bcl-xL has also been shown to block apoptosis where Bcl-2 is ineffectual (Gottschalk, A. R., et al., Proc. Natl. Acad. Sci. USA, 91: 7350-7354, 1994). In addition, a new member of the Bcl-2 family called Bak has also been isolated which like Bax promotes apoptosis (Keifer, M. C., et al, Nature, 374: 736-739, 1995). Bak heterodimerizes with Bcl-xL but not Bcl-2, and may also facilitate the generation of free Bax resulting in the formation of Bax homodimers (Keifer, M. C., et al., Nature, 374: 736-739, 1995). A novel protein, Bag-1, which binds to Bcl-2 but is not its homolog, synergizes with Bcl-2 to inhibit apoptosis (Takayama, S., Cell, 80: 275-284, 1995).
- Bcl-2 and Bcl-xL as Membrane Channel Proteins
- Recently, the three-dimensional structure of Bcl-xL has been shown to have two central hydrophobic helices surrounded by five amphipathic helices, as well as a 60-residue flexible loop domain (Muchmore, S. W., et al., Nature, 381: 335-341, 1996). This structure has homology to the pore-forming domains of bacterial toxins. Similarly, in the membranes, Bcl-xL forms an ion-conducting channel that displays multiple conductance states (Minn, A. J., et al., Nature, 385: 353-357, 1997). These conductance states of Bcl-xL, including a more complex large conductance channel, could result either from interaction with the other members of the pore-forming Bcl-2 families of proteins or from the distinct conformations that Bcl-xL may adopt (Minn, A. J., et al., Nature, 385: 353-357, 1997). The channel property of Bcl-xL may influence the mitochondrial permeability transition and other important mitochondrial functions (Zoratti, M., et al., Biochimica et Biophysica Acta, 1241: 139-176, 1994). In addition to being an ion-selective channel, Bcl-xL may facilitate the passage of other important proteins, such as cyt c, that trigger the cleavage and activity of caspase-3 and apoptosis (Golstein, P., Science, 275: 1081-1082, 1997). Interaction of Bcl-xL with Bax or other Bcl-2-related proteins could also influence the channel function of Bcl-xL for cyt c (Gajewski, T. F., et al., Cell, 87: 589-592, 1996). Furthermore, the post-translational modification of Bcl-2 and Bcl-xL by phosphorylation may also modulate its channel function, because Bcl-2 phosphorylation has been shown to be associated with an increase in free Bax levels and induction of apoptosis (Ibrado, A. M., et al., Cancer Res. 57: 1109-1115, 1997; Halder S., et al., Proc. Natl. Acad. Sci USA, 92: 4507-4511, 1995; Blagosklonny, M. V., et al., Cancer Res., 57: 130, 1997). Collectively, these observations help explain and are consistent with the finding that the over expressed Bcl-2 or Bcl-xL dimerized with Bax inhibits mitochondrial release of cyt c, which appears to precede the Δψm collapse and increase in the ROS (Kim, C. N., et al., Cancer Res., 57: 3115-3120, 1997).
- V. Inhibition of Protein Kinase C
- Protein kinase C (calcium/phospholipid protein kinase; referred to below as PKC) catalyzes the phosphorylation of the amino acids serine and threonine (Edelman, A., et al.,Ann. Rev. Biochem. 56:567, 1987). The enzyme was first characterized from brain tissue (Takei, et al., J. Biol. Chem. 252:3692, 1977) and is now known to occur in virtually all tissues of the body (Kuo, et al., Proc. Natl. Acad. Sci. USA. 97:7039, 1980). At least seven isozymes of PKC have been purified, cloned, and expressed. The distribution of the known isozymes of PKC varies significantly among different tissues (Huang, F., et al., J. Biol. Chem. 262:15714, 1987), suggesting that different isozymes may have different functions (Coussens, L., et al., Science 233:859, 1986; Ono, Y. and Kikkawa, U., Trends Biochem. Sci 12:421, 1987).
- The isozymes of PKC have been shown to have a varying dependency on three allosteric modulators: Ca2+, phosphatidylserine, and diacylglycerol (Nishizuka, Y., Nature 334:661, 1988). The mechanism of PKC activation by diacylglycerol, Ca2+, and phospholipid is complex and not entirely understood.
- The binding of a wide variety of extracellular hormones, neurotransmitters, and growth factors to their extracellular receptors stimulates the hydrolysis of phosphatidylinositols (Berridge, M.,Ann. Rev. Biochem. 56:159, 1987), phosphatidylcholines (Besterman, J., et al., Proc. Natl. Acad. Sci. USA. 83:6785, 1986), and phosphatidylethanolamines (Kester, M., et al., J. Clin. Invest. 83:718, 1989) to yield diacylglycerol. Production of diacylglycerol in turn stimulates protein phosphorylation by PKC. These pathways suggest that PKC may play an important role in signal transduction, cellular proliferation and differentiation, tumor promotion, and neurotransmission.
- The importance of PKC in cellular regulation is highlighted by the observation that phorbol diesters, which initiate cell proliferation, differentiation, arachidonate metabolism, oxygen metabolism, tumor promotion, and intense inflammation, bind to PKC at the same site as diacylglycerol and activate the enzyme (Niedel, et al.,Proc. Natl. Acad. Sci. USA. 80:36, 1983). Phorbol esters are derivatives of cyclopropabenzazulene. PKC is now thought to mediate most, if not all, of the biological effects of the diesters.
- Inactive PKC is largely cytosolic, and upon activation, is rapidly translocated to biological membranes. Phosphatidylserine is the most effective phospholipid in activating PKC when added with diacylglycerol and probably serves to mimic a biological membrane to which active PKC always binds.
- Many studies have suggested that diacylglycerol (DAG) has an important role in stimulating leukocytes. Stimulants of PKC, such as phorbol esters, cause redistribution of PKC from the cytosol to particulate fraction in neutrophils and monocytes (Snyderman, R. and Uhing, R., In:Inflammation: Basic Principles and Clinical Correlates, 309, edited by Gallin J. I., et al. (New York: Raven Press, Ltd. 1988). In addition, phorbol myristate acetate, in the presence of cytochalasin B, stimulates neutrophil degranulation (Goldstein, I., Contemp. Top. Immunobiol. 14:189, 1984). The relative potencies of various phorbol esters to cause PKC translocation are similar to their stimulatory effects on white cell superoxide production (Myers, M., et al., J. Immunol. 135:3411, 1985). The bacterial cell wall-derived peptide, formyl-Met-Leu-Phe (fMLP), a very potent chemotactic factor for leukocytes, increases membrane-associated PKC at concentrations that also stimulate respiratory burst (Pike, M., et al. Blood 67:909, 1986; McPhail, L., et al. Fed. Proc. 43:1661, 1984). Agents that inhibit chemo-attractant activation of neutrophil respiratory burst specifically inhibit the translocation of PKC to the plasma membrane (Pike, M., et al., Blood. 67:909, 1986). Thus, translocation of PKC to the plasma membrane appears to be crucial for activation of the respiratory burst induced in neutrophils by fMLP. Evidence indicates that both neutrophil secretion and respiratory burst may be regulated either by different compartments of PKC, or different isozymes of PKC (Cox, C., et al., J. Immunol. 136:4611, 1986). There is also data to suggest that the differentiation of monocytes to macrophages is mediated by PKC (Snyderman, R. and Uhing, R., In: Inflammation: Basic Principles and Clinical Correlates, edited by Gallin, J., et al. (New York: Raven Press, Ltd., 309, 1988)).
- In light of the wide ranging biological functions of PKC, it would be of great therapeutic value to have specific modulators of the enzyme. For example, interleukin-1 is a primary mediator of inflammatory diseases such as rheumatoid arthritis, and evidence exists to suggest that PKC mediates some of the effects of interleukin-1. Thus, a PKC inhibitor may be useful for treatment of inflammatory disease, blocking the effects of interleukin-1 as well as other inflammatory mediators such as bradykinin and substance P. Since activation of PKC serves as a powerful proliferative signal in many tissues, a PKC inhibitor may also be of utility in proliferative diseases such as psoriasis, cancer and other metastatic illnesses. In addition, the brain and several endocrine organs contain large amounts of protein kinase C. As a result, a PKC inhibitor may find utility in certain neurological or endocrine diseases. In addition, a vascular PKC inhibitor may have utility as a therapy for essential hypertension.
- PKC inhibitors include sphingosine and certain related sphingolipids. (Bell, R., et al.Cold Spr. Harbor Sym. Quant. Biol. 53:103, 1988). This group of compounds compete with the phorbol ester binding site and thus have the potential for specificity. However, not only has sphingosine also been reported to inhibit Ca2+/calmodulin protein kinase (Jefferson, A. and Schulman, H., J. Biol. Chem. 263:15241, 1988), but sphingosines may inhibit other biological processes in a nonselective manner (Pittet, D., et al., J. Biol. Chem. 262:10072, 1987; Winicov, I. and Gershengorn, M., J. Biol. Chem. 263:12179, 1988).
- As one embodiment of the invention disclosed herein, a sphingolipid metabolic altering compound is administered in an effective treatment amount to inhibit protein kinase C in a host in need of treatment. By administering the sphingolipid in this type of prodrug state, wherein R2 is either one of the listed groups that can be cleaved by an enzyme in vivo, or wherein R2 is a targeting moiety, one can ameliorate problems associated with nonselective responses. An example of this targeting would be the feeding of complex sphingolipids that are digested in the colon to release the sphingoid base (for example, sphingosine) backbone, to inhibit protein kinase C in colon tumors.
- As one aspect of this invention, inflammatory disorders that are mediated by PKC can be treated by administration of an antiinflammatory treatment amount of a sphingolipid metabolism altering compound, or its pharmaceutically acceptable salt. An inflammatory response is a pathologic condition that can occur in response to immunologically non-specific injury, either from physical (such as trauma), chemical, or biologic agents. An inflammatory response is characterized by increased blood flow and redness in the inflamed area, increased capillary permeability and edema, and recruitment of immunologically non-specific white blood cells, especially neutrophils, that remove injurious material and promote repair. Cellular products of lymphocytes may contribute to or induce an inflammatory response. Examples of inflammatory disorders that may be treated by the sphingolipid metabolism altering compound include but are not limited to inflammatory bowel disease, psoriasis, proliferation of smooth muscle cells in the course of development of plaques in vascular tissue.
- In one example, the initial phase of anaphylaxis, including attacks of allergic asthma, is due largely to degranulation and mediator release from mast cells (Friedman, M. and Kaliner, M.,Am. Rev. Respir. Dis. 135:1157, 1987; Kaplan, A. and Silverberg, M., Methods Enzymol. 163:3, 1988). These mediators, including histamine and several eicosanoids, cause airway smooth muscle spasm, vasodilation and plasma extravasation, and are the major culprits in acute allergic inflammation. The biochemical mechanisms leading to cell activation subsequent to IgE binding to and cross-linking of its receptors on the mast cell surface are not completely understood. However, mast cell mediator release is calcium-dependent (Pearce, F., I. Asthma Reviews, I:95, edited by Morley J. (London: Academic Press Ltd., 1987)); (Siraganian, R., Inflammation: Basic Principles and Clinical Correlates, edited by Gallin, J., et al. (New York: Raven Press Ltd., 513, 1988)). Increased turnover of mast cell phosphoinositides (PI), following both IgE-mediated and pharmacological stimulation has been established (Pearce, F., I. Asthma Reviews,
Volume 1, edited by Morley J. London: Academic Press Ltd., 95, 1987), and PI turnover closely correlates with histamine secretion. It has also been suggested that the PI response generates arachidonic acid, that is metabolized further to produce thromboxane, prostanoids and leukotrienes. In addition, the PI cycle generates DAG which, as has already been discussed, stimulates PKC. PKC acts synergistically in many cells to evoke the secretory response (Drummond, A. and Maclntyre, D., Trends Pharmacol. Sci. 6:233, 1985). Indeed, phorbol esters, by activating PKC, stimulate mediator secretion both from mast cells and basophils (Siraganian, R., Inflammation: Basic Principles and Clinical Correlates, 513, edited by Gallin, J., et al. (New York: Raven Press Ltd., 1988); Schleimer, R., et al., J. Immunol. 126:570, 1981.) Further, during mast cell activation there is an increase in membrane-associated PKC. (White, J., et al., Proc. Natl. Acad. Sci. USA. 82:8193, 1985.) - VI. Modification of the Colonization of Microfora
- Many microorganisms, microbial toxins, bacteria and viruses have receptors which bind to cells via sphingolipids. Therefore, populating the binding sites with sphingolipid analogs, including but not limited to the compounds described herein, in the prodrug state or as metabolized, serves to (i) decrease the colonization of the microorganism, and (ii) modify the colonization of microfora that influence colon cancer and other disorders of the intestine. The compound binds to the sphingolipid receptor of the microorganism, saturating the receptor and facilitating elimination of the organisms and toxins.
- In an additional embodiment of the present invention, a process for modifying the colonization of microfora that influence colon cancer and other intestinal disorders is provided that comprises administering an effective amount of a sphingolipid derivative to a host.
- These compounds can in particular be used to treat infections caused by bacteria (gram negative and gram positive) and viruses which have receptors for sphingolipids as anchoring means for colonization. Nonlimiting examples of microorganisms that can be treated using this method include cholera toxin, verotoxin, Shiga-like toxin 2e, Clostridium botulinum type B neurotoxin,Escherichia coli, Haemophilus influenzae; Helicobacter pylori; Borrelia burgdorferi, Pseudomonas aeruginosa, Candida albicans, HIV, Sendai virus, and influenza viruses. In this embodiment, an effective amount of a selected compound falling within the above formula is administered to decrease or prevent colonization of the selected microorganism.
- VII. Preparation of Active Compounds
- Compounds described herein can be prepared using literature methods, including for example, in U.S. Pat. Nos. 5,232,837, 5,518,147, and 5,110,987, or routine modifications of these methods. The addition of the R2 groups can be accomplished using the method described below or a modification thereof.
- Additional information concerning the synthesis of compounds described herein can be obtained from the following references: Bruzik, K. S. The synthesis and absolute configuration of thiosphingomyelins (Journal of the Chemical Society. Chemical Communication, 329-331, 1986.) Synthesis and spectral properties of chemically and stereochemically homogenous sphingomyelin and its analogues (Bruzik, K. S., et al., Journal of Chemical Society. Perkin Trans. 1:423-431, 1988.) H-Phosphonate and phosphoramidite methods for the synthesis of sphingophospholipids (Frantova, A. Y., et al., Bioorganicheskaya Khimiya.; 17:1562-1573, 1991.) Facile synthesis of α- and β-O-glycosyl imidates; preparation of glycosides and disaccharides (Schmidt, R. R., et al., Angewandte Chemie, Int. Ed. Engl.; 19:731-732,1980); Short Synthesis of Cerebrosides, (Schmidt, R. R., et al., Angewandte Chemie. Int. Ed. Engl., 24(1): 65-66, 1985); Selective Synthesis of Cerebrosides: (2S, 3R, 4E)-1-O-β-D-galactopyranosyl-N-(2′-hydroxytetracosanoyl-sphingenine (Koike, K. et al., Glycoconjugate Journal,; 2:105-108, 1985); The synthesis of aryl-D-β-glucopyranosiduronic acids, (Bollenback, G. N., et al., Journal of the American Chemical Society. 77:3310-3315, 1955); Stereoselective total synthesis of wheat flour ceramide dihexoside. (Koike, K., et al., Agricultural and Biological Chemistry, 54:2931-2939, 1990); Einfache Synthese von, β-D-Glucopyranosyluronaten. (Schmidt, R. R., et al., Synthesis, 885-887, 1981); The Synthesis and Configurational Stability of Differentially Protected β-Hydroxy-α-amino Aldehydes. (Gamer, P., et al., Journal of Organic Chemistry; 52:2361-2364, 1987); 1,1-Dimethylethyl (S)- or (R)-4-formyl-2,2-dimethyl-3-oxazolidinecarboxylate: a useful serinal derivative. (Garner, P. et al., Organic Synthesis, 70:18-28, 1991); Synthesis of D-erythro- and D-threo-sphingosine derivatives from L-serine. (Herold, P., Helvetica Chimica Acta, 71:354-362, 1988); A stereodivergent synthesis of D-erithro-sphingosine and D-threo-sphingosine from L-serine. (Garner, P. et al., Journal of Organic Chemistry, 53:4395-4398, 1988); Total Synthesis of Symbioramide, a Novel Ca-2+-ATPase Activator from Symbiodinium-Sp. (Yoshida, J. et al., Journal of the Chemical Society. Perkin Transaction, 1:343-350, 1992); Synthesis of Sphingosine Relatives, x[V. A New Synthesis of Symbioramide, a Ca++-ATPase Activator from Symbiodinium sp. (Mori, K. et al., Liebigs Annalen der Chemie, 41-48, 1994); Shapiro, D., Chemistry of sphingolipids. Paris, 1969); Synthesis of D-Erythro-Sphingomyelin and D-Erythro-Ceramide-1-Phosphoinositol. (Kratzer, B. et al., Tetrahedron Letters, 34:6881-6884, 1993); Efficient Synthesis of Sphingosine-1-phosphate, Ceramid-1-phosphate, Lysosphingomyelin, and Sphingomyelin. (Kratzer, B., et al., Liebigs Ann., 957-963, 1995).
- FIG. 6 illustrates a short seven-step synthesis of D-erythro-3-O-benzoylceramides (8a,b), that includes use of commercially available N-Boc-L-Ser-OMe (1) as the starting material. The synthesis provided yields of 27 and 31%, respectively. Phosphytilation with O-methyl-N,N-diisopropylaminophosphorochloridite was employed for the introduction of the phosphoryl choline moiety into (8a,b). This allowed for the preparation of D-erythro-N-palmitoylsphingomyelin (17a) and D-erythro-N-palmitoyldihydrosphingomyelin (17b) in
total yields - Material and Analytical Procedures.
- Palmitoyl chloride, benzoyl chloride, N-Boc-L-serine methylate (1), chloro (N,N-diisopropylamino)-methoxyphosphine, D-gluronolactone (18), borontrifluoride etherate, 2,2-dimethoxypropane, 1H-tetrazole (sublimated), hydrazine acetate, triethylamine were purchased from Aldrich and used without further purification. tert-Butylhydroperoxide, DIBAL-H, n-BuLi (1.6 M solution in hexanes), LAH (1.0 M solution in THF), were purchased from Aldrich. Pentadecyne was purchased from Lancaster. Choline tosylate was purchased from Sigma or prepared from choline hydroxide (from Aldrich) and p-oluenesulfonic acid monohydrate. All melting points are uncorrected. Unless otherwise stated, IR spectra were recorded as a film with mineral oil on sodium chloride discs using an Impact 400 IR spectrometer and only the structurally important peaks are listed.1H and 13C NMR spectra were recorded on a General Electric QE-300 (300 MHZ 1H, 75.5 MHZ 13C) spectrometer in deuteromethanol and/or deuterochloroform. The positive and negative ion FAB mass spectra were taken on JEOL spectrometer.
Merck Silica Gel 60 TLC plates of 0.25 mm thickness were used to monitor the reactions, with visualization by heating with the Sigma spray reagent molybedenum blue (for phosphorus containing compounds) and Horcinol spray reagent. Flash column chromatographies were performed using Silica Gel 60 (Merck, 230-400 mesh ASTM). Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, Ga. Optical rotations were measured in 1 dm tube with a Perkin-Elmer Polarimeter 241 MC (USA). - Experimental Procedures.
- The synthesis of 3-O-benzoylceramides (8a,b).
- According to the methods given in Garner, P. et al., (J. Org. Chem. 52:2361-2364, 1987; Orgainic Synthesis, 70:18-28, 1991), the synthesis of 3-(1,1-dimethylethyl)-4-methyl-(S)-2,2-dimethyl-3,4-oxazolidinedi-carboxylate from N-Boc-L-Ser-OMe was carried out in a yield of 76-78%, [a]D 25−57.63° (c=1.30, CHCl3). Lit. [α]D−46.7° (c=1.30, CHCl3). The reduction of isopropylidene derivative with DIBAL leads to the aldehyde in a yield of 84-85%. [a]D 25−96.40° (c=1.34, CHCl3). Lit. [α]D−91.7° (c=1.34, CHCl3). The condensation of pentadecyne to aldehyde lead to the formation of 1,1-dimethyl [R(R*,S*)]-2,2-dimethyl-4-(]-hydroxy-2-hexadecynyl)-3-oxazolidinecarboxylate as described in Harold, P., Helvetica Chimica Acta 71:354-362, 1988; and Garner, P., et al., J. Org. Chem. 53:4395-4398, 1988. Yield 58.0%, [α]D 23−39.0° (c=1.43, CHCl3). Mass-spectrum, m/z: 438.36. (M+H)+ C26H48NO4 requires 438.36. Lit. [α]D−39.7° (c=1.41, CHCl3).
- 1,1-Dimethyl [R-(R*,S*)]-2,2-dimethyl-4-(1-benzoyloxy-2-hexadecynyl)-3-oxazolidinecarboxylate (6a). A solution of hexadecyne derivative (4) (6.30 g, 14.39 mmol) in THF (500 mL) was added dropwise to a solution of Li (5.2 g) in liquid ammonia (500 mL) at −75° C. for 6 h, after which ammonium chloride (125 g), ethylacetate (650 mL), and water (400 mL) were sequentially added. The organic layer was separated and the aqueous layer was washed with EtOAc (2×500 mL). The organic solutions were combined, dried with magnesium sulfate, and concentrated in vacuo. The residue, 1,1-dimethyl [R-(R*,S*)]-2,2-dimethyl-4-(1-hydroxy-2-hexadecenyl)-3-oxazolidinecarboxylate (5a) (6.3 g, ˜100%, homogeneous by TLC analysis using hexane-EtOAc, 3:1; Rf 0.37) was taken up by a mixture of methylene dichloride (70 mL) and pyridine (8 mL) and to this was added benzoyl chloride (5.0 mL, 6.1 g, 43 mmol) at 0° C. over a period of 15-20 min. The reaction mixture was allowed to warm to room temperature over a period of 5 h. Water (3 mL) was then added and stirring was continued overnight. The reaction mixture was diluted with ether (1 L) and the ether solution was washed sequentially with 10% sodium bicarbonate solution (2×100 mL), brine (2×100 mL), dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel (270 g) using hexane-EtOAc, 9:1 as the eluent. Yield 6.75 g (86.3%). Rf 0.50 (Hexane-EtOAc, 6:1), [α]D 23−30.2° (c=1.49, CHCl3), IR (neat): 1723, 1702, 1268, 1175, 1107, 1069 (cm−1). Calculated %: C 72.89; H 9.82; N 2.58 for C33H53NO5. Found %: C 72.84; H 9.85; N 2.55. Mass-spectrum, m/z: 550.41, (M+Li)+ C33H53NO5Li requires 550.41.
- 1,1-Dimethyl [R-(R*,S*)]-2,2-dimethyl-4-(1-benzoyloxy-2-hexadecynyl)-3-beoxazolidinecarboxylate (6b). According to the method described in Yoshida, J., et al.,J. of the Chemical Society. Perkin Transaction I 343-350, 1992, alkyne derivative (4) (16.82 g, 38,43 mmol) was hydrogenated at room temperature in ethyl acetate (200 mL) over platinum oxide with hydrogen at atmospheric pressure for 2 h (yield ˜100%). The product 5b exhibited the following characteristics: Rf 0.46 (Hexane-EtOAc, 9:2), [α]D 25−13.74° (c=0.84, CHCl3), IR (neat): 3434, 1697, 1675, 1459, 1381, 1252, 1170, 1092, 1066, 841 (cm−1). Mass-spectrum: m/z: 442.39. (M+H)+ C26H52NO4 requires 442.39. Lit. [α]D 21−13.0° (c==1.03, CHCl3) [15]. The product 5b was transformed to 6b using the procedure employed for the conversion of 5a to 6a [yield 95-98%, Rf 0.55 (Hexane-EtOAc, 6:1), IR (neat): 2916, 2851, 1722, 1699, 1454, 1389, 1269, 1172, 1103, 849, 706 (cm−1). Mass-spectrum: m/z: 546.41. (M+H)+ (C33H56NO5 requires 546.41).
- D-erythro-3-Benzoyl-2-N-palmitoyl-sphingosine (3-O-benzoylceramide) (8a). To a solution of a
benzoyl derivative 6a (6.75 g, 12.4 mmol) in methylene dichloride (150 mL) was added trimethylsilyl iodide (2.2 mL, 3.1 g, 15.5 mmol), and reaction mixture was stirred at 20-25° C. for 2-3 h. A water methanol mixture (1:4, 10 mL) was added and after 15 min the reaction mixture was concentrated in vacuo. The residue [crude 3-O-benzoylsphingenine (7a), Rf 0.58, chloroform-methanol-25% ammonium hydroxide, 7:1:0.1] was taken up in a mixture of THF (160 mL) and IM acetic acid (60 mL) and a solution of palmitoyl chloride (3.70 g, 13.5 mmol) in THF (30 mL) and saturated solution of sodium acetate (160 mL) were added simultaneously. The reaction mixture was allowed to stir at 20-25° C. for 2 h, after which the mixture was diluted with water (250-300 mL). The precipitate was separated by filtration, washed sequentially with 5% sodium bicarbonate and water, dried in air, and crystallized from ethanol (150 mL). The yield was 5.71 g (71.7%). Mp 88.0-88.5° C., [α]D 25+21.0° (c=1.07, CHCl3). Lit. Mp 88-90° C., [α]D+13.0° [Shapiro, D. Chemistry of sphingolipids, Paris, 1969]. - D-erythro-3-Benzoyl-2-N-palmitoyldihydrosphingosine (3-O-benzoyldihydroceramide) (8b). Starting from 3-O-benzoyl derivative (6b) (4.63 g, 8.48 mmol) 3-benzoylceramide (8b) was prepared with the yield 82-83%. Mp 75.0-75.5° C. (MeOH), [α]D 25+32.56° (c=1.26, CHCl3). IR (in mineral oil): 3427 (OH), 3300 (NH), 1717 and 1693 (C═O of benzoate), 1638 (amide I), 1537 (amide II), 1276 (C—O of benzoate) (cm−1). Lit. Mp 78-80° C., [α]D+26.0° [Shapiro, D. Chemistry of sphingolipids, Paris, 1969].
- The synthesis of sphingomyelins (17a,b).
- D-erythro-3-O-Benzoyl-2-N-palmitoylsphingenine-1-phosphorylcholine (3-O-benzoylsphingomyelin) (16a). To a solution of 3-O-benzoylceramide (8a) (2.79 g, 4.34 mmol) in methylene dichloride (25 mL) were added triethylamine (1.4 mL, 1.02 g, 10.08 mmol) and chloro (N,N-diisopropylamino)methoxyphosphine (1.20 g, 1.18 mL, 6.1 mmol), and the resulting reaction mixture was allowed to stir at 20-25° C. for 1 h. After this time the reaction appeared to be complete (TLC control, hexane-ether-Et3N, 20:40:1) and so the reaction mixture was concentrated in vacuo, dried by reevaporation with toluene. The residue (
crude amidite 13a), was dissolved in THF (20 mL) and to the solution were added choline tosylate (4.60 g, 16.7 mmol) in acetonitrile (35 mL) and 1H-tetrazole (1.20 g, 16.9 mmol) in acetonitrile (25 mL). The reaction mixture was allowed to stir at 20-25° C. for 2.5 h. After the reaction appeared to be complete (TLC control, hexane-Et3N, 20:1), tert-butyl hydroperoxide (5.0-6.0 M solution in 2,2,4-trimethylpentane) (2.5 mL) was added and the reaction mixture was allowed to stir at 20-25° C. for 2 h. After the oxidation of phosphite triester (14a) to its corresponding phosphate triester (15a) appeared to be complete (TLC control, chloroform-methanol-ammonium hydroxide, 25%, 7:1:0.1), the reaction mixture was concentrated in vacuo and the residue was dissolved in methylene dichloride (20 mL). tert-Butylamine (10 mL) was then added and the reaction mixture was allowed to stir at 20-25° C. overnight. The reaction mixture was concentrated in vacuo and the residue was chromatographed on silica gel (175 g) using a mixture chloroform-methanol-water, 65:35:4, yielding 2.35 g (67.1%) of 3-O-benzoylsphingomyelin (16a), amorphous solid, Rf 0.51 (chloroform-methanol-acetic acid-water, 100:50:16:8). [α]D 23+6.08° (c=1.15, CHCl3). IR (in mineral oil): 3500, 3300, 1715 (C═O of benzoate), 1645 (amide I), 1540 (amide II), 1262 (C—O of benzoate), 1119-1034 (PO3), 966, 716 (cm−1). Mass-spectrum: m/z: 807.60 (M+H)+ (C46H84N2O7 requires 807.60). - D-erythro-2-N-Palmitoylsphingenine-1-phosphorylcholine (N-Palmitoylsphingomyelin) (17a). To a solution of 3-O-benzoylsphingomyelin (16a) (2.06 g, 2.55 mmol) in methanol (25 mL) was added 2M sodium methoxide solution in methanol (2.5 mL), and the reaction mixture was allowed to stir at 20-25° C. for 2 h. The reaction mixture was neutralized with acetic acid, concentrated in vacuo and the residue was chromatographed on silica gel using a mixture chloroform-methanol-water (65:35:4) yielding 1.74 g (97.2%) of sphingomyelin (17a) (monohydrate). Mp˜190° C., Rf=0.36 (chloroform-methanol-acetic acid-water, 100:50:16:8). [α]D 22+5.6° (c=1.02, CHCl3—MeOH, 1:1) or +4.3° (c=1.07, CHCl3—MeOH—H2O, 65:35:4). Mass spectrum: m/z: 703.58 (M+H)+ (C39H8N2O6P requires 703.58). Lit. mp 215-217° C., [α]D 25+6.1°, or [α]D+6° [c=1, CHCl3—MeOH, 1:1] [Kratzer B., Tetrahedron Letters, 34:6881-6884, 1993; and Kratzer, B., et al., Liebigs Ann. 957-963, 1995].
- D-erythro-3-O-Benzoyl-2-N-palmitoylsphinganine-1-phosphorylcholine(3-O-benzoyldihydrosphingomyelin) (16b). To a solution of 3-O-benzoyldihydroceramide (8b) (4.84 g, 7.51 mmol) in methylene dichloride (40 mL) were added triethylamine (2.42 mL) and chloro (N,N-diisopropylamino) methoxyphosphine (2.07 g, 2.03 mL, 10.5 mmol), and the reaction mixture was allowed to stir at 20-25° C. for 1 h. After the reaction appeared to reach completion (TLC control, hexane-ether-Et3N, 20:40:1), the reaction mixture was concentrated in vacuo and dried by reevaportion with toluene. The residue (crude amidite 13b), was dissolved in THF (36 mL) and choline tosylate (7.90 g, 28.7 mmol) in acetonitrile (86 mL) and 1H-tetrazole (2.02 g) in acetonitrile (50 mL) were added. The reaction mixture was allowed to stir at 20-25° C. for 4.5 h. After reaction appeared to reach completion (TLC control, hexane-Et3N, 20:1), tert-butyl hydroperoxide (5.0-6.0 M solution in 2,2,4-trimethylpentane) (8.0 mL) was added and the reaction mixture was allowed to stir at 20-25° C. for 1.5 h. After oxidation of phosphite triester (14b) to the corresponding phosphate triester (15b) appeared to be completed (TLC control, chloroform-methanol-ammonium hydroxide, 25%, 7:1:0.1), the reaction mixture was concentrated in vacuo and the residue was dissolved in methylene dichloride (50 mL). tert-Butylamine (50 mL) was added and the reaction mixture was allowed to stir at 20-25° C. for ˜20 h. The reaction mixture was concentrated in vacuo and the residue was chromatographed on silica gel (175 g) using a mixture chloroform-methanol-water (165:35:4). The resulting product was further purified via an Amberlite MB-3 column by using a mixture of chloroform-methanol-water (7:7: 1) as the eluent. Yield=4.39 g (71.9%), amorphous product 16b (as monohydrate), Rf=0.51 (CHCl3-methanol-acetic acid-water, 100:50:16:8), IR (in mineral oil): 3343, 1704 (C═O), 1651 (amide I), 1531 (amide II), 1277, 1180, 1117, 976, 720 cm−1. Mass-spectrum: m/z: 809.62. (M+H)+ (C46H86N2O7P requires 809.62).
- D-erythro-2-N-Palmitoylsphinganine-1-phosphorylcholine-(N-Palmitoyl-dihydrosphingomyelin) (17b). To a solution of 3-O-benzoyldihydrosphingomyelin (16b) (1.97 g, 2.38 mmol) in methanol (35 mL) was added a 2M sodium methoxide solution in methanol (3.5 mL). The reaction mixture was allowed to stir at 20-25° C. for 2-3 h, then neutralized with acetic acid and concentrated in vacuo. The residue was washed with acetone and the crude product was purified via an Amberlite MB-3 column using a mixture of chloroform-methanol-water (7:7:1 (50 mL)). Yield=1.58 g (91.9%), monohydrate of (17b). Mp 220-221° C., Rf=0.36 (CHCl3-methanol-acetic acid-water, 100:50:16:8). [α]D 25+24.04° (c=0.92, CHCl3—MeOH, 1:1). IR (in mineral oil): 3286 (NH and OH), 1641 (amide I), 1549 (amide II), 1229 (C—O of benzoate), 1087 and 1059 (PO3 −), 970, 830, 721 cm−1. Mass spectrum: m/z: 705.59. (M+H)+ (C39H82N2O6P requires 705.59). Lit. mp 222-223° C., [α]D 2+22.5° [Shapiro, D. Chemistry of Sphingolipids, Paris, 1969].
- The synthesis of B-D-Glucuronocerebroside (27).
- According to the procedure provided in Bollenback, G. N., et al.,J. of the American Chemical Society 77:3310-3315, the synthesis of B-D-tetra-O-acetylglucoronic acid methyl ester (20) was performed from D-glucoronolactone (18) in a yield of 32.4%, [α]D 25+8.3° (c=2.26, CHCl3). M.p. 175.0° C. Mass spectrum: m/z: 377.11. (M+H)+ (C15H21O11 requires 377.11). Lit.: [α]D 25+8.7° (c=1, CHCl3), m.p. 176.5-178° C.
- 2,3,4-Tri-O-acetyl-D-glucoronic acid methyl ester (21). A mixture of β-acetoxy-glucuronic acid methyl ester (20) (4.9 g, 13.0 mmol) and hydrazine acetate (2.1 g, 22.8 mmol) in DMFA (100 mL) was stirred at room temperature for 1.5 h. The mixture was diluted with ethyl acetate (1 L), washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel (hexane-ether, 1:4, then ether), to give compound (21). Yield 4.2 g (96.5%). Rf=0.40 (hexane-THF, 3:2). [α]D 22+85.2° (c=1.01, chloroform). IR (in mineral oil): 3450, 1760, 890 (cm−1). Mass spectrum: m/z: 341.11 (M+Li)+ (C13H18O10Li requires 3.41.11).
- O-(2,3,4-Tri-O-acetyl-a-D-glucuronopyranosyl methylate)-trichloroacetimidate (22). To a solution of hemiacetal (21) (6.3 g, 18.9 mmol) in methylene dichloride (130 mL) were added trichloroacetonitrile (19.0 mL, 190 mmol) and potassium hydride (0.74 g, 72 mmol) and resulting reaction mixture was allowed to stir at room temperature. In 2-3 h the reaction mixture was filtered through Celite 500 and the filtrate was concentrated in vacuo. The residue was passed through short column of silica gel using ether as the eluent to give compound (21). Yield=7.6 g (84.3%). Rf0.75 (ether). [a]D 22+93.6° (c=1.0, chloroform). Mass spectrum: m/z: 484.02. (M+Li)+ C15H18NO10Li requires 484.02.
- I-O-B-D-Glucuronoyl-2N-palmitoylsphingosine (27). A mixture of 3-O-benzoylceramide (8a) (1.62 g, 2.52 mmol), imidate (22) (2.43 g, 5.07 mmol) and
molecular sieves 4 Å (11.7 g) was dried in vacuo for 36-40 h. This mixture was taken up into methylene dichloride (75 mL), and a solution of borontrifluoride etherate in methylene dichloride (1:9, 8 mL, ˜5 mmol) was added in 1 mL portions for 30 min at −50° C. The reaction mixture was allowed to stir at the same temperature for 5-6 h and stored in a refrigerator overnight. The next morning 2 g of sodium bicarbonate was added and in 15-20 minutes the reaction mixture was filtered through Celite 500 and the filtrate concentrated in vacuo. The residue was chromatographed on silica gel using a mixture hexane-ethyl acetate (2:1) to yield compound 23 [Rf 0.40 (chloroform-methanol, 20:0.5). Mass spectrum, m/z: 964.63. (M+Li)+ C54H87NO13Li requires 964.63. Calculated %: C 67.68; H 9.15; N 1.46. Found %: C 67.46; H 9.21; N 1.43.], contaminated with 1-O-acetyl-3-O-benzoylceramide (25) [Rf 0.50 (chloroform-methanol, 20:0.5. Mass spectrum, m/z: 690.57;] and 3-O-benzoylceramide (8a) (2.15 g). This mixture was dissolved in chloroform-methanol-water (7:7:1, 100 mL) and a 0.5 M solution of potassium hydroxide in methanol (40 mL) was added. The reaction mixture was allowed to stir at room temperature for 20-24 h. The potassium salt of compound (27) was separated by filtration, dissolved in a mixture of chloroform-methanol-water (7:7:1, 150 mL) and was shaken with Amberlyst 15 (500 mg) for 25-30 minutes. The resin was removed by the filtration, the filtrate was washed with water (3×50 mL) and concentrated in vacuo. The residue was chromatographed on silica gel using a mixture chloroform-methanol-acetic acid-water (100:20:12:5) as the eluent to yield 0.50 g (27.8%) of β-D-glucuronylceramide (27) as white solid. R=0.35 (chloroform-methanol-acetic acid-water, 100:20:12:5). Mass spectrum: m/z: 712.54. (M−H)− (C40H74O9 requires 712.54). - Coupling a protected alkynyl derivative to an oxazolidine aldehyde is an efficient and versatile preparation of sphingolipids with a polar terminus, such as an amine, hydroxyl, or carboxyl group. After the addition reaction, a terminal hydroxyl group is available for conversion into a variety of other functionality. These terminally polar sphingolipids are an important class of molecules because they can attach to a solid support creating an affinity column for enzymes (Raun, F., et al.,Tetrahedron Lett., 36:6615, 1995; and Kozikowski, A., et al., Tetrahedron Lett., 37:3279, 1996). They are also interesting because they are structurally similar to a class of mycotoxins called the Fumonisins.
- The synthesis of these molecules began with readily available alkynes (28), (FIG. 10). The treatment of the alkyne with lithium diisopropylamide (LDA) generated the alkynyllitheate which was then reacted with paraformaldyhyde to produce the propargyl alcohol (29). A contra thermodynamic acetylene-zipper reaction migrated the triple bond away from the hydroxyl group (29a) (Brown, C. A., et al., J. Am. Chem. Soc. 1975, 97, 891). Then 1,1-dimethylethyl-dimethyl-silyl (TBDMS) protection of the alcohol completed the preparation of the alkynol segment (Corey, E. J. et al., J. Am. Chem. Soc. 1972, 94, 6190). In a few instances, analogs of (30) were purchased directly.
- The oxazolidine aldehyde (31) was prepared according to a procedure by Garner (Garner, P. et al.,J. Org. Chem., 52:2361, 1987). The coupling of protected alkynyl derivatives to (31) was accomplished by first producing the litheate of the alkyne with LDA and then slowly adding (31). The propargyl alcohol (32) was protected as the acetate by treating with triethylamine and acetic anhydride. The silyl ether was cleaved by stirring (33) in the presence of an acidic resin, Amberlyst-15. At this point, the compound (33a) may be modified in several ways: oxidation to produce the acid or ester, fluorination, elimination, or substitution. In order to attach the sphingolipid to a solid support, an amine terminus was desired. This functionality was introduced by first preparing the mesylate of (34) by adding triethylamine and methansulfonyl chloride. Displacement of the mesylate with sodium azide in DMF produced compound (35). Azide reduction with thiophenol, tin chloride, and triethylamine gives (36). Reduction of the triple bond with Red-AI efficiently produces the E isomer (37). The final steps in this sythesis were deprotection of the acetate with potassium carbonate in methanol (Plattner, J. J.; Gless, R. D.; Rapoport, H., J. Am. Chem. Soc., 94:8613, 1972), and then removal of the acetonide and t-butoxy carbonyl (BOC) group with HCL to yield (38). This synthesis is illustrated in FIG. 11.
- Experimental Procedures
- 2-nonyn-1-ol (40) (
compound 29 where x=4). In a 250-mL flask equipped with a stir bar, I-Pr2NH (7.34 g, 72.5 mmol) and THF (20 mL) were stirred under argon and cooled to 0° C. A 2.5-M solution of n-BuLi in toluene (29.0 mL, 72.5 mmol) was added slowly to the stirring solution. The reaction was stirred for 30 min at 0° C. and then cooled to −78° C. in a dry ice/acetone bath. Then 1-octyne was added slowly via syringe to the reaction and a white precipitate formed. To dissolve the precipitate, HMPA (23.6 g, 132 mmol) was added in one portion. The cloudy solution was stirred under argon at −78° C. for 30 minutes before warming to 0° C. when the precipitate dissolved. A solution of paraformaldehyde (CH2O)n (5.94 g, 198 mmol) in THF (60 mL) was stirred under argon at −78° C. The alkynyllitheate was then added via cannula with positive argon pressure to the (CH2O)n solution. The reaction was then allowed to warm slowly to room temperature. The reaction was quenched with water and extracted with Et2O. The organic layers were combined, washed with water and brine, dried with MgSO4, and concentrated. This produced 24.4 g of orange oil. The product was purified with flash column chromatography on silica gel (10% Et2O in hexane) to give 5.07 g of amber oil (55%): IR (neat) ν 3331, 2933, 2224 cm−1; 1H-NMR δ4.22 (t, 2H, J=2.0 Hz), 2.18 (m, 2H), 2.07 (s, 1H), 1.45 (m, 2H), 1.27 (m, 8H), 0.87 (t, 3H, J=6.9 Hz); 13C-NMRδ86.5, 78.3, 51.2 31.3, 28.5 (2C), 22.5 18.7, 14.0; MS m/z 147.08 (M++Li). Anal. Calcd for C9H16O: C, 77.09; H, 11.50. Found: C, 76.93; H, 11.41. - 2-pentadecyn-1-ol (41) (
compound 29 where x=10). The same procedure for 2-nonyn-1-ol was followed with 1-tetradecyne (7.38 g, 38.0 mmol), I-Pr2NH (4.23 g, 41.8 mmol), n-BuLi (16.7 mL of a 2.5-M solution, 41.8 mmol), HMPA (13.6 g, 76.0 mmol), and (CH2O)n (3.42 g, 114 mmol). This produced 12.8 g of crude orange oil. The product was crystallized from hexane to yield 4.51 g of white solid (62%): mp 40-42° C. IR (KBr) ν 3200, 2917, 2260 cm−1; 1H NMR δ 4.23 (t, 2H, J=2.0 Hz), 2.18 (m, 2H), 1.47-1.24 (m, bm, 20H), 0.86 (t, 3H, J=6.5 Hz); 13C-NMR δ 86.6, 78.2, 51.4, 31.9, 29.4 (2C), 29.3, 29.2, 28.5, 28.4 (2C), 26.6, 22.7, 18.7, 14.1; MS m/z 231.19 (M++Li). Anal. Calcd for C15H280: C, 80.29; H, 12.58. Found: C, 80.36; H, 12.52. - 8-nonyn-1-ol (42) (
compound 30 where x=4). In a round-bottom flask equipped with a stir bar and under an atmosphere of argon was added KH (4.46 g, 111 mmol). The flask was cooled to 0° C. and 1,3-diaminopropane (50 mL) was added slowly via syringe. The solution was stirred for 45 min. Then 2-nonyn-1-ol, dissolved in of 1,3-diaminopropane (30 mL), was added dropwise via syringe to the stirring solution. The reaction was stirred for an additional 30 min at 0° C. before warming to room temperature overnight. The reaction was again cooled to 0° C. before quenching with water. The compound was extracted with Et2O, washed with HCL, water, and brine, dried with MgSO4, and concentrated. This produced 4.94 g of dark orange oil which was purified by flash column chromatography on silica gel (2.5% Et2O in hexane to 50% Et2O in hexane) to give 3.21 g of clear oil (67%): IR (near) ν 3409, 2931, 2242 cm−1, 1H-NMR δ 3.59 (t, 2H, J=7.0 Hz), 2.14 (td, 2H, J=3.0 Hz, 7.0 Hz), 2.10 (s, 1H), 1.91 (t, 1H, J=3.0 Hz), 1.50 (bm, 4H), 1.30 (bm, 6H); 13C-NMR δ 84.6, 68.1, 62.8, 32.6, 28.8, 28.6, 28.3, 25.6, 18.3; MS m/z 147.10 (M++Li). Anal. Calcd for C9H6O: C, 77.09; H, 11.46. Found: C, 77.00; H, 11.46. - 6-heptyn-1-ol (43)(
compound 30 where x=2). The same procedure for 8-nonyn-1-ol was followed with 3-heptyn-1-ol (7.96 g, 71.0 mmol), KH (8.54 g, 21.3 mmol), and 1,3-diaminopropane (70 mL). It produced 5.86 g of clear yellowish liquid (74%): IR (neat) ν 3300, 2940, 2116 cm−1; 1H-NMR δ 3.52 (t, 2H, J=6.5 Hz), 2.93 (s, 1H), 2.11 (td, 2H, J=2.6 Hz, 6.8 Hz), 1.88 (t, 1H, J=2.6), 1.40-1.50 (bm, 6H); 13C-NMR δ 84.4, 68.3, 62.2, 32.0, 28.2, 24.8, 18.3. - 7-octyn-1-ol (44) (
compound 30 where x=3). The same procedure for 8-nonyn-1-ol was followed with 3-octyn-1-ol (6.89 g, 54.6 mmol), KH (6.57 g, 16.4 mmol), and 1,3-diaminopropane (60 mL). This produced 6.09 g of clear yellowish liquid (88%): IR (neat)ν 3360, 2896, 2116 cm−1; 1H-NMR δ 3.44 (t, 2H, J=6.6 Hz), 3.27 (bs, 1H), 2.04 (td, 2H, J=2.6 Hz, 6.6 Hz), 1.83 (t, 1H, J=2.6 Hz), 1.39 (m, 4H), 1.25 (m, 4H); 13C NMR δ 84.5, 68.3, 62.2, 32.3, 28.3, 25.2 (2C), 18.2; MS m/z 136.00 (m++Li). Anal. Calcd for C8H14O: C, 76.14; H, 11.18. Found: C, 76.04; H, 11.16. - 11-dodecyn-1-ol (45) (
compound 30 where x=7). The same procedure for 8-nonyn-1-ol was followed with 9-dodecyn-1-ol (4.68 g, 25.7 mmol), KH (3.09 g, 77.0 mmol), and 1,3-diaminopropane (70 mL). This produced 4.33 g of yellow oil (93%): IR (neat) ν 3317, 2930, 2121 cm−1; 1H-NMR δ 3.62 (t, 2H, J=6.6 Hz), 2.17 (td, 2H, J=2.6 Hz, 7.1 Hz), 1.93 (t, 1H, J=2.6 Hz), 1.76 (bs, 1H), 1.55 (m, 4H), 1.28 bm, 12H); 13C-NMR δ 84.8, 68.0, 63.0, 32.7, 29.5, 29.4 (2C), 29.0, 28.7, 28.4, 25.7, 18.4; MS m/z 189.18 (M++Li). - 14-pentadecyn-1-ol (46) (
compound 30 where x=10). The same procedure for 8-nonyn-1-ol was followed with 2-pentadecyn-1-ol (4.51 g, 20.1 mmol), KH (2.38 g, 59.4 mmol), and 1,3-diaminopropane (65 mL). This produced 3.18 g of white solid (70%): mp 42-44° C. IR (thin film) ν 3430, 2926, 2252 cm−1: 1H-NMR δ 4.30 (t, 1H, J=5.0 Hz), 3.64 (t, 2H, J=6.6 Hz), 2.18 (td, 2H, J=2.6 Hz, 6.6 Hz), 1.94 (t, 1H, J=2.6 Hz), 1.49-1.26 (bm, 22H); 13C-NMR δ 84.8, 68.0, 63.1, 32.8, 29.6 (2C), 29.5 (2C), 29.4, 28.9, 28.5, 28.7, 28.0, 25.7, 18.4; MS m/z 231.53 (M++Li). Anal. Calcd for C15H28O: C, 80.29; H, 12.58. Found: C, 18.20; H, 12.50. - 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (47) (
compound 30 where x=0). A 100-mL flask equipped with a stir bar and septum was charged with 4-pentyn-1-ol (5.32 g, 63.2 mmol) and DMF (25 mL). The solution was stirred under argon and imidazole (10.8 g, 158 mmol), and then TBDMS-Cl (11.4 g, 75.8 mmol), was added. The reaction mixture was poured into water and extracted with Et2O. The organic layers were combined, washed with water and brine, dried with MgSO4, and concentrated. This produced 12.5 g of a yellow liquid. The compound was then vacuum distilled and yielded 9.21 g of clear liquid (74%): IR (neat) ν 3307, 2955, 2116 cm−1; 1H-NMR δ 3.67 (t, 2H, J=5.8 HZ), 2.24 (td, 2H, J=2.6 Hz, 6.5 Hz), 1.90 (t, 1H, J=2.6 Hz), 0.86 (s, 9H), 0.03 (s, 6H); 13C-NMR δ 84.2, 68.2, 61.4, 31.5, 25.9 25.7, 14.8, −5.4. Anal. Calcd for C11H22OSi: C, 66.60; H, 11.18. Found: C, 66.50; H, 11.10. - 5-hexyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (48) (
compound 30 where x=1). The same procedure for 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether was followed with 5-hexyn-1-ol (5.69 g, 58.0 mmol), imidazole (9.87 g, 145 mmol), and TBDMS-Cl (10.5 g, 69.6 mmol). This produced 9.44 g of clear liquid (77%): IR (neat) ν 3314, 2944, 2125 cm−1; 1H-NMR δ 3.62 (t, 2H, J=5.8 Hz), 2.20 (m, 2H), 1.92 (t, 1H, J=2.6 Hz), 1.60 (m, 4H), 0.88 (s, 9H), 0.04 (2, 6H); 13C-NMR δ 84.4, 68.2, 62.5, 31.8, 25.9, 25.6, 24.9, 18.2, −5.3. Anal. Calcd for C12H24OSi: C, 67.86; H, 11.39. Found: C, 68.05; H, 11.38. - 6-heptyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (49) (
compound 30 where x=2). The same procedure for 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether was followed with 5-heptyn-1-ol (5.86 g, 52.2 mmol), imidazole (8.89 g, 131 mmol), and TBDMS-Cl (9.44 g, 62.7 mmol). This produced 8.16 g of clear liquid (69%): IR (neat) ν 3311, 2926, 2116 cm−1; 1H-NMR δ 3.59 (t, 2H, J=5.8 Hz), 2.16 (td, 2H, J=2.6 Hz, 6.6 Hz), 1.90 (t, 1H, J=2.6 Hz), 1.50 (bm, 6H), 0.87 (s, 9H), 0.02 (s, 6H); 13C-NMR δ 84.4, 68.2, 62.9, 62.2, 32.3, 28.3, 26.0, 25.8, 25.0, 18.4, −5.5; MS m/z 227.93 (M++H). Anal. Calcd for C13H26OSi: C, 68.96; H, 11.57. Found: C, 68.92; H, 11.46. - 7-octyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (50) (
compound 30 where x=3). The same procedure for 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether was followed with 7-octyn-1-ol (5.77 g, 45.7 mmol), imidazole (7.79 g, 114 mmol), TBDMS-Cl (8.27 g, 54.9 mmol). The compound was purified by flash column chromatography on silica gel (25% Et2O in hexane to 50% Et2O in hexane) to give 10.73 g of clear liquid (98%): IR (neat)ν 3310, 2926, 2119 cm−1; 1H-NMR δ 3.60 (t, 2H, J=7.5 Hz), 2.17 (td, 2H, J=2.6 Hz, 6.8 Hz), 1.91 (t, 1H, J=2.6 Hz), 1.51 (bm, 4H), 1.35 (bm, 4H), 0.88 (s, 9H), 0.03 (s, 6H); 13C-NMR δ 84.6, 68.1, 63.1, 32.7, 28.5, 26.0, 25.9, 25.7, 25.3, 18.3, −5.4; MS m/z 241.37 (M++H). Anal. Calcd for C14H28OSi: C, 69.93; H, 11.74. Found: C, 69.76; H, 11.60. - 8-nonyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (51) (
compound 30 where x=4). The same procedure for 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether was followed with 8-nonyn-1-ol (2.99 g, 21.33 mmol), imidazole (3.63 g, 53.3 mmol), and TBDMS-Cl (3.86 g, 25.6 mmol). The compound was purified by flash column chromatography on silica gel (10% Et2O in hexane) to give 4.53 g of pale yellow oil (83%): IR (neat) ν 3313, 2930, 2117 cm−1; 1H-NMR δ 3.59 (t, 2H, J=6.6 Hz), 2.17 (td, 2H, J=2.6 Hz, 7.0 Hz, 7.0 Hz)), 1.92 (t, 1H, J=2.6 Hz), 1.50 (m, 4H), 1.30 (bm, 6H), 0.88 (s, 9H), 0.04 (s, 6H); 13C-NMR δ 84.8, 68.2, 63.2, 32.8, 28.9, 28.7, 28.4, 26.1, 25.9, 25.7, 18.4, −5.3. Anal. Calcd for C15H30OSi: C, 70.80; H, 11.88. Found: C, 70.69; H, 11.76. - 10-undecyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (52) (
compound 30 where x=6). The same procedure for 7-octyn-1-(1,1-dimethylethyl)-dimethylsilyl ether was followed with 10-undecyn-1-ol (6.73 g, 40.0 mmol), imidazole (6.80 g, 99.9 mmol), TBDMS-Cl (7.23 g, 48.0 mmol). This produced 7.58 g of clear liquid (67%): IR (neat) ν 3315, 2926, 2119 cm−1; 1H-NMR δ 3.56 (t, 2H, J=7.0 Hz), 2.14 (td, 2H, J=2.5 Hz, 7.0 Hz), 1.89 (t, 1H, J=2.5 Hz), 1.47-1.26 (bm, 14H), 0.86 (s, 9H), 0.01 (s, 6H); 13C-NMR δ 84.6, 68.0, 63.2, 32.8, 29.4, 29.3 (2C), 29.0, 28.7, 28.5, 25.9, 25.8, 18.3, −5.3. MS m/z 283.24 (M++H). Anal. Calcd for C17H32OSi: C, 72.27; H, 12.13. Found: C, 72.38; H, 12.05. - 11-dodecyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (53) (
compound 30 where x=7) The same procedure for 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether was followed with 1 ]-dodecyn-1-ol (4.28 g, 23.5 mmol), imidazole (4.00 g, 58.7 mmol), TBDMS-Cl (4.25 g, 28.2 mmol). This produced 4.97 g of clear liquid (71%): IR (neat) ν 33158, 2935, 2120 cm−1; 1H-NMR 63.59 (t, 2H, J=6.6 Hz), 2.17 (td, 2H, J=2.6 Hz, 7.1 Hz), 1.93 (t, 1H, J=2.6 Hz), 1.50 (bm, 6H), 1.27 (bm, 10H), 0.89 (s, 9H), 0.04 (s, 6H); 13C-NMR δ 84.8, 68.0, 63.3, 32.9, 29.6, 29.4 (2C), 29.1, 28.8, 28.5, 26.0, 25.8, 22.7, 18.4, −5.3. MS m/z 297.35 (M+). Anal. Calcd for C18H36OSi: C, 72.90; H, 12.24. Found: C, 72.99; H, 12.19. - 14-pentadecyn-1-(1,1-dimethylethyl)-dimethylsilyl ether (54) (
compound 30 where x=10). The same procedure for 7-octyn-1-(1,1-dimethylethyl)-dimethylsilyl ether was followed with 14-pentadecyn-1-ol (3.16 g, 14.1 mmol), imidazole (2.40 g, 35.2 mmol), TBDMS-Cl (2.55 g, 16.9 mmol). This produced 4.28 g of clear oil (90%): IR (neat) ν 3312, 2927, 2117 cm−1; 1H-NMR δ 3.59 (t, 2H, J=6.5 Hz), 2.16 (td, 2H, J=2.5 Hz, 6.5 Hz), 1.92 (t, 1H, J=2.5 Hz), 1.50 (bm, 8H), 1.25 (bm, 18H), 0.88 (s, 9H), 0.04 (s, 6H); 13C-NMR δ 84.7, 68.0, 63.3, 32.9, 29.6 (4C), 29.5, 29.4, 29.1, 28.8, 28.5, 26.0, 25.8, 18.4 (2C), −5.3; MS m/z 339.44 (M++H). Anal. Calcd for C21H42OSi: C, 74.48; H, 12.50. Found: C, 74.56; H, 12.41. - Coupling reaction (55) (
compound 32 where x=O). A three necked flask equipped with a low temperature thermometer, stir bar, and septa was charged with I-Pr2NH (1.12 g, 11.1 mmol) and THF (50 mL). The solution was cooled to 0° C. and stirred under nitrogen before n-BuLi (4.44 mL of a 2.5-M solution in hexane, 11.1 mmol) was slowly added. After stirring for 30 min, the solution was cooled to −78° C. in a dry ice/acetone bath. Then 4-pentyn-1-(1,1-dimethylethyl)-dimethylsilyl ether 40, which was dissolved in THF (10 mL) was slowly added via syringe in a manner to keep the temperature below −70° C. This solution was stirred for 30 min at −78° C., then warmed to 0° C. for 30 min, and then back down to −78° C. This solution was added via cannula over 1 h to a stirring solution of the oxazolidine aldehyde 5 (2.08 g, 9.07 mmol) in THF (10 mL) at −78° C. with positive nitrogen pressure. The reaction was stirred for 1 h before quenching with water and extracting with Et2O. The organic layers were washed with brine, dried with MgSO4, and concentrated. This produced 5.56 g of cloudy-amber oil. The compound was then purified flash column chromatography on silica gel (10% Et2O in hexane) to give 2.92 g of clear oil (68%): IR (neat) ν 3459, 2935, 2232, 1740 cm−1; 1H-NMR δ 4.73 (m, 05H), 4.46 (m, 0.5H), 4.04 (m, 3H), 3.87 (bm, 1H), 3.62 (t, 3H, J=6.0 Hz), 2.25 (td, 2H, J=1.0 Hz, 7.0 Hz), 1.65 (m, 2H), 1.47 (bs, 6H), 1.46 (bs, 9H), 0.85 (s, 9H), 0.01 (s, 6H); 13C-NMR δ 94.9, 61.5 (2C), 31.7, 31.6, 28.4 (2C), 28.2, 25.9 (2C), 25.7, 18.3, 15.2, −5.4. - Acetate protection (56) (
compound 33 where x=O). To a 100-mL flask equipped with a stir bar and septum was added the oxazolidine alkyne (55) (2.89 g, 6.75 mmol) and CH2Cl2 (50 mL). The solution was stirred under a nitrogen atmosphere at room temperature when Et3N (1.71 g, 16.9 mmol) and then Ac2O (9.827 g, 8.10 mmol) were added dropwise. A catalytic amount of DMAP (10 mg) was added and the reaction was stirred for 24 h. The reaction was poured into water and extracted with Et2O. The organic layers were combined, washed with water and brine, dried with MgSO4; and concentrated. This produced 2.92 g of amber oil. The compound was purified by flash column chromatography on silica gel (10% Et2O in hexane) to give 2.29 g of clear oil (72%): IR (neat) ν 2947, 2234, 1761, 1704 cm−1; 1H-NMR δ 5.84 (d, 1H, J=1.8 Hz), 4.00-4.30 (bm, 3H), 2.27 (td, 2H, J=1.2 Hz, 7.0 Hz), 3.64 (t, 2H, J=5.8 Hz), 2.08 (s, 3H), 1.68 (m, 2H), 1.53 (bs, 6H), 1.47 (bs, 9H), 0.87 (s, 9H), 0.03 (s, 6H); 13C-NMR δ 160.1, 64.3, 63.0, 61.4, 61.3, 59.9, 31.3, 28.3 (2C), 25.9 (2C), 25.7, 23.3, 21.1, 18.3, 15.1, −5.4. Anal. Calcd for C24H43O6NSi: C, 61.37; H, 9.23; N, 2.98. Found: C, 61.50; H, 9.20; N, 3.01. - Desilylation (57) (
compound 34 where x=0). The acylated oxazolidine alkyne (56) (2.17 g, 4.61 mmol) was dissolved in MeOH (40 mL) in a 100 mL-flask. The solution was stirred with a magnetic stir bar under a nitrogen atmosphere and cooled to 0° C. Amberlyst-15 was washed with MeOH (20 mL) on a fritted glass funnel before being added to the solution in one portion. The reaction was stirred at 0° C. for 45 min before being warmed to room temperature and stirred for an additional hour. The reaction was filtered through celite and concentrated to give 1.85 g of pale yellow oil. The compound was purified by flash column chromatography on silica gel (25% EtOAc in hexane) to give 1.32 g of amber oil (80%): IR (neat) ν 3478, 2978, 2239, 1752, 1700 cm−1; 1H-NMR δ 5.79 (bs, 1H), 4.26-4.00 (bm, 3H), 3.70 (t, 2H, J=6.1 Hz), 2.32 (m, 2H), 2.09 (s, 3H), 1.75 (bm, 2H), 1.53 (s, 3H), 1.50 (s, 3H), 1.46 (s, 9H); 13C-NMR δ 150.0, 81.7, 80.6, 64.3, 63.9, 33.2, 63.0, 61.4, 59.8, 31.0, 30.8, 28.3, 26.7, 25.7, 23.2, 21.1, 15.2. Anal. Calcd for C18H29O6N: C, 60.83; H, 8.22; N, 3.94. Found: C, 60.91; H, 8.17; N, 3.88. - N-Palmitoyl-FB1: FB1 (1 mg, 1.38 μmol) and 4.4 mg of palmitic anhydride (6.92 μmol) were dissolved in 1 ml of methanol (MeOH):CHCl3 (1:1). The mixture was kept at room temperature for up to 48 hr. The reaction was checked by
TLC using silica 60 TLC plates and CHCl3:MeOH:H2O (90:20:0.5) as solvent system. To detect fumonisins, the plates were sprayed with a 0.5% p-anisaldehyde solution in MeOH:acetic acid:sulfuric acid (85:10:5), heated to 100° C. for 10 minutes, and visually examined. The clean-up was carried out by extraction with n-butanol as described for the ceramide synthase assay of FB1. Results: yield 40-50%; ESI-MS: m/z 960.6 [M+H]+. - N-Palmitoyl-AP1: AP1 (the product of removal of the tricarballylic acids from FB1) (0.91 mg, 2.67 μmol) and 5.3 mg of palmitic anhydride (10.68 μmol) were dissolved in 1.5 ml of MeOH:CHCl3 (1:1). The mixture was kept at room temperature for up to 48 hr. The reaction was checked by TLC as described above. The reaction mixture (0.5 ml) was applied to a SiO2 SPE column (waters, 500 mg capacity), which was preconditioned with CHCl3. The minicolumn was washed with 6 ml of CHCl3 followed by 6 ml of CHCl3/MeOH (95:5). PAP1 was finally eluted with 6 ml of CHCl3/MeOH (95:10). Results: yeild 70-80%; FAB-MS (NBA-Li-Matrix): m/z 650.5 [M+Li]+, ESI-MS: m/z 644.8=[M+H]+.
- Biological Activity of Synthetic Glucuronoylceramide
- Glucoronoylceramide (GluAcCer), a ceramide with a glucuronic acid headgroup was synthesized according to the methods described above. The metabolism of GluAcCer requires β-glucuronidase, an enzyme found in bacteria but not in human intestinal cells. Accordingly, dietary GluAcCer cannot be digested in the small intestine but should be hydrolyzed in the colon by the colonic microflora. This digestion would result in releasing the same metabolites as seen from the other dietary sphingolipids, namely ceramide and sphingosine. The ability of GluAcCer to be cleaved by bacterial enzymes was established using β-glucuronidase fromE. coli (Sigma) assayed according to the supplier's instructions.
- To evaluate the efficacy of GluAcCer in the suppression of the early stages of colon cancer, a model of chemically induced colon cancer was used. Female CF1 mice were injected with DMH to initiate colonic tumors. After initiation, the mice were fed and AIN 76A diet supplemented with GluAcCer (0.025 or 0.1% of the diet). The control group was fed the AIN 76A diet without supplements (one group without DMH and the other with DMH only). After four weeks, the mice were killed, the colons excised, and evaluated for the appearance of ACF. Both groups fed the supplemented diet showed fewer ACF than the control group (21±2.94, and 19.2±3.09 in the groups fed 0.025 and 0.1% GluAcCer in the diet, respectively, versus 30.2±4.19 in the control). The data demonstrate that GluAcCer inhibited ACF formation by 20-30% (FIG. 12).
- The effect of GluAcCer on cell proliferation was also investigated since a deregulation of cell growth is observed in carcinogenesis. GluAcCer at 0.15 reduced the proliferation in the lower half of the colonic crypts, but more importantly, both concentrations reduced proliferation in the upper half of the crypts in a dose dependent manner (FIGS. 13a and 13 b). Therefore, feeding synthetic GluAcCer to mice suppresses the formation of early stages in colon carcinogenesis, possibly by restricting the proliferation to the lower half of the colonic crypt.
- Induction of Cell Death by Sphingolipids
-
- An MTT assay was used to determine the cytotoxicity of the compounds shown above. Only cells with intact mitochondria are able to form formazane crystals, whereas late apoptotic and necrotic cells are not. The optical density of formazane crystals is used to infer cell viability. A 15 uM treatment of 1-deoxy-5-hydroxy-sphinganine results in nearly 100% cell death in HT-29 cells after 24 hours. A 50 um treatment of sphingosine and a 50 uM treatment of sphinganine were required to produce comparable cell death in HT-29 cells after 24 hours. As a result, it was concluded that (a) sphinganine and sphingosine show similar cytotoxicity in HT-29 cells, and (b) 1-deoxy-5-hydroxysphinganine is at least twice as potent in inducing cell death in HT-29 cells as sphingosine and sphinganine. The results of this assay are shown in FIG. 14.
- Mammals, and specifically humans, suffering from any of the above-described conditions can be treated by the topical or systemic administration to the patient of an effective amount of one or more of the compounds described herein, including a sphingolipid metabolism altering compound, or pharmaceutically acceptable salt, optionally in the presence of a pharmaceutically acceptable carrier or diluent.
- The sphingolipid compound is administered subcutaneously, intravenously, intra peritoneally, intramuscularly, parenterally, orally, submucosally, by inhalation, transdermally via a slow release patch, or topically, in an effective dosage range to treat the target condition. Typical systemic dosages for all of the herein described conditions are those ranging from 0.1 mg/kg to 500 mg/kg of body weight per day as a single daily dose or divided daily doses. Typical dosages for topical application are those ranging from 0.001 to 100% by weight of the active compound.
- The compound is administered for a sufficient time period to alleviate the undesired symptoms and the clinical signs associated with the condition being treated.
- The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutic amount of compound in vivo in the absence of serious toxic effects.
- The concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
- A preferred mode of administration of the active compound for systemic delivery is oral. Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
- The compound or its salts can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
- The compound can also be mixed with other active materials which do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, antiinflammatories, antivirals, or other immunosuppressive agents.
- Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- If administered intravenously, preferred carriers are physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the compound is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
- Suitable vehicles or carriers for topical application can be prepared by conventional techniques, such as lotions, suspensions, ointments, creams, gels, tinctures, sprays, powders, pastes, slow-release transdermal patches, suppositories for application to rectal, vaginal, nasal or oral mucosa. In addition to the other materials listed above for systemic administration, thickening agents, emollients, and stabilizers can be used to prepare topical compositions. Examples of thickening agents include petrolatum, beeswax, xanthan gum, or polyethylene, humectants such as sorbitol, emollients such as mineral oil, lanolin and its derivatives, or squalene. A number of solutions and ointments are commercially available, especially for ophthalmic applications.
- Modifications and variations of the present invention will be obvious to those skilled in the art from the foregoing description of the invention. Such modifications and variations are intended to come within the scope of the appended claims.
Claims (28)
1. A sphingolipid derivative of the formula:
wherein
A is a spacer group which is (CH2)m where m=0-14, where any of the hydrogens may be independently replaced by R1 or X and where any two adjacent carbons may be independently replaced by a C3-C8 cycloalkyl group, a 1,2-, 1,3-, or 1,4-disubstituted benzene group, or a 2,3-, 2,4- or 2,5-disubstituted thiophene, furan or pyrrole group;
X, Y, V, and Q are independently hydrogen, OR1, NR2, CN, alkyl, acyl, carboxylate, and wherein alternatively, V and Y or Y and Q or Q and A can together constitute a double or triple bond;
W=no substituent, H, alkyl, aryl, alkenyl, alkynyl, alkaryl, aralkyl, C(O)(CH2)nCO2H, C(O)(CH2)nCW′2CO2H, or OR1;
W′ is selected independently from H, alkyl, aryl, (CH2)nCO2H; (CH2)nCH(CO2H)CH2CO2H; and (CH2)nCH(CO2H)CH(CH2CO2H)CO2H;
Z is H, O, NH, NR, NHC(O), CO2, C(O)NH, or C(O)NR;
R is selected independently from H, alkyl, acyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, or heteroaryl;
R1 is R or R2;
R2 is phosphate (OP(OR3), wherein at least one R is not hydrogen), b-D-galactoside, N-acetyl-b-D-glucosamine, a-D-mannoside, an organic azo-bond containing moiety that can be reduced by an azoreductase, b-D-cellobiosides, b-D-glucopyranosides, b-D-galactopyranosides, b-D-glucuronides, starch, lactose, raffinose, stachyose, fructooligosaccharides, an amide or ester of b-cyclodextrin, dextran linked via succinate and glutarate, an amino acid or peptide, or a polyamino acid or polypeptide, furanose and pyranose carbohydrates, sulfonate (and esters thereof), phosphocholine, phosphoserine, and phosphoethanolamine;
wherein there is at least one R2 substituent in the sphingolipid derivative.
2. A sphingolipid derivative of the formula:
wherein
A is alkyl, alkenyl, alkynyl, alkaryl, or aralkyl;
X, Y, V, and Q are independently hydrogen, OR1, NR2, OH, CN, alkyl, C(O)R, OC(O)R, and wherein alternatively, V and Y or Y and Q or Q and A can together constitute a double or triple bond;
W is no substituent, H, alkyl, aryl, alkenyl, alkynyl, alkaryl, aralkyl, C(O)(CH2)nCO2H, C(O)(CH2)nCW′2CO2H, or OR1;
W′ is selected independently from H, alkyl, aryl, (CH2)nCO2H; (CH2)nCH(CO2H)CH2CO2H; and (CH2)nCH(CO2H)CH(CH2CO2H)CO2H;
Z is H, O, NH, NR, NHC(O), CO2, C(O)NH, or C(O)NR;
R is selected independently from H. alkyl, acyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, or heteroaryl;
R1 is R or R2;
R2 is a “targeting moiety” that binds to a receptor molecule on the target membrane's surface, selected from the group consisting of steroids, hormones, hormone receptors, cell specific receptors and ligands that bind to cell specific receptors, antibodies, antibody fragments, antigens, T cell receptor fragments, and T cell receptor variable regions;
wherein there is at least one R2 substituent in the sphingolipid derivative.
3. A compound selected from the group consisting of ceramide β-glucuronide; sphinganine β-glucuronide; dihydroceramide β-glucuronide; sphingomyelin β-glucuronide; sphingosine β-glucuronide; ceramide b-D-galactoside; sphinganine b-D-galactoside dihydroceramide b-D-galactoside; sphingomyelin b-D-galactoside; sphingosine b-D-galactoside; ceramide N-acetyl-b-D-glucosamine, sphinganine N-acetyl-b-D-glucosamine; dihydroceramide N-acetyl-b-D-glucosamine; sphingomyelin N-acetyl-b-D-glucosamine; sphingosine N-acetyl-b-D-glucosamine; ceramide a-D-mannoside; sphinganine a-D-mannoside; dihydroceramide a-D-mannoside; sphingomyelin a-D-mannoside; sphingosine a-D-mannoside; ceramide b-D-cellobioside; sphinganine b-D-cellobioside; dihydroceramide b-D-cellobioside; sphingomyelin b-D-cellobioside; ceramide b-D-glucopyranosides; sphinganine b-D-glucopyranosides; dihydroceramide b-D-glucopyranosides, sphingomyelin b-D-glucopyranosides; sphingosine b-D-glucopyranosides; ceramide b-D-galactopyranosides; sphinganine b-D-galactopyranosides; dihydroceramide b-D-galactopyranosides, sphingomyelin b-D-galactopyranosides; and sphingosine b-D-galactopyranosides.
5. The compound of claims 1 or 2, wherein the bond between V and Y, Y and Q or Q and A is double bond.
6. A fumonisin analog to which is directly or indirectly bound an R2 group selected from the group consisting of phosphate (OP(OR3), (wherein at least one R is not hydrogen), b-D-galactoside, N-acetyl-b-D-glucosamine, a-D-mannoside, an organic azo-bond containing moiety that can be reduced by an azoreductase, b-D-cellobiosides, b-D-glucopyranosides, b-D-galactopyranosides, b-D-glucuronides, resistant starch, lactose, raffinose, stachyose, fructooligosaccharides, an amide or ester of b-cyclodextrin, dextran linked via succinate and glutarate, an amino acid or peptide, or a polyaminoacid or polypeptide, furanose and pyranose carbohydrates, sulfonate (and esters thereof), phosphocholine, phosphoserine, and phosphoethanolamine.
7. A fumonisin analog to which is directly or indirectly bound an R2 is a “targeting moiety” that binds to a receptor molecule on the target membrane's surface, selected from the group consisting of steroids, hormones, hormone receptors, cell specific receptors and ligands that bind to cell specific receptors, antibodies, antibody fragments, antigens, T cell receptor fragments, and T cell receptor variable regions.
8. The compound 1-deoxy-5-hydroxy-sphinganine, wherein at least one R2 is covalently bound to either hydroxyl group or the amino function of the molecule.
9. A method for the treatment of abnormal cell proliferative disorder comprising administering an effective treatment amount of a compound of any one of claims 1-8 to a host in need thereof.
10. A method for the treatment of a benign or malignant tumor comprising administering an effective treatment amount of a compound of any one of claims 1-8 to a host in need thereof.
11. The compound of claim 1 or 6 that is cleaved by an appropriate enzyme in vivo to release a parent moiety for desired therapy.
12. The method of claim 9 , wherein the proliferative disorder is selected from the group consisting of colon cancer, intestinal polyps, intestinal tumors, inflammatory bowel diseases, ulcerative colitis and Crohn's disease, necrotizing enterocolitis, ileocecitis, other inflammations of the lower bowel, antibiotic associated colitis, and tumors of the urogenital tract.
13. The method of claim 9 , wherein the disorder is colon cancer.
14. The method of claim 9 , wherein the benign tumor is selected from the group consisting of papilloma, adenoma, firoma, chondroma, osteoma, lipoma, hemangioma, lymphangioma, leiomyoma, rhabdomyoma, meningioma, neuroma, ganglioneuroma, nevus, pheochromocytoma, neurilemona, fibroadenoma, teratoma, hydatidiform mole, granuosa-theca, Brenner tumor, arrhenoblastoma, hilar cell tumor, sex cord mesenchyme, interstitial cell tumor, and thyoma.
15. The method of claim 10 , wherein the tumor is selected from the group consisting of malignant tumors (cancer), prostatic adenocarcinoma, bladder carcinoma, and adenocarcinoma, fibrosarcoma, chondrosarcoma, osteosarcoma, liposarcoma, hemangiosarcoma, lymphangiosarcoma, leiomyosarcoma, rhabdomyosarcoma, myelocytic leukemia, erythroleukemia, multiple myeloma, glioma, meningeal sarcoma, thyoma, cystosarcoma phyllodes, nephroblastoma, teratoma choriocarcinoma, cutaneous T-cell lymphoma (CTCL), cutaneous tumors primary to the skin, breast and other tumors infiltrating the skin, Kaposi's sarcoma, and premalignant and malignant diseases of mucosal tissues.
16. The method of claim 9 , wherein the disorder is selected form the group consisting of preneoplastic lesions, mycosis fungoides, psoriasis, dermatomyositis, rheumatoid arthritis, viruses, molluscum contagiosum, premalignant and malignant diseases of the female genital tract.
17. A method for triggering the release of cytochrome c in a patient in need thereof comprising administering an effective amount of a compound selected from the group consisting of sphinganine, dihydroceramide, ceramide, sphingomyelin, ceramide, and sphingosine, or pharmaceutically acceptable salt or an acylated derivative thereof.
18. A method for triggering the release of cytochrome c in a patient in need thereof comprising administering an effective treatment amount of a compound of any one of claims 1-8.
19. A method for inhibiting protein kinase c in a patient in need thereof, comprising administering an effective treatment amount of a compound of any one of claim 1-8.
20. A method for promoting cell differentiation in a patient in need thereof, comprising administering an effective treatment amount of a compound of any one of claims 1-8.
21. A method for treating a tumor in a patient comprising administering an effective treatment amount of a compound of claim 6 or 7 in combination with a chemotherapeutic agent.
22. The method of claim 21 , wherein the chemotherapeutic agent is doxorubicin.
23. A method for the treatment or prevention of a microbial infection caused by a microorganism bearing a sphingolipid receptor which binds to a sphingolipid compound as a means to anchor the microbe and initiate colonization, comprising administering to the host an effective amount of a compound of any one of claim 1-8, or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier.
24. The method of claim 23 , wherein the microbe is a bacteria.
25. The method of claim 23 , wherein the microbe is a virus.
26. The method of claim 23 , wherein the microbe is selected form the group consisting of cholera toxin, verotoxin, Shiga-like toxin 2e, Clostridium botulinum type B neurotoxin, Escherichia coli, Haemophilus influenzae; Helicobacter pylori; Borrelia burgdorferi, Pseudomonas aeruginosa, Candida albicans, HIV, Sendai virus, and influenza viruses.
27. A method for modifying the colonization of microfora that influence colon cancer and other intestinal disorders in a patient, comprising administering an effective treatment amount of a compound of any one of claims 1-8.
28. The method of claim 23 wherein the microfora are selected from the group consisting of cholera toxin, verotoxin, Shiga-like toxin 2e, Clostridium botulinum type B neurotoxin, Escherichia coli, Haemophilus influenzae; Helicobacter pylori; Borrelia burgdorferi, Pseudomonas aeruginosa, Candida albicans, HIV, Sendai virus, and influenza viruses.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/647,801 US20040039212A1 (en) | 1998-02-12 | 2003-08-25 | Sphingolipid derivatives and their methods of use |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7453698P | 1998-02-12 | 1998-02-12 | |
US09/249,211 US6610835B1 (en) | 1998-02-12 | 1999-02-12 | Sphingolipid derivatives and their methods of use |
US10/647,801 US20040039212A1 (en) | 1998-02-12 | 2003-08-25 | Sphingolipid derivatives and their methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/249,211 Continuation US6610835B1 (en) | 1998-02-12 | 1999-02-12 | Sphingolipid derivatives and their methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040039212A1 true US20040039212A1 (en) | 2004-02-26 |
Family
ID=22120088
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/249,211 Expired - Fee Related US6610835B1 (en) | 1998-02-12 | 1999-02-12 | Sphingolipid derivatives and their methods of use |
US10/647,801 Abandoned US20040039212A1 (en) | 1998-02-12 | 2003-08-25 | Sphingolipid derivatives and their methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/249,211 Expired - Fee Related US6610835B1 (en) | 1998-02-12 | 1999-02-12 | Sphingolipid derivatives and their methods of use |
Country Status (6)
Country | Link |
---|---|
US (2) | US6610835B1 (en) |
EP (1) | EP1053243B1 (en) |
AU (1) | AU765809B2 (en) |
CA (1) | CA2320117A1 (en) |
DE (1) | DE69943314D1 (en) |
WO (1) | WO1999041266A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008112320A1 (en) * | 2007-03-15 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | Inhibition of ion channel function |
US20120171193A1 (en) * | 2007-07-31 | 2012-07-05 | New York University | Diagnostic and Treatment Methods for Characterizing Bacterial Microbiota in Skin Conditions |
US20120277187A1 (en) * | 2006-08-04 | 2012-11-01 | Hiroshi Kawakami | Agent for Preventing Infection |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU765809B2 (en) * | 1998-02-12 | 2003-10-02 | Emory University | Sphingolipid derivatives and their methods of use |
US6682545B1 (en) * | 1999-10-06 | 2004-01-27 | The Penn State Research Foundation | System and device for preventing restenosis in body vessels |
WO2001037836A1 (en) * | 1999-11-24 | 2001-05-31 | Emory University | Diimino-piperazine derivatives for use as modulators of cell regulation |
US6552025B1 (en) | 1999-11-24 | 2003-04-22 | Emory University | Diimino-piperazine derivatives for use as modulators of cell regulation |
AU782539B2 (en) * | 2000-01-14 | 2005-08-04 | Meiji Dairies Corporation | Antigen-specific IgE antibody production inhibitors |
US6448023B1 (en) | 2000-09-14 | 2002-09-10 | Atairgin Technologies, Inc. | Enzyme method for detecting sphingosine-1-phosphate (S1P) |
AU2002239721C1 (en) | 2000-12-22 | 2008-04-24 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
ATE536185T1 (en) | 2001-03-26 | 2011-12-15 | Dana Farber Cancer Inst Inc | METHOD FOR ATTENUATE REACTIONS TO SKIN IRRITANTS |
US20050043534A1 (en) * | 2001-07-11 | 2005-02-24 | Alicja Bielawska | Modulators of ceramidase and methods of used based thereon |
MXPA04003245A (en) | 2001-10-04 | 2004-08-11 | Elan Pharm Inc | Hydroxypropylamines. |
WO2003048373A1 (en) * | 2001-12-04 | 2003-06-12 | The Kitasato Institute | Novel substance fki-0550 and process for producing the same |
FR2834213B1 (en) * | 2001-12-27 | 2004-06-04 | Pharmascience Lab | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE ALKANOLAMIDE FOR INHIBITING LANGERHAN CELL MIGRATION, AND USES THEREOF |
WO2004058686A1 (en) | 2002-04-30 | 2004-07-15 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of alzheimer’s disease |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
KR20040048231A (en) * | 2002-12-02 | 2004-06-07 | 주식회사 두산 | Inhibitor of angiogenesis and kit for treating cancer comprising the inhibitor |
US7968529B2 (en) | 2003-01-20 | 2011-06-28 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels |
NL1022443C2 (en) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipids for improving the composition of the intestinal flora. |
GB0301395D0 (en) * | 2003-01-21 | 2003-02-19 | Univ Aston | Inflammatory disorder treatment |
US20070184058A1 (en) * | 2003-02-27 | 2007-08-09 | Yaron Ilan | Glucocerebroside treatment of pulmonary or respiratory diseases or disorders |
WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US9717754B2 (en) | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US7645873B2 (en) * | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
WO2005014008A2 (en) * | 2003-07-17 | 2005-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of disorders associated with natural killer t cells |
ES2329374T3 (en) * | 2003-11-14 | 2009-11-25 | Het Nederlands Kanker Instituut (The Netherlands Cancer Institute) | PHARMACEUTICAL FORMULATIONS THAT USE SHORT CHAIN SPHYNOLIPIDS AND USES OF THE SAME. |
AU2004293115A1 (en) * | 2003-11-25 | 2005-06-09 | Mount Sinai School Of Medicine Of New York University | Chaperone-based therapy for Niemann-Pick disease |
US7687652B2 (en) | 2004-01-15 | 2010-03-30 | Biolab Ltd | Sphingomyelin, intermediates thereof and methods for preparation of same |
CA2558429C (en) | 2004-03-02 | 2011-02-01 | Mcgill University | Compositions and methods for preventing or treating an inflammatory response |
DE602005026785D1 (en) * | 2004-03-16 | 2011-04-21 | Tno | USE OF SPHINGOLIPIDES IN THE TREATMENT AND PREVENTION OF TYPE 2 DIABETES MELLITUS, INSULIN RESISTANCE AND METABOLISM SYNDROME |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
EP1750673B1 (en) * | 2004-05-17 | 2009-12-02 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
EP2065040A3 (en) * | 2004-06-29 | 2009-09-09 | Jado Technologies GmbH | Sphingolipids against pathological processes in lipid rafts |
EP1618876A1 (en) * | 2004-07-19 | 2006-01-25 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of sphingolipids for prevention and treatment of atherosclerosis |
CA2585645C (en) * | 2004-10-29 | 2014-10-21 | Musc Foundation For Research Development | Ceramides and apoptosis-signaling ligand |
EP1814854B1 (en) * | 2004-10-29 | 2015-02-25 | MUSC Foundation For Research Development | Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer |
AU2005310341A1 (en) | 2004-11-30 | 2006-06-08 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae |
PL2056842T3 (en) | 2006-04-07 | 2013-03-29 | Scripps Research Inst | Modified-galactosyl ceramide for the treatment of cancerous diseases |
US9217749B2 (en) | 2006-05-31 | 2015-12-22 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
US9274129B2 (en) * | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
WO2008030840A2 (en) * | 2006-09-06 | 2008-03-13 | Emory University | Synthesis of sphingosines and their derivatives |
CN101687031B (en) * | 2006-10-27 | 2014-05-14 | 勒帕斯公司 | Compositions and methods for treating ocular diseases and conditions |
PT2087002E (en) | 2006-10-27 | 2014-11-26 | Lpath Inc | Compositions and methods for binding sphingosine-1-phosphate |
EP1923060A1 (en) * | 2006-11-08 | 2008-05-21 | Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO | Combinations of a sphingolipid and an HMG-CoA reductase inhibitor for treating hypercholesterolemia |
US8916164B2 (en) * | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
EP2058011A1 (en) * | 2007-11-07 | 2009-05-13 | Wittycell | Nkt cell activating gycolipids covalently bound antigens and/or drug |
AU2008350531B2 (en) * | 2007-12-05 | 2014-01-23 | Abivax | Use of glycosylceramides for enhancing the immune response to antigens |
WO2009076598A1 (en) | 2007-12-12 | 2009-06-18 | Children's Hospital & Research Center At Oakland | Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer |
CN102215864A (en) * | 2008-10-08 | 2011-10-12 | 威蒂赛尔公司 | Vaccine composition for use against influenza |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
CA2742866C (en) | 2008-11-06 | 2017-10-24 | Musc Foundation For Research Development | Lysosomotropic inhibitors of acid ceramidase |
CA2752182C (en) | 2009-02-16 | 2017-11-28 | Cerenis Therapeutics Sa | Apolipoprotein a-i mimics |
SG10201604731SA (en) | 2010-10-18 | 2016-07-28 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
FR2972112B1 (en) * | 2011-03-01 | 2020-11-06 | Oreal | USE OF A COMPOUND FOR THE TREATMENT OF INFLAMMATORY DERMATOSES |
US20150045291A1 (en) * | 2012-04-04 | 2015-02-12 | Yeda Research And Development Co., Ltd. | Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides |
US20150258043A1 (en) * | 2012-10-15 | 2015-09-17 | Yeda Research And Development Co. Ltd. | Use of sphingoid long chain bases and their analogs in treating and preventing bacterial infections |
SG10201804887YA (en) * | 2013-03-15 | 2018-07-30 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
EP3091971A1 (en) | 2014-01-08 | 2016-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination |
EA201892448A1 (en) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS |
IL260690A (en) | 2018-07-19 | 2018-12-31 | Yeda Res & Dev | Sphingosine analogs and use thereof against bacterial lung infections |
AU2020328474A1 (en) * | 2019-08-12 | 2022-03-03 | Integrated Nanotherapeutics Inc. | Lipids for delivery of charged material, formulations thereof and method for making same |
Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880572A (en) * | 1987-05-28 | 1989-11-14 | Mect Corporation | Un-natural ceramide related compounds and preparation thereof |
US4937232A (en) * | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
US5103002A (en) * | 1989-05-17 | 1992-04-07 | Felix Wieland | Ceramide derivatives and their use as inhibitors of sphingolipid synthesis |
US5110987A (en) * | 1988-06-17 | 1992-05-05 | Emory University | Method of preparing sphingosine derivatives |
US5122450A (en) * | 1985-10-24 | 1992-06-16 | Research Corporation Limited | Biochemical reagent |
US5190876A (en) * | 1988-12-27 | 1993-03-02 | Emory University | Method of modifying cellular differentiation and function and compositions therefor |
US5232837A (en) * | 1991-08-05 | 1993-08-03 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
US5430169A (en) * | 1994-02-14 | 1995-07-04 | The United States Of America Represented By The Department Of Health And Human Services | Method for preparation of sphingoid bases |
US5440012A (en) * | 1991-05-31 | 1995-08-08 | Sumitomo Metal Industries, Ltd. | Calcitonin and method for the preparation and use thereof |
US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US5488166A (en) * | 1993-10-18 | 1996-01-30 | Virginia Tech Intellectual Properties, Inc. | Synthesis of sphingosines |
US5571900A (en) * | 1988-11-27 | 1996-11-05 | Behringwerke Aktiengesellschaft | Glycosphingolipids with a group capable of coupling in the sphingoid portion, the preparation and use thereof |
US5610040A (en) * | 1993-05-06 | 1997-03-11 | Gist-Brocades, N.V. | Enzymatic synthesis of ceramides and hybrid ceramides |
US5616577A (en) * | 1994-08-25 | 1997-04-01 | Smithkline Beecham Corporation | Protein Kinase C inhibitor |
US5635536A (en) * | 1994-12-07 | 1997-06-03 | Pharmacia & Upjohn Aktiebolag | Emulsion suitable for administering a sphingolipid |
US5672693A (en) * | 1991-01-23 | 1997-09-30 | Kabushikikaisha Kibun Shokuhin | Glycosphingolipids |
US5736533A (en) * | 1995-06-07 | 1998-04-07 | Neose Technologies, Inc. | Bacterial inhibition with an oligosaccharide compound |
US5770593A (en) * | 1988-08-18 | 1998-06-23 | Boehringer Mannheim Gmbh | Method of determining a pharmaceutical combination preparations for use in anti-neoplastic therapy |
US5790441A (en) * | 1995-09-27 | 1998-08-04 | Nec Corporation | Lossless transform coding system for digital signals |
US5849716A (en) * | 1992-10-22 | 1998-12-15 | Kirin Beer Kabushiki Kaisha | Sphingoglycolipids, their preparation, and therapeutic methods of use |
US5910425A (en) * | 1993-11-03 | 1999-06-08 | Gist-Brocades, N.V. | Microbial strains producing sphingolipid bases |
US5916911A (en) * | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
US6010733A (en) * | 1996-01-12 | 2000-01-04 | Ajinomoto Co., Inc. | Aspartylamide derivatives and sweeteners |
US6043218A (en) * | 1996-10-22 | 2000-03-28 | Medical University Of South Carolina | Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides |
US6063796A (en) * | 1997-04-04 | 2000-05-16 | Merck & Co., Inc. | Somatostatin agonists |
US6610835B1 (en) * | 1998-02-12 | 2003-08-26 | Emory University | Sphingolipid derivatives and their methods of use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2588729B2 (en) * | 1987-10-05 | 1997-03-12 | 塩野義製薬株式会社 | Sphingosine derivative |
HU209312B (en) * | 1992-02-11 | 1994-04-28 | Richter Gedeon Vegyeszet | Process for producing short peptide and pseudopeptide amides inhibiting the proliferation of the cells of small cellular and epithelial lung cancer, as well as pharmaceutical compositions comprising same as active ingredient |
SG42995A1 (en) * | 1992-03-12 | 1997-10-17 | Bio Mega Boehringer Ingelheim | Isosteric antiherpes peptide derivatives |
US5780441A (en) * | 1993-04-15 | 1998-07-14 | Kirin Beer Kabushiki Kaisha | Sphingoglycolipid compounds and therapeutic uses thereof |
JPH06321998A (en) * | 1993-05-10 | 1994-11-22 | Kikkoman Corp | Anti-fumonisin monoclonal antibody, hybridoma, hapten antigen and their production |
DE19602108A1 (en) | 1996-01-22 | 1997-07-24 | Beiersdorf Ag | Substances effective against bacteria, parasites, protozoa, mycota and viruses |
EP0821068A3 (en) * | 1996-03-29 | 1999-06-02 | Rohm And Haas Company | Novel sphingolipids and a process thereto |
-
1999
- 1999-02-12 AU AU27644/99A patent/AU765809B2/en not_active Ceased
- 1999-02-12 US US09/249,211 patent/US6610835B1/en not_active Expired - Fee Related
- 1999-02-12 CA CA002320117A patent/CA2320117A1/en not_active Abandoned
- 1999-02-12 DE DE69943314T patent/DE69943314D1/en not_active Expired - Lifetime
- 1999-02-12 EP EP99908143A patent/EP1053243B1/en not_active Expired - Lifetime
- 1999-02-12 WO PCT/US1999/003093 patent/WO1999041266A1/en active IP Right Grant
-
2003
- 2003-08-25 US US10/647,801 patent/US20040039212A1/en not_active Abandoned
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122450A (en) * | 1985-10-24 | 1992-06-16 | Research Corporation Limited | Biochemical reagent |
US4937232A (en) * | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
US4880572A (en) * | 1987-05-28 | 1989-11-14 | Mect Corporation | Un-natural ceramide related compounds and preparation thereof |
US5110987A (en) * | 1988-06-17 | 1992-05-05 | Emory University | Method of preparing sphingosine derivatives |
US5770593A (en) * | 1988-08-18 | 1998-06-23 | Boehringer Mannheim Gmbh | Method of determining a pharmaceutical combination preparations for use in anti-neoplastic therapy |
US5599914A (en) * | 1988-11-27 | 1997-02-04 | Behringwerke Aktiengesellschaft | Glycosphingolipids with a group capable of coupling in the sphingoid portion, the preparation and use thereof |
US5571900A (en) * | 1988-11-27 | 1996-11-05 | Behringwerke Aktiengesellschaft | Glycosphingolipids with a group capable of coupling in the sphingoid portion, the preparation and use thereof |
US5190876A (en) * | 1988-12-27 | 1993-03-02 | Emory University | Method of modifying cellular differentiation and function and compositions therefor |
US5459057A (en) * | 1988-12-27 | 1995-10-17 | Emory University | Method of modifying cellular differentiation and function and compositions therefor |
US5103002A (en) * | 1989-05-17 | 1992-04-07 | Felix Wieland | Ceramide derivatives and their use as inhibitors of sphingolipid synthesis |
US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US5672693A (en) * | 1991-01-23 | 1997-09-30 | Kabushikikaisha Kibun Shokuhin | Glycosphingolipids |
US5440012A (en) * | 1991-05-31 | 1995-08-08 | Sumitomo Metal Industries, Ltd. | Calcitonin and method for the preparation and use thereof |
US5518879A (en) * | 1991-08-05 | 1996-05-21 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
US5232837A (en) * | 1991-08-05 | 1993-08-03 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
US6127578A (en) * | 1991-08-05 | 2000-10-03 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
US5849716A (en) * | 1992-10-22 | 1998-12-15 | Kirin Beer Kabushiki Kaisha | Sphingoglycolipids, their preparation, and therapeutic methods of use |
US5610040A (en) * | 1993-05-06 | 1997-03-11 | Gist-Brocades, N.V. | Enzymatic synthesis of ceramides and hybrid ceramides |
US5488166A (en) * | 1993-10-18 | 1996-01-30 | Virginia Tech Intellectual Properties, Inc. | Synthesis of sphingosines |
US5910425A (en) * | 1993-11-03 | 1999-06-08 | Gist-Brocades, N.V. | Microbial strains producing sphingolipid bases |
US5430169A (en) * | 1994-02-14 | 1995-07-04 | The United States Of America Represented By The Department Of Health And Human Services | Method for preparation of sphingoid bases |
US5616577A (en) * | 1994-08-25 | 1997-04-01 | Smithkline Beecham Corporation | Protein Kinase C inhibitor |
US5635536A (en) * | 1994-12-07 | 1997-06-03 | Pharmacia & Upjohn Aktiebolag | Emulsion suitable for administering a sphingolipid |
US5736533A (en) * | 1995-06-07 | 1998-04-07 | Neose Technologies, Inc. | Bacterial inhibition with an oligosaccharide compound |
US5916911A (en) * | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
US5790441A (en) * | 1995-09-27 | 1998-08-04 | Nec Corporation | Lossless transform coding system for digital signals |
US6010733A (en) * | 1996-01-12 | 2000-01-04 | Ajinomoto Co., Inc. | Aspartylamide derivatives and sweeteners |
US6043218A (en) * | 1996-10-22 | 2000-03-28 | Medical University Of South Carolina | Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides |
US6063796A (en) * | 1997-04-04 | 2000-05-16 | Merck & Co., Inc. | Somatostatin agonists |
US6610835B1 (en) * | 1998-02-12 | 2003-08-26 | Emory University | Sphingolipid derivatives and their methods of use |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120277187A1 (en) * | 2006-08-04 | 2012-11-01 | Hiroshi Kawakami | Agent for Preventing Infection |
WO2008112320A1 (en) * | 2007-03-15 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | Inhibition of ion channel function |
US20120171193A1 (en) * | 2007-07-31 | 2012-07-05 | New York University | Diagnostic and Treatment Methods for Characterizing Bacterial Microbiota in Skin Conditions |
US8529892B2 (en) * | 2007-07-31 | 2013-09-10 | New York University | Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions |
Also Published As
Publication number | Publication date |
---|---|
EP1053243A1 (en) | 2000-11-22 |
CA2320117A1 (en) | 1999-08-19 |
US6610835B1 (en) | 2003-08-26 |
AU2764499A (en) | 1999-08-30 |
AU765809B2 (en) | 2003-10-02 |
EP1053243B1 (en) | 2011-03-30 |
WO1999041266A9 (en) | 2000-11-16 |
DE69943314D1 (en) | 2011-05-12 |
WO1999041266A1 (en) | 1999-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6610835B1 (en) | Sphingolipid derivatives and their methods of use | |
US11136342B2 (en) | Carbonate prodrugs and methods of using the same | |
NL192683C (en) | "4" -Demethyl-epipodophyllotoxin glucoside compound as well as pharmaceutical composition with anti-tumor activity | |
US20050192232A1 (en) | Novel acyl-dipeptide-like compounds bearing an accessory functional side chain spacer, a method for preparing the same and pharmaceutical compositions containing such products | |
US5369097A (en) | Phosphonates as anti-cancer agents | |
KR102162619B1 (en) | Organic compounds | |
EP2205074A2 (en) | Moenomycin analogs, methods of synthesis, and uses thereof | |
EP2725029A1 (en) | New antibacterial compounds and biological applications thereof | |
EP1305322B1 (en) | Derivatives of branched-chain lipophilic molecules and uses thereof | |
EP0061872B1 (en) | Ethyleneglycol derivatives, their production and use | |
US5227508A (en) | 3-deoxy-3-substituted analogs of phosphatidylinositol | |
AU705056B2 (en) | Modified ether glyceroglycolipids | |
AU2003235051A1 (en) | Sphingolipid derivatives and their methods of use | |
CA2358420C (en) | New compounds for the treatment of cancer | |
Mäntylä et al. | Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone | |
JP2011503050A (en) | A new synthetic analog of sphingolipid | |
US5432267A (en) | Amino sugar derivatives | |
JP2018080118A (en) | Injury therapeutic agent | |
US20130022628A1 (en) | Acyl pseudopeptides which carry a functionalized auxiliary arm | |
TW202206417A (en) | Methods for treating cancer using a modified monosaccharide compound | |
US7465817B2 (en) | Inositolized phospholipids | |
EP1480991A1 (en) | Substituted inositols and their use | |
EP1580187A1 (en) | Apoptogenic and antiproliferative analogs of ceramide | |
WO2002004467A1 (en) | Novel cytotoxic compounds and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |